<SEC-DOCUMENT>0001019687-16-006120.txt : 20160505
<SEC-HEADER>0001019687-16-006120.hdr.sgml : 20160505
<ACCEPTANCE-DATETIME>20160505133401
ACCESSION NUMBER:		0001019687-16-006120
CONFORMED SUBMISSION TYPE:	S-3
PUBLIC DOCUMENT COUNT:		10
FILED AS OF DATE:		20160505
DATE AS OF CHANGE:		20160505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AETHLON MEDICAL INC
		CENTRAL INDEX KEY:			0000882291
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				133632859
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		S-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-211151
		FILM NUMBER:		161622888

	BUSINESS ADDRESS:	
		STREET 1:		9635 GRANITE RIDGE DRIVE, SUITE 100
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123
		BUSINESS PHONE:		858-459-7800

	MAIL ADDRESS:	
		STREET 1:		9635 GRANITE RIDGE DRIVE, SUITE 100
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BISHOP EQUITIES INC
		DATE OF NAME CHANGE:	19930602
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>aethlon_s3.htm
<DESCRIPTION>FORM S-3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">As filed with the Securities and Exchange
Commission on May 5, 2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No. 333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM S-3</B><BR>
<B>REGISTRATION STATEMENT</B><BR>
Under The Securities Act of 1933</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: black 1pt solid; text-align: center; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AETHLON MEDICAL, INC.</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: center; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact name of registrant as specified in its charter)</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; font-size: 10pt">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; text-align: center; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevada</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: center; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction of incorporation or organization)</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; font-size: 10pt">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; text-align: center; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13-3632859</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: center; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer Identification Number)</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; font-size: 10pt">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">9635 Granite Ridge Drive, Suite 100</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">San Diego, California 92123</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(858) 459-7800</P></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address, including zip code, and telephone number, including area code, of registrant&rsquo;s principal executive offices)</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; font-size: 10pt">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">James A. Joyce</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">9635 Granite Ridge Drive, Suite 100</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">San Diego, California 92123</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(858) 459-7800</P></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: center; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name, address, including zip code, and telephone number, including area code, of agent for service)</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; font-size: 10pt">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">With copies of all correspondence to:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Jennifer A. Post, Esq.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Raines Feldman LLP</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">9720 Wilshire Boulevard, Fifth Floor</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Beverly Hills, California 90212</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(310) 440-4100</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Approximate Date of Commencement of the Proposed Sale to
the Public: </B>As soon as practicable after this registration statement becomes effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If the only securities being registered on this Form are being
offered pursuant to dividend or interest reinvestment plans, please check the following box: [_]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under
the Securities Act of 1933, other than securities offered in connection with dividend or interest reinvestment plans, check the
following box: </FONT><FONT STYLE="font-family: Wingdings">x</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this Form is filed to register additional securities for
an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp; [_]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this Form is a post-effective amendment filed pursuant to
Rule&nbsp;462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of
the earlier effective registration statement for the same offering.&nbsp;&nbsp; [_]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this Form is a registration statement pursuant to General
Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to
Rule 462(e) under the Securities Act, check the following box.&nbsp;&nbsp; [_]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this Form is a post-effective amendment to a registration
statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities
pursuant to Rule 413(b) under the Securities Act, check the following box.&nbsp;&nbsp; [_]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of &quot;large accelerated
filer,&quot; &quot;accelerated filer,&quot; and &quot;smaller reporting company&quot; in Rule&nbsp;12b-2 of the Exchange Act.
(Check one):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 20%; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer &nbsp;&nbsp; [_]</font></td>
    <td style="width: 20%; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer &nbsp;&nbsp; [_]</font></td>
    <td style="width: 35%; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer &nbsp;&nbsp; [_]</font><br>
<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Do not check if a smaller reporting company) </font></td>
    <td style="width: 25%; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company &nbsp;&nbsp;</font><font style="font-family: Wingdings; font-size: 10pt">x</font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CALCULATION OF REGISTRATION FEE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center">Title of Each Class of<BR> Securities to be Registered</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">Amount to be Registered(1)(2)(3)</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">Proposed Maximum<BR> Offering Price Per<BR> Security (3)(4)</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Proposed Maximum</B></FONT><BR> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Aggregate Offering</B></FONT><BR> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Price (3)(4)</B></FONT></TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Amount of</B></FONT><BR> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Registration Fee (3)(5)</B></FONT></TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Common Stock, $0.001 par value</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>Debt Securities(6)</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Warrants(7)</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>Units(8)</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 28%">Total</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 15%">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 15%">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">12,500,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">1,258.75</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(1) There are being registered hereunder such indeterminate
number of (i) shares of common stock; (ii) debt securities; (iii) warrants; and (iv) units as shall have an aggregate initial offering
price not to exceed $12,500,000. Such indeterminate amounts may from time to time be issued at indeterminate prices in U.S. dollars.
Any securities registered hereunder may be sold separately, or as units with other securities registered hereunder. This registration
statement also includes such presently indeterminate number of securities as may be issuable from time to time upon conversion
or upon exercise of, or in exchange for, any such convertible or exchangeable securities registered hereunder or pursuant to the
anti-dilution provisions of any such securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(2) Pursuant to Rule 416 under the Securities Act of 1933, as
amended (the &ldquo;Securities Act&rdquo;), the securities offered hereby shall be deemed to cover additional securities to be
offered to prevent dilution resulting from stock splits, stock dividends or similar transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(3) The amount to be registered, proposed maximum aggregate
offering price per security and proposed maximum aggregate offering price are not specified as to each class of security pursuant
to General Instruction II.D of Form S-3 under the Securities Act. The proposed maximum aggregate offering price is estimated solely
for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(4) The proposed maximum per unit and aggregate offering prices
per security will be determined, from time to time, by the registrant in connection with the issuance by the registrant of the
securities registered hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(5) With respect to securities to be offered for sale by the
Registrant in the primary offering, the registration fee is calculated in accordance with Rule 457(o) of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(6) May include senior or subordinated debt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(7) Warrants may entitle the holder to purchase our debt securities
or common stock or any combination thereof. Warrants may be issued independently or together with shares of common stock, debt
securities or any combination thereof, and the warrants may be attached to or separate from such securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(8) Each unit may consist of one or more of the other securities
described in this prospectus in any combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The registrant hereby amends this registration statement
on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which
specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities
Act of 1933 or until the registration statement shall become effective on such date as the Commission, acting pursuant to said
Section 8(a), may determine.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: red">The information in this prospectus is not complete
and may be changed. We may not sell these securities until the registration statement filed with the Commission is effective. This
prospectus is not an offer to sell these securities, and we are not soliciting offers to buy these securities in any state where
the offer or sale is not permitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: red"><B>PROSPECTUS (Subject to Completion, Dated&nbsp;May
5, 2016)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: red"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Aethlon Medical, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>$12,500,000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock<BR>
Debt Securities<BR>
Warrants<BR>
Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">From time to time, we may offer up to $12,500,000 of any combination
of the securities described in this prospectus, either individually or in units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus provides a general description of the securities
we may offer. Each time we sell securities, we will provide specific terms of the securities offered in a supplement to this prospectus.
We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. The prospectus
supplement and any related free writing prospectus may also add, update or change information contained in this prospectus. You
should carefully read this prospectus, the applicable prospectus supplement and any related free writing prospectus, as well as
any documents incorporated by reference herein and therein, before you invest in any securities. This prospectus may not be used
to consummate a sale of securities unless accompanied by the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our common stock is listed on the Nasdaq Capital Market
under the symbol &quot;AEMD.&quot; On May 2, 2016, the last reported sale price for our common stock was $5.16 per share. The
applicable prospectus supplement will contain information, where applicable, as to any other listing on the Nasdaq Capital
Market or any securities market or other exchange of the securities, if any, covered by the prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>INVESTING IN OUR SECURITIES INVOLVES RISKS. YOU SHOULD
REVIEW CAREFULLY THE RISKS AND UNCERTAINTIES DESCRIBED UNDER THE HEADING &quot;RISK FACTORS&quot; ON PAGE  5 AND CONTAINED IN
THE APPLICABLE PROSPECTUS SUPPLEMENT AND ANY RELATED FREE WRITING PROSPECTUS AND UNDER SIMILAR HEADINGS IN THE OTHER
DOCUMENTS THAT ARE INCORPORATED BY REFERENCE INTO THIS PROSPECTUS.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will sell these securities directly to investors, through
agents designated from time to time or to or through underwriters or dealers. For additional information on the methods of sale,
you should refer to the section entitled &quot;Plan of Distribution&quot; in this prospectus. If any underwriters are involved
in the sale of any securities with respect to which this prospectus is being delivered, the names of such underwriters and any
applicable commissions or discounts will be set forth in a prospectus supplement. The price to the public of such securities and
the net proceeds we expect to receive from such sale will also be set forth in a prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete.
Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The date of this prospectus is &nbsp;
&nbsp; &nbsp; &nbsp; , 2016.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>






<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 90%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center; border-bottom: Black 1pt solid"><B>Page</B></TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">About this Prospectus</TD>
    <TD STYLE="text-align: center">1</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Cautionary Note Regarding Forward-Looking Statements</TD>
    <TD STYLE="text-align: center">2</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Prospectus Summary</TD>
    <TD STYLE="text-align: center">3</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Risk Factors</TD>
    <TD STYLE="text-align: center">5</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>Use of Proceeds</TD>
    <TD STYLE="text-align: center">23</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Dilution</TD>
    <TD STYLE="text-align: center">23</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Securities We May Offer</TD>
    <TD STYLE="text-align: center">24</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Description of Capital Stock</TD>
    <TD STYLE="text-align: center">24</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Description of Debt Securities</TD>
    <TD STYLE="text-align: center">26</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Description of Warrants</TD>
    <TD STYLE="text-align: center">31</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>Description of Units</TD>
    <TD STYLE="text-align: center">33</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Plan of Distribution</TD>
    <TD STYLE="text-align: center">34</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>Experts</TD>
    <TD STYLE="text-align: center">35</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Legal Matters</TD>
    <TD STYLE="text-align: center">35</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Information Incorporated by Reference</TD>
    <TD STYLE="text-align: center">35</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Where You Can Find More Information</TD>
    <TD STYLE="text-align: center">36</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Value: 1; Name: PageNo -->i<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>No dealer, salesperson, or other person has been authorized
to give any information or to make any representation not contained in this prospectus, and, if given or made, such information
and representation should not be relied upon as having been authorized by us. This prospectus does not constitute an offer to sell
or a solicitation of an offer to buy any of the securities offered by this prospectus in any jurisdiction or to any person to whom
it is unlawful to make such offer or solicitation. Neither the delivery of this prospectus nor any sale made hereunder shall under
any circumstances create an implication that there has been no change in the facts set forth in this prospectus or in our affairs
since the date hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ABOUT THIS PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus is a part of a registration statement that we
filed with the Securities and Exchange Commission (the &quot;Commission&quot;) utilizing a &quot;shelf&quot; registration process.
Under this shelf registration process, we may sell any combination of the securities described in this prospectus in one or more
offerings up to a total dollar amount of $12,500,000. This prospectus provides you with a general description of the securities
we may offer. Each time we sell securities under this shelf registration, we will provide a prospectus supplement that will contain
specific information about the terms of that offering. We may also authorize one or more free writing prospectuses to be provided
to you that may contain material information relating to these offerings. The prospectus supplement and any related free writing
prospectus that we may authorize to be provided to you may also add, update or change information contained in this prospectus
or in any documents that we have incorporated by reference into this prospectus. You should read this prospectus, any applicable
prospectus supplement and any related free writing prospectus, together with the information incorporated herein by reference as
described under the heading &quot;Where You Can Find More Information.&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You should rely only on the information that we have provided
or incorporated by reference in this prospectus, any applicable prospectus supplement and any related free writing prospectus that
we may authorize to be provided to you. We have not authorized any dealer, salesman or other person to give any information or
to make any representation other than those contained or incorporated by reference in this prospectus, any applicable prospectus
supplement or any related free writing prospectus that we may authorize to be provided to you. You must not rely upon any information
or representation not contained or incorporated by reference in this prospectus or the accompanying prospectus supplement. This
prospectus and the accompanying supplement to this prospectus do not constitute an offer to sell or the solicitation of an offer
to buy any securities other than the registered securities to which they relate, nor do this prospectus and the accompanying supplement
to this prospectus constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person
to whom it is unlawful to make such offer or solicitation in such jurisdiction. You should not assume that the information contained
in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate on any date subsequent
to the date set forth on the front of the document or that any information we have incorporated by reference is correct on any
date subsequent to the date of the document incorporated by reference, even though this prospectus, any applicable prospectus supplement
or any related free writing prospectus is delivered or securities sold on a later date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For investors outside the United States, we have not done
anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for
that purpose is required, other than in the United States. You are required to inform yourselves about and to observe any restrictions
relating to this offering and the distribution of this prospectus outside of the United States.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As permitted by the rules and regulations of the Commission,
the registration statement, of which this prospectus forms a part, includes additional information not contained in this prospectus.
You may read the registration statement and the other reports we file with the Commission at the Commission's web site or at the
Commission's offices described below under the heading &quot;Where You Can Find Additional Information.&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You should assume that the information contained or incorporated
by reference in this prospectus, any prospectus supplement or other offering materials is accurate only as of the dates of those
documents or documents incorporated by reference, as applicable. Our business, financial condition, results of operations and
prospects may have changed since those dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unless the context requires otherwise or unless otherwise noted,
all references to &quot;Aethlon&quot; are to Aethlon Medical, Inc., a Nevada corporation, and all references to &quot;we,&quot;
&quot;us&quot; or &quot;our&quot; are to Aethlon Medical, Inc. and its subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Trademarks, service marks or trade names of any other companies
appearing in this prospectus are the property of their respective owners. Use or display by us of trademarks, service marks or
trade names owned by others is not intended to and does not imply a relationship between us and, or endorsement or sponsorship
by, the owners of the trademarks, service marks or trade names.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Value: 1; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Cautionary Note Regarding Forward-Looking
Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus, in particular the &ldquo;Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations&rdquo; incorporated herein by reference, contains certain
&ldquo;forward-looking statements&rdquo; within the meaning of Section 27A of the Securities Act and Section 21E of the Securities
Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;). These forward-looking statements represent our expectations,
beliefs, intentions or strategies concerning future events, including, but not limited to, any statements regarding our assumptions
about financial performance; the continuation of historical trends; the sufficiency of our cash balances for future liquidity and
capital resource needs; the expected impact of changes in accounting policies on our results of operations, financial condition
or cash flows; anticipated problems and our plans for future operations; and the economy in general or the future of the medical
device industry, all of which are subject to various risks and uncertainties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">When used in this prospectus as well as in reports, statements,
and information we have filed with the Commission, in our press releases, in presentations to securities analysts or investors,
or in oral statements made by or with the approval of an executive officer, the words or phrases &ldquo;believes,&rdquo; &ldquo;may,&rdquo;
&ldquo;will,&rdquo; &ldquo;expects,&rdquo; &ldquo;should,&rdquo; &ldquo;continue,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;intends,&rdquo;
&ldquo;will likely result,&rdquo; &ldquo;estimates,&rdquo; &ldquo;projects&rdquo; or similar expressions and variations thereof
are intended to identify such forward-looking statements. However, any statements contained in this prospectus that are not statements
of historical fact may be deemed to be forward-looking statements. We caution that these statements by their nature involve risks
and uncertainties, certain of which are beyond our control, and actual results may differ materially depending on a variety of
important factors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>This summary highlights information included or incorporated
by reference in this prospectus. This summary may not contain all of the information that may be important to you. Before making
an investment decision, you should read carefully this entire prospectus, any accompanying prospectus supplement and any other
offering materials, together with the additional information described under the heading &quot;Where You Can Find More Information&quot;
on page  36 of this prospectus.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Company Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our mission is to create innovative medical devices that address
unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT&trade; system provides
a platform to develop medical devices that target the selective removal of disease-promoting particles from the circulatory system.
At present, the Aethlon ADAPT product pipeline includes the Aethlon Hemopurifier&reg; to address infectious disease and cancer,
and a medical device being developed under a five-year contract with the Defense Advanced Research Projects Agency, or DARPA, to
reduce the incidence of sepsis in combat-injured soldiers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the treatment of infectious diseases, the Hemopurifier is
designed for the single-use removal of viruses and shed glycoproteins from circulation. In cancer-related therapy situations, we
are exploring the potential use of the Hemopurifier to remove tumor-secreted exosomes, which promote cancer progression. <I>In
vitro </I>studies have demonstrated that our Hemopurifier can capture exosomes underlying a broad-spectrum of cancer indications.
To support our endeavors, we applied for and have received patent protection for the capture of tumor-secreted exosomes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In June 2013, the U.S. Food and Drug Administration, or FDA,
approved an investigational device exemption that allows us to initiate human feasibility studies of the Aethlon Hemopurifier in
the U.S. Under our approved feasibility study protocol, we will study ten end-stage renal disease patients who are infected with
the Hepatitis C virus to demonstrate the safety of Hemopurifier therapy. Assuming successful completion of this study, we will
be able to initiate further stage studies required for market clearance to treat Hepatitis C and other viral pathogens.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We began enrolling patients for the study at the DaVita Dialysis
Medical Center in Houston, Texas in February 2015. We expect to complete the study by the end of 2016. However, we cannot assure
you that the clinical trial will be completed by then.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 30, 2011, we entered into a $6.8 million multi-year
contract with DARPA, which will terminate on September 30, 2016 unless further extended by DARPA. Under this contract, our tasks
include the development of a dialysis-like device to prevent sepsis, a fatal bloodstream infection that is often the cause of death
in combat-injured soldiers. To date, we have billed and collected $5,548,573 for achieving 27 milestones under this contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Through our majority-owned subsidiary, Exosome Sciences, Inc.,
we are also developing exosome-based products to diagnose and monitor neurological disorders and cancer. To date, we are still
in the product development stage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Since inception, we have primarily financed our operations through
net proceeds obtained from the private placement of our debt and equity securities. At December 31, 2015, we had a cash balance
of $3,250,897 and working capital of $2,551,395. In June 2015, we raised $5,591,988 in net proceeds from a financing, which, coupled
with previously existing funds on hand and expected revenues from our government contracts, should finance our operations through
June 30, 2016. We will require significant additional financing to complete additional future clinical trials in the U.S., as well
as fund all of our continued research and development activities for the Hemopurifier and products on the Aethlon ADAPT platform.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Associated with our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have experienced substantial operating losses since inception.
As of December 31, 2015, we had an accumulated deficit of $82,254,522, which included losses of approximately $3,624,808 and $5,910,444
for the nine-month periods ended December 31, 2015 and 2014, respectively. Historically, our losses have resulted principally from
costs incurred in the research and development of our medical devices, and general and administrative expenses, which together
were approximately $3,980,367 and $3,423,985 for the nine-month periods ended December 31, 2015 and 2014, respectively. We may
continue to incur losses in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Although we have made substantial progress in the development
and testing of our devices, and have begun to generate revenue under our contract with DARPA as we meet billable milestones under
such contract, we are not yet able to commercialize our devices and may never obtain the approvals necessary to commercialize our
products or technologies in the U.S. or elsewhere. Our contract with DARPA is time limited. DARPA may determine to terminate our
contract, and we cannot assure you that we will enter into any new government contracts with the Department of Defense or otherwise.
We compete with U.S. and foreign companies that have greater scientific and organizational resources, market presence and financial
backing than we have. We may be unable to obtain FDA or international clearance of the Hemopurifier. Even if we do achieve such
regulatory clearances, we may be unable to successfully manufacture, market and sell our devices in the U.S. or elsewhere. These
risks and others are discussed more fully in the section of this prospectus entitled &ldquo;Risk Factors&rdquo; immediately following
this prospectus summary. You should read these risks before you invest in our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Corporate History</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 10, 1999, Aethlon, Inc., a California corporation,
Hemex, Inc., a Delaware corporation and the accounting predecessor to Aethlon, Inc., and Bishop Equities, Inc., a publicly traded
Nevada corporation, completed an Agreement and Plan of Reorganization structured to result in Bishop Equities, Inc.'s acquisition
of all of the outstanding common shares of Aethlon, Inc. and Hemex, Inc. Under the plan's terms, Bishop Equities, Inc. issued shares
of its common stock to the stockholders of Aethlon, Inc. and Hemex, Inc. such that Bishop Equities, Inc. then owned 100% of each
company. Upon completion of the transaction, Bishop Equities, Inc. was renamed Aethlon Medical, Inc. In 2009, we formed Exosome,
which today is a majority-owned subsidiary focused on identifying and monitoring neurological conditions and cancer. We commenced
formal operations of Exosome in 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Contact Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our executive offices are located at 9635 Granite Ridge Drive,
Suite 100, San Diego, California 92123. Our telephone number is (858) 459-7800. Our website address is www.aethlonmedical.com.
Our website and the information contained on our website are not incorporated by reference into this prospectus or the registration
statement of which it forms a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Securities We May Offer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">With this prospectus, together with any applicable prospectus
supplement and related free writing prospectus, we may offer common stock, debt securities and warrants, or any combination of
the foregoing, either individually or as units comprised of one or more of the other securities. The aggregate initial offering
price of all securities we sell in the primary offering under this prospectus will not exceed $12,500,000. If we issue debt securities
at a discount from their original stated principal amount, then, for purposes of calculating the total dollar amount of all securities
issued under this prospectus, we will treat the initial offering price of the debt securities as the total original principal amount
of the debt securities. Each time we offer securities with this prospectus, we will provide offerees with a prospectus supplement
that will contain the specific terms of the securities being offered. The following is a summary of the securities we may offer
with this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may sell the securities to or through underwriters, dealers
or agents or directly to purchasers. We, as well as any agents acting on our behalf, reserve the sole right to accept and to reject
in whole or in part any proposed purchase of securities. Each prospectus supplement will set forth the names of any underwriters,
dealers or agents involved in the sale of securities described in that prospectus supplement and any applicable fee, commission
or discount arrangements with them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Common Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may offer shares of our common stock, par value $0.001 per
share, either alone or underlying other registered securities convertible into or exercisable for our common stock. Holders of
our common stock are entitled to such dividends as our Board of Directors may declare from time to time out of legally available
funds. Currently, we do not pay any dividends. Each holder of our common stock is entitled to one vote per share. In this prospectus,
we provide a general description of, among other things, our dividend policy and the rights and restrictions that apply to holders
of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Debt Securities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may offer general debt obligations, which may be secured
or unsecured, senior or subordinated and convertible into shares of our common stock. In this prospectus, we refer to the senior
debt securities and the subordinated debt securities together as the &quot;debt securities.&quot; We may issue debt securities
under a note purchase agreement or under an indenture to be entered between us and a trustee. If we issue debt securities under
an indenture, a form of the indenture will be filed as an exhibit to the registration statement of which this prospectus is a part,
or will be incorporated by reference from a current report on Form 8-K that we file with the Commission. The senior debt securities
will have the same rank as all of our other indebtedness that is not subordinated. The subordinated debt securities will be subordinated
to our senior debt on terms set forth in the applicable prospectus supplement. In addition, the subordinated debt securities will
be effectively subordinated to creditors of our subsidiaries. Our Board of Directors will determine the terms of each series of
debt securities being offered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus contains only general terms and provisions of
the debt securities. The applicable prospectus supplement will describe the particular terms of the debt securities offered thereby.
We urge you to read the prospectus supplements and any free writing prospectus that we may authorize to be provided to you related
to the debt securities being offered, as well as the complete indentures that contain the terms of the debt securities. Although
the forms of indentures may be filed as exhibits to the registration statement to which this prospectus is a part, supplemental
indentures and forms of debt securities containing the terms of debt securities being offered will be incorporated by reference
into the registration statement of which this prospectus is a part in reports we file with the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may offer warrants for the purchase of debt securities or
shares of common stock. We may issue the warrants by themselves or together with debt securities or common stock, and the warrants
may be attached to or separate from any offered securities. Each series of securities warrants will be issued under a separate
warrant agreement to be entered into between us and the investors or a warrant agent. Our Board of Directors will determine the
terms of the warrants. This prospectus contains only general terms and provisions of the warrants. The applicable prospectus supplement
will describe the particular terms of the warrants being offered thereby. We urge you to read the prospectus supplements and any
free writing prospectus that we may authorize to be provided to you related to the warrants being offered, as well as the complete
warrant agreements and warrant certificates that contain the terms of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Units</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may offer units consisting of common stock, debt securities
and/or warrants to purchase any of such securities in one or more series. In this prospectus, we have summarized certain general
features of the units under &quot;Description of Units.&quot; We urge you, however, to read the prospectus supplements and any
free writing prospectus that we may authorize to be provided to you related to the series of units being offered, as well as the
unit agreements that contain the terms of the units. We will file as exhibits to the registration statement of which this prospectus
is a part, or will incorporate by reference from a current report on Form 8-K that we file with the Commission, the form of unit
agreement and any supplemental agreements that describe the terms of the series of units we are offering before the issuance of
the related series of units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will evidence each series of units by unit certificates that
we will issue under a separate agreement. We will enter into the unit agreements with a unit agent. Each unit agent will be a bank
or trust company that we select. We will indicate the name and address of the unit agent in the applicable prospectus supplement
relating to a particular series of units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>An investment in our securities involves a high degree of
risk. You should carefully consider the risks described below as well as the other information in this prospectus before deciding
to invest in or maintain your investment in our company. The risks described below are not intended to be an all-inclusive list
of the potential risks relating to an investment in our securities. Any of the risk factors described below could significantly
and adversely affect our business, prospects, financial condition and results of operations. Additional risks and uncertainties
not currently known or that are currently considered to be immaterial may also materially and adversely affect our business. As
a result, the trading price or value of our securities could be materially adversely affected and you may lose all or part of your
investment.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Relating to Our Financial Position and Need for Additional
Capital</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We have incurred significant losses and expect to continue
to incur losses for the foreseeable future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have never been profitable. We have generated revenues during
the fiscal years ended March 31, 2015 and March 31, 2014, in the amounts of $762,417, and $1,623,769, respectively, primarily from
our contract with DARPA. During the nine-month periods ended December 31, 2015 and December 31, 2014, we generated revenues in
the amounts of $681,907 and $563,805, respectively, primarily from our contract with DARPA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">However, our revenues continue to be
insufficient to cover our cost of operations.&nbsp;Future profitability, if any, will require the successful commercialization
of our Hemopurifier technology, other products that may emerge from our Aethlon ADAPT platform or from additional government contract
or grant income. We cannot assure you when or if we will be able to successfully commercialize one or more of our products, or
if commercialization is successful, whether we will ever be profitable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our internal control over financial reporting does not
currently meet the standards required by Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, as amended, and failure to achieve
and maintain effective internal control over financial reporting in accordance with Section&nbsp;404 of the Sarbanes-Oxley Act
of 2002 could result in material misstatements of our annual or interim financial statements and have a material adverse effect
on our business and share price.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are not currently required to make a formal assessment of
the effectiveness of our internal control over financial reporting for purposes of compliance with the Commission&rsquo;s rules
that implement Section&nbsp;404 of the Sarbanes-Oxley Act of 2002. We are, however, required to comply with certain of these rules,
which require management to certify financial and other information in our quarterly and annual reports and provide an annual management
report on the effectiveness of our internal control over financial reporting. This assessment must include the disclosure of any
material weaknesses or significant deficiencies in our internal control over financial reporting identified by our management or
our independent registered public accounting firm. A material weakness is a deficiency, or a combination of deficiencies, in internal
control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim
financial statements will not be prevented or detected on a timely basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with our audits for the years ended March&nbsp;31,
2015 and 2014, our Chief Executive Officer and Chief Financial Officer concluded that, as of the end of such periods, due to the
material weaknesses in our internal controls over financial reporting identified in our Annual Report on Form 10-K for the year
ended March 31, 2015, our disclosure controls and procedures are not effective in recording, processing, summarizing and reporting,
on a timely basis, information required to be disclosed by us in the reports that we file or submit under the Exchange Act and
are not effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange
Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate
to allow timely decisions regarding required disclosure. Our management identified material weaknesses related to a lack of segregation
of duties and a lack of sufficient staffing in our accounting department.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are in the process of developing and implementing remediation
plans to address these material weaknesses. We cannot assure you that our plans will sufficiently address these issues, nor can
we assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting
in the future. A failure to remediate these issues may lead to significant year-end audit adjustments to our consolidated financial
statements and related disclosures or to material misstatement of our annual or interim financial statements. Additionally, in
the event that our internal control over financial reporting is perceived as inadequate, or that we are unable to produce timely
or accurate financial statements, investors may lose confidence in our operating results, we may be unable to raise capital and
the trading price of our common stock could decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We will require additional financing to sustain our operations,
and without it, we will not be able to continue operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In June 2015, we raised $5,591,988 in net proceeds from a financing.
That amount, coupled with previously existing funds on hand and expected revenues from our government contracts, should finance
our operations through June 30, 2016. We will require significant additional financing to complete additional future clinical trials
in the U.S., as well as fund all of our continued research and development activities for the Hemopurifier and products on our
Aethlon ADAPT platform. In addition, as we expand our activities, our overhead costs to support personnel, laboratory materials
and infrastructure will increase. The financing we require to sustain our working capital needs may not be available to us on reasonable
terms, if at all, when we require it. In addition, raising funds at a price below $6.30 per share of common stock will require
us to obtain the consent of certain of our investors, which they may or may not be willing to provide. Therefore, we may be unable
to support our research and FDA clearance activities including our planned clinical trials. The failure to implement our research
and clearance activities would have a material adverse effect on our ability to commercialize our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We will need to raise additional funds through debt or
equity financings in the future to achieve our business objectives and to satisfy our cash obligations, which would dilute the
ownership of our existing stockholders.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will need to raise additional funds through debt or equity
financings in order to complete our ultimate business objectives, including funding working capital to support development and
regulatory clearance of our products. We also may choose to raise additional funds in debt or equity financings if they are available
to us on reasonable terms to increase our working capital and to strengthen our financial position. Any sales of additional equity
or convertible debt securities would result in dilution of the equity interests of our existing stockholders, which could be substantial.
Also, new investors may require that we and certain of our stockholders enter into voting arrangements that give them additional
voting control or representation on our Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Our Business Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We face intense competition in the medical device industry</I></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We compete with numerous U.S. and foreign companies in the medical
device industry, and many of our competitors have greater financial, personnel and research and development resources than we have.
Our competitors are developing vaccine candidates, which could compete with the Hemopurifier medical device candidates we are developing.
Our commercial opportunities will be reduced or eliminated if our competitors develop and market products for any of the diseases
we target that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</td>
    <TD STYLE="width: 0.5in"><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">are more effective;</font></td></tr>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td style="width: 150px">&nbsp;</td>
    <td style="width: 75px"><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">have fewer or less severe adverse side effects;</font></td></tr>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td style="width: 150px">&nbsp;</td>
    <td style="width: 75px"><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">are better tolerated;</font></td></tr>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td style="width: 150px">&nbsp;</td>
    <td style="width: 75px"><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">are more adaptable to various modes of dosing;</font></td></tr>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td style="width: 150px">&nbsp;</td>
    <td style="width: 75px"><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">are easier to administer; or</font></td></tr>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td style="width: 150px">&nbsp;</td>
    <td style="width: 75px"><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">are less expensive than the products or product candidates we are developing.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Even if we are successful in developing the Hemopurifier and
other Aethlon ADAPT-based products, and obtain FDA and other regulatory approvals necessary for commercializing them, our products
may not compete effectively with other successful products. Researchers are continually learning more about diseases, which may
lead to new technologies for treatment. Our competitors may succeed in developing and marketing products either that are more effective
than those that we may develop, alone or with our collaborators, or that are marketed before any products we develop are marketed.
Our competitors include fully integrated pharmaceutical companies and biotechnology companies as well as universities and public
and private research institutions. Many of the organizations competing with us have substantially greater capital resources, larger
research and development staffs and facilities, greater experience in product development and in obtaining regulatory approvals,
and greater marketing capabilities than we have. If our competitors develop more effective pharmaceutical treatments for infectious
disease or cancer, or bring those treatments to market before we can commercialize the Hemopurifier for such uses, we may be unable
to obtain any market traction for our products, or the diseases we seek to treat may be substantially addressed by competing treatments.
If we are unable to successfully compete against larger companies in the pharmaceutical industry, we may never generate significant
revenue or be profitable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We have limited experience in identifying and working
with large scale contracts with medical device manufacturers. Manufacture of our devices must comply with good manufacturing practices
in the U.S.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To achieve the levels of production necessary to commercialize
our Hemopurifier and other future Aethlon ADAPT-based products, we will need to secure large-scale manufacturing agreements with
contract manufacturers that comply with good manufacturing practice standards and other standards prescribed by various federal,
state and local regulatory agencies in the U.S. and any other country of use. We have limited experience coordinating and overseeing
the manufacture of medical device products on a large scale. We cannot assure you that manufacturing and control problems will
not arise as we attempt to commercialize our products or that such manufacturing can be completed in a timely manner or at a commercially
reasonable cost. In addition, we cannot assure you that we will be able to adequately finance the manufacture and distribution
of our products on terms acceptable to us, if at all. If we cannot successfully oversee and finance the manufacture of our products
when they have obtained regulatory clearances, we may never generate revenue from product sales and we may never be profitable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our Aethlon ADAPT technology may become obsolete.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our Aethlon ADAPT products may be made unmarketable by new scientific
or technological developments where new treatment modalities are introduced that are more efficacious and/or more economical than
our Aethlon ADAPT products. The homeland security industry is growing rapidly with many competitors that are trying to develop
products or vaccines to protect against infectious disease. Any one of our competitors could develop a more effective product that
would render our technology obsolete. Further, our ability to achieve significant and sustained penetration of our key target markets
will depend upon our success in developing or acquiring technologies developed by other companies, either independently, through
joint ventures or through acquisitions. If we fail to develop or acquire, and manufacture and sell, products that satisfy our customers&rsquo;
demands, or we fail to respond effectively to new product announcements by our competitors by quickly introducing competitive products,
then market acceptance of our products could be reduced and our business could be adversely affected. We cannot assure you that
our products will remain competitive with products based on new technologies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our use of hazardous materials, chemicals and viruses
exposes us to potential liabilities for which we may not have adequate insurance.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our research and development involves the controlled use of
hazardous materials, chemicals and viruses. The primary hazardous materials include chemicals needed to construct the Hemopurifier
cartridges and the infected plasma samples used in pre-clinical testing of the Hemopurifier. All other chemicals are fully inventoried
and reported to the appropriate authorities, such as the fire department, who inspect our facilities on a regular basis. We are
subject to federal, state, local and foreign laws governing the use, manufacture, storage, handling and disposal of such materials.
Although we believe that our safety procedures for the use, manufacture, storage, handling and disposal of such materials comply
with the standards prescribed by federal, state, local and foreign regulations, we cannot completely eliminate the risk of accidental
contamination or injury from these materials. We have had no incidents or problems involving hazardous chemicals or biological
samples. In the event of such an accident, we could be held liable for significant damages and/or fines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We currently carry a limited amount of insurance to protect
us from damages arising from hazardous materials. Our product liability policy has a $3,000,000 limit of liability that would cover
certain releases of hazardous substances away from our facilities. For our facilities, our property policy provides $25,000 in
coverage for contaminant clean-up or removal and $50,000 in coverage for damages to the premises resulting from contamination.
Should we violate any regulations concerning the handling or use of hazardous materials, or should any injuries or death result
from our use or handling of hazardous materials, we could be the subject of substantial lawsuits by governmental agencies or individuals.
We may not have adequate insurance to cover all or any of such claims, if any. If we were responsible to pay significant damages
for violations or injuries, if any, we might be forced to cease operations since such payments could deplete our available resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our success is dependent in part on a few key executive
officers.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our success depends to a critical extent on the continued services
of our Chief Executive Officer, James A. Joyce, and our President, Rodney S. Kenley. If one or both of these key executive officers
were to leave us, we would be forced to expend significant time and money in the pursuit of a replacement, which would result in
both a delay in the implementation of our business plan and the diversion of limited working capital. The unique knowledge and
expertise of these individuals would be difficult to replace within the biotechnology field. We can give you no assurances that
we can find satisfactory replacements for these key executive officers at all, or on terms that are not unduly expensive or burdensome
to us. Although Mr. Joyce has signed an employment agreement providing for his continued service to us, this agreement will not
preclude him from leaving us should we be unable to compete with offers for employment he may receive from other companies. We
do not currently carry key man life insurance policies on either of our key executive officers, which would assist us in recouping
our costs in the event of the loss of those officers. If either of our key officers were to leave us, it could make it impossible,
if not cause substantial delays and costs, to implement our long-term business objectives and growth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our inability to attract and retain qualified personnel
could impede our ability to achieve our business objectives.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have five full-time employees consisting of our Chief Executive
Officer, our President, our Chief Financial Officer, a research scientist and an executive assistant and one consultant acting
in the capacity of Chief Science Officer. We utilize consultants, whenever appropriate, in order to conserve cash and resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Although we believe that these employees and consultants will
be able to handle most of our additional administrative, research and development and business development in the near term, we
will nevertheless be required over the longer term to hire highly skilled managerial, scientific and administrative personnel to
fully implement our business plan and growth strategies, including to mitigate the material weakness in our internal control over
financial reporting described above. Due to the specialized scientific nature of our business, we are highly dependent upon our
ability to attract and retain qualified scientific, technical and managerial personnel. Competition for these individuals, especially
in San Diego, California, where many biotechnology companies are located, is intense, and we may not be able to attract, assimilate
or retain additional highly qualified personnel in the future. We cannot assure you that we will be able to engage the services
of such qualified personnel at competitive prices or at all, particularly given the risks of employment attributable to our limited
financial resources and lack of an established track record. Also, if we are required to attract personnel from other parts of
the U.S. or abroad, we may have significant difficulty doing so due to the high cost of living in the Southern California area
and due to the costs incurred with transferring personnel to the area. If we cannot attract and retain qualified staff and executives,
we will be unable to develop our products and achieve regulatory clearance, and our business could fail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We plan to grow rapidly which will strain our resources.
Our inability to manage our growth could delay or derail implementation of our business objectives.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will need to significantly expand our operations to implement
our longer-term business plan and growth strategies. We also will be required to manage multiple relationships with various strategic
partners, technology licensors, customers, manufacturers and suppliers, consultants and other third parties. This expansion and
these expanded relationships will require us to significantly improve or replace our existing managerial, operational and financial
systems, procedures and controls; to improve the coordination between our various corporate functions; and to manage, train, motivate
and maintain a growing employee base. The time and costs to effectuate these steps may place a significant strain on our management
personnel, systems and resources, particularly given the limited amount of financial resources and skilled employees that may be
available at the time. We cannot assure you that we will institute, in a timely manner or at all, the improvements to our managerial,
operational and financial systems, procedures and controls necessary to support our anticipated increased levels of operations
and to coordinate our various corporate functions, or that we will be able to properly manage, train, motivate and retain our anticipated
increased employee base. If we cannot manage our growth initiatives, we will be unable to commercialize our products on a large
scale in a timely manner, if at all, and our business could fail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>As a public company with limited financial resources undertaking
the launch of new medical technologies, we may have difficulty attracting and retaining executive management and directors.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The directors and management of publicly traded corporations
are increasingly concerned with the extent of their personal exposure to lawsuits and stockholder claims, as well as governmental
and creditor claims that may be made against them, particularly in view of recent changes in securities laws imposing additional
duties, obligations and liabilities on management and directors. Due to these perceived risks, directors and management are also
becoming increasingly concerned with the availability of directors&rsquo; and officers&rsquo; liability insurance to pay on a timely
basis the costs incurred in defending such claims. While we currently carry directors&rsquo; and officers&rsquo; liability insurance,
such insurance is expensive and difficult to obtain. If we are unable to continue to provide directors&rsquo; and officers&rsquo;
liability insurance at affordable rates or at all, it may become increasingly more difficult to attract and retain qualified outside
directors to serve on our Board of Directors. We may lose potential independent board members and management candidates to other
companies in the biotechnology field that have greater directors&rsquo; and officers&rsquo; liability insurance to insure them
from liability or to biotechnology companies that have revenues or have received greater funding to date that can offer greater
compensation packages. The fees of directors are also rising in response to their increased duties, obligations and liabilities.
In addition, our products could potentially be harmful to users, and we are exposed to claims of product liability including for
injury or death. We have limited insurance and may not be able to afford robust coverage even as our products are introduced into
the market. As a company with limited resources and potential exposures to management, we will have a more difficult time attracting
and retaining management and outside independent directors than a more established public or private company due to these enhanced
duties, obligations and potential liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If we fail to comply with extensive regulations of U.S.
and foreign regulatory agencies, the commercialization of our products could be delayed or prevented entirely.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our Hemopurifier products are subject to extensive government
regulations related to development, testing, manufacturing and commercialization in the U.S. and other countries. The determination
of when and whether a product is ready for large-scale purchase and potential use will be made by the U.S. Government through consultation
with a number of governmental agencies, including the FDA, the National Institutes of Health, the Centers for Disease Control and
Prevention and the Department of Homeland Security. Our product candidates are in the pre-clinical and clinical stages of development
and have not received required regulatory approval from the FDA, or any foreign regulatory agencies, to be commercially marketed
and sold. The process of obtaining and complying with FDA and other governmental regulatory approvals and regulations in the U.S.
and in foreign countries is costly, time consuming, uncertain and subject to unanticipated delays. Obtaining such regulatory approvals,
if any, can take several years. Despite the time and expense exerted, regulatory approval is never guaranteed. We also are subject
to the following risks and obligations, among others:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</td>
    <TD STYLE="width: 0.5in"><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA may refuse to approve an application if it believes that applicable regulatory criteria are not satisfied;</font></td></tr>

<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA may require additional testing for safety and effectiveness;</font></td></tr>

<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA may interpret data from pre-clinical testing and clinical trials in different ways than we interpret them;</font></td></tr>

<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if regulatory approval of a product is granted, the approval may be limited to specific indications or limited with respect to its distribution; and</font></td></tr>

<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA may change its approval policies and/or adopt new regulations.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Failure to comply with these or other regulatory
requirements of the FDA may subject us to administrative or judicially imposed sanctions, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</td>
    <TD STYLE="width: 0.5in"><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warning letters;</font></td></tr>

<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">civil penalties;</font></td></tr>

<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">criminal penalties;</font></td></tr>

<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions;</font></td></tr>

<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product seizure or detention;</font></td></tr>

<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product recalls; and</font></td></tr>

<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">total or partial suspension of productions.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Delays in successfully completing our planned clinical
trials could jeopardize our ability to obtain regulatory approval.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our business prospects will depend on our ability to complete
studies and clinical trials, obtain satisfactory results, obtain required regulatory approvals and successfully commercialize our
Hemopurifier product candidates. Completion of our clinical trials, announcement of results of the trials and our ability to obtain
regulatory approvals could be delayed for a variety of reasons, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</td>
    <TD STYLE="width: 0.5in"><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">serious adverse events related to our medical device candidates;</font></td></tr>

<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unsatisfactory results of any clinical trial;</font></td></tr>

<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the failure of our principal third-party investigators to perform our clinical trials on our anticipated schedules; and</font></td></tr>

<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">different interpretations of our pre-clinical and clinical data, which could initially lead to inconclusive results.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our development costs will increase if we have material delays
in any clinical trial or if we need to perform more or larger clinical trials than planned. If the delays are significant, or if
any of our product candidates do not prove to be safe or effective or do not receive required regulatory approvals, our financial
results and the commercial prospects for our product candidates will be harmed. Furthermore, our inability to complete our clinical
trials in a timely manner could jeopardize our ability to obtain regulatory approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If we or our suppliers fail to comply with ongoing FDA
or other foreign regulatory authority requirements, or if we experience unanticipated problems with our products, these products
could be subject to restrictions or withdrawal from the market.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any product for which we obtain clearance or approval, and the
manufacturing processes, reporting requirements, post-approval clinical data and promotional activities for such product, will
be subject to continued regulatory review, oversight and periodic inspections by the FDA and other domestic and foreign regulatory
bodies. In particular, we and our third-party suppliers may be required to comply with the FDA&rsquo;s Quality System Regulation.
These FDA regulations cover the methods and documentation of the design, testing, production, control, quality assurance, labeling,
packaging, sterilization, storage and shipping of our products. Compliance with applicable regulatory requirements is subject to
continual review and is monitored rigorously through periodic inspections by the FDA. If we, or our manufacturers, fail to adhere
to Quality System Regulation requirements in the U.S., this could delay production of our products and lead to fines, difficulties
in obtaining regulatory clearances, recalls, enforcement actions, including injunctive relief or consent decrees, or other consequences,
which could, in turn, have a material adverse effect on our financial condition or results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, the FDA assesses compliance with the Quality System
Regulation through periodic announced and unannounced inspections of manufacturing and other facilities. The failure by us or one
of our suppliers to comply with applicable statutes and regulations administered by the FDA, or the failure to timely and adequately
respond to any adverse inspectional observations or product safety issues, could result in any of the following enforcement actions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</td>
    <TD STYLE="width: 0.5in"><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">untitled letters, warning letters, fines, injunctions, consent decrees and civil penalties;</font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unanticipated expenditures to address or defend such actions;</font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">customer notifications or repair, replacement, refunds, recall, detention or seizure of our products;</font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">operating restrictions or partial suspension or total shutdown of production;</font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusing or delaying our requests for 510(k) clearance or premarket approval of new products or modified products;</font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawing 510(k) clearances or premarket approvals that have already been granted;</font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal to grant export approval for our products; or</font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">criminal prosecution.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any of these sanctions could have a material adverse effect
on our reputation, business, results of operations and financial condition. Furthermore, our key component suppliers may not currently
be or may not continue to be in compliance with all applicable regulatory requirements, which could result in our failure to produce
our products on a timely basis and in the required quantities, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If our products, or malfunctions of our products, cause
or contribute to a death or a serious injury, we will be subject to medical device reporting regulations, which can result in voluntary
corrective actions or agency enforcement actions.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the FDA medical device reporting regulations, medical
device manufacturers are required to report to the FDA information that a device has or may have caused or contributed to a death
or serious injury or has malfunctioned in a way that would likely cause or contribute to death or serious injury if the malfunction
of the device or one of our similar devices were to recur. If we fail to report these events to the FDA within the required timeframes,
or at all, the FDA could take enforcement action against us. Any such adverse event involving our products also could result in
future voluntary corrective actions, such as recalls or customer notifications, or agency action, such as inspection or enforcement
action. Any corrective action, whether voluntary or involuntary, as well as defending ourselves in a lawsuit, will require the
dedication of our time and capital, will distract management from operating our business, and may harm our reputation and financial
results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>In the future, our products may be subject to product
recalls. A recall of our products, either voluntarily or at the direction of the FDA or another governmental authority, including
a third-country authority, or the discovery of serious safety issues with our products, could have a significant adverse impact
on us.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The FDA and similar foreign governmental authorities have the
authority to require the recall of commercialized products in the event of material deficiencies or defects in design or manufacture.
In the case of the FDA, the authority to require a recall must be based on an FDA finding that there is reasonable probability
that the device would cause serious injury or death. In addition, foreign governmental bodies have the authority to require the
recall of our products in the event of material deficiencies or defects in design or manufacture. Manufacturers may, under their
own initiative, recall a product if any material deficiency in a device is found. The FDA requires that certain classifications
of recalls be reported to the FDA within 10 working days after the recall is initiated. A government-mandated or voluntary recall
by us or one of our international distributors could occur as a result of an unacceptable risk to health, component failures, malfunctions,
manufacturing errors, design or labeling defects or other deficiencies and issues. Recalls of any of our products would divert
managerial and financial resources and have an adverse effect on our reputation, results of operations and financial condition,
which could impair our ability to produce our products in a cost-effective and timely manner in order to meet our customers&rsquo;
demands. We may also be subject to liability claims, be required to bear other costs, or take other actions that may have a negative
impact on our future sales and our ability to generate profits. Companies are required to maintain certain records of recalls,
even if they are not reportable to the FDA or another third-country competent authority. We may initiate voluntary recalls involving
our products in the future that we determine do not require notification of the FDA or another third-country competent authority.
If the FDA disagrees with our determinations, they could require us to report those actions as recalls. A future recall announcement
could harm our reputation with customers and negatively affect our sales. In addition, the FDA could take enforcement action for
failing to report the recalls when they occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are also required to follow detailed recordkeeping requirements
for all company-initiated medical device corrections and removals. In addition, in December 2012, the FDA issued a draft guidance
intended to assist the FDA and industry in distinguishing medical device recalls from product enhancements. Per the guidance, if
any change or group of changes to a device addresses a violation of the Federal Food, Drug, and Cosmetic Act, as amended, 21 U.S.C.
&sect; 301 et seq., that change would generally constitute a medical device recall and require submission of a recall report to
the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We outsource almost all of our operational and development
activities, and if any party to which we have outsourced certain essential functions fails to perform its obligations under agreements
with us, the development and commercialization of our lead product candidate and any future product candidates that we may develop
could be delayed or terminated.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We generally rely on third-party consultants or other vendors
to manage and implement the day-to-day conduct of our operations, including conducting clinical trials and manufacturing our current
product candidates and any future product candidates that we may develop. Accordingly, we are and will continue to be dependent
on the timeliness and effectiveness of their efforts. Our dependence on third parties includes key suppliers and third-party service
providers supporting the development, manufacture and regulatory approval of our products as well as support for our information
technology systems and other infrastructure. While our management team oversees these vendors, failure of any of these third parties
to meet their contractual, regulatory and other obligations or the development of factors that materially disrupt the performance
of these third parties could have a material adverse effect on our business. For example, all of the key oversight responsibilities
for the development and manufacture of our lead product candidate are conducted by our management team but all activities are the
responsibility of third-party vendors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If a clinical research organization that we utilize is unable
to allocate sufficient qualified personnel to our studies in a timely manner or if the work performed by it does not fully satisfy
the requirements of the FDA or other regulatory agencies, we may encounter substantial delays and increased costs in completing
our development efforts. Any manufacturer that we select may encounter difficulties in the manufacture of new products in commercial
quantities, including problems involving product yields, product stability or shelf life, quality control, adequacy of control
procedures and policies, compliance with FDA regulations and the need for further FDA approval of any new manufacturing processes
and facilities. If any of these occur, the development and commercialization of our product candidates could be delayed, curtailed
or terminated because we may not have sufficient financial resources or capabilities to continue such development and commercialization
on our own. If we rely on only one source for the manufacture of the clinical or commercial supplies of any of our product candidates
or products, any production problems or supply constraints with that manufacturer could adversely impact the development or commercialization
of that product candidate or product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If we or our contractors or service providers fail to
comply with regulatory laws and regulations, we or they could be subject to regulatory actions, which could affect our ability
to develop, market and sell our product candidates and any future product candidates that we may develop and may harm our reputation.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If we or our manufacturers or other third-party contractors
fail to comply with applicable federal, state or foreign laws or regulations, we could be subject to regulatory actions, which
could affect our ability to develop, market and sell our current product candidates or any future product candidates under development
successfully and could harm our reputation and lead to reduced acceptance or non-acceptance of our proposed product candidates
by the market. Even technical recommendations or evidence by the FDA through letters, site visits, and overall recommendations
to academia or biotechnology companies may make the manufacturing of a clinical product extremely labor intensive or expensive,
making the product candidate no longer viable to manufacture in a cost-efficient manner. The mode of administration may make the
product candidate not commercially viable. The required testing of the product candidate may make that candidate no longer commercially
viable. The conduct of clinical trials may be critiqued by the FDA, or a clinical trial site&rsquo;s institutional review board
or institutional biosafety committee, which may delay or make impossible clinical testing of a product candidate. The institutional
review board for a clinical trial may stop a trial or deem a product candidate unsafe to continue testing. This may have a material
adverse effect on the value of the product candidate and our business prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We will need to outsource and rely on third parties for
the clinical development and manufacture, sales and marketing of our current product candidates or any future product candidates
that we may develop, and our future success will be dependent on the timeliness and effectiveness of the efforts of these third
parties.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We do not have the required financial and human resources to
carry out on our own all the pre-clinical and clinical development for our current product candidates or any future product candidates
that we may develop, and we do not have the capability and resources to manufacture, market or sell our current product candidates
or any future product candidates that we may develop. Our business model calls for the partial or full outsourcing of the clinical
and other development and manufacturing, sales and marketing of our product candidates in order to reduce our capital and infrastructure
costs as a means of potentially improving our financial position. Our success will depend on the performance of these outsourced
providers. If such providers fail to perform adequately, our development of product candidates may be delayed and any delay in
the development of our product candidates would have a material and adverse effect on our business prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We are and will be exposed to product liability risks,
and clinical and pre-clinical liability risks, which could place a substantial financial burden upon us should we be sued.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our business exposes us to potential product liability and other
liability risks that are inherent in the testing, manufacturing and marketing of medical devices. We cannot be sure that claims
will not be asserted against us. A successful liability claim or series of claims brought against us could have a material adverse
effect on our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We cannot give assurances that we will be able to continue to
obtain or maintain adequate product liability insurance on acceptable terms, if at all, or that such insurance will provide adequate
coverage against potential liabilities. Claims or losses in excess of any product liability insurance coverage that we may obtain
could have a material adverse effect on our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our Hemopurifier products may be used in connection with medical
procedures in which it is important that those products function with precision and accuracy. If our products do not function as
designed, or are designed improperly, we may be forced by regulatory agencies to withdraw such products from the market. In addition,
if medical personnel or their patients suffer injury as a result of any failure of our products to function as designed, or our
products are designed inappropriately, we may be subject to lawsuits seeking significant compensatory and punitive damages. The
risk of product liability claims, product recalls and associated adverse publicity is inherent in the testing, manufacturing, marketing
and sale of medical products. We have recently obtained general clinical trial liability insurance coverage. We cannot give assurances
that our insurance coverage will be adequate or available. We may not be able to secure product liability insurance coverage on
acceptable terms or at reasonable costs when needed. Any product recall or lawsuit seeking significant monetary damages may have
a material adverse effect on our business and financial condition. Any liability for mandatory damages could exceed the amount
of our coverage. Moreover, a product recall could generate substantial negative publicity about our products and business and inhibit
or prevent commercialization of other future product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We have not received, and may never receive, approval
from the FDA to market a medical device in the United States.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Before a new medical device can be marketed in the U.S., it
must first receive either premarket approval or 510(k) clearance from the FDA, unless an exemption exists. A premarket approval
submission, which is a higher standard than a 510(k) clearance, is used to demonstrate to the FDA that a new or modified device
is safe and effective. A 510(k) submission is used to demonstrate that a device is &ldquo;substantially equivalent&rdquo; to a
predicate device (one that has been cleared by the FDA). A 510(k) submission is cleared when the FDA issues an order finding the
device to be substantially equivalent to the predicate device and stating that the device can be marketed in the U.S. We expect
that any product we seek regulatory approval for will require a premarket approval. The FDA approval process involves, among other
things, successfully completing clinical trials and filing for and obtaining a premarket approval. The premarket approval process
requires us to prove the safety and effectiveness of our products to the FDA&rsquo;s satisfaction. This process, which includes
pre-clinical studies and clinical trials, can take many years and requires the expenditure of substantial resources and may include
post-marketing surveillance to establish the safety and efficacy of the product. Notwithstanding the effort and expense incurred,
the process may never result in the FDA granting a premarket approval. Data obtained from pre-clinical studies and clinical trials
are subject to varying interpretations that could delay, limit or prevent regulatory approval. Delays or rejections may also be
encountered based upon changes in governmental policies for medical devices during the period of product development. The FDA can
delay, limit or deny approval of a premarket approval application for many reasons, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</td>
    <TD STYLE="width: 0.5in"><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD STYLE="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our inability to demonstrate safety or effectiveness to the FDA&rsquo;s satisfaction;</font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD STYLE="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">insufficient data from our pre-clinical studies and clinical trials to support approval;</font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD STYLE="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure of the facilities of our third-party manufacturer or suppliers to meet applicable requirements;</font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD STYLE="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inadequate compliance with pre-clinical, clinical or other regulations;</font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD STYLE="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our failure to meet the FDA&rsquo;s statistical requirements for approval; and</font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD STYLE="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in the FDA&rsquo;s approval policies, or the adoption of new regulations that require additional data or additional clinical studies.</font></td></tr>
<tr>
    <td colspan="3" style="text-align: center">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Modifications to products that are approved through a premarket
approval application generally need FDA approval. Similarly, some modifications made to products cleared through a 510(k) may require
a new 510(k). The FDA&rsquo;s 510(k) clearance process usually takes from three to 12 months, but may last longer. The process
of obtaining a premarket approval is much more costly and uncertain than the 510(k) clearance process and generally takes from
one to three years, or even longer, from the time the application is submitted to the FDA until an approval is obtained. Any of
our products considered to be a class III device, which are considered to pose the greatest risk and the approval of which is governed
by the strictest guidelines, will require the submission and approval of a premarket approval in order for us to market them in
the U.S. We also may design new products in the future that could require the clearance of a 510(k).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Although we have received approval to proceed with clinical
trials in the U.S. under the investigational device exemption, we cannot assure you that the current approval from the FDA to proceed
will not be revoked, that the study will be successful, or that the FDA premarket approval will eventually be obtained and not
revoked. Even if we obtain approval, the FDA or other regulatory authorities may require expensive or burdensome post-market testing
or controls. Any delay in, or failure to receive or maintain, clearance or approval for our future products could prevent us from
generating revenue from these products or achieving profitability. Additionally, the FDA and other regulatory authorities have
broad enforcement powers. Regulatory enforcement or inquiries, or other increased scrutiny on us, could dissuade some physicians
from using our products and adversely affect our reputation and the perceived safety and efficacy of our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The approval requirements for medical products used to
fight bioterrorism are still evolving, and we cannot be certain any products we develop for such uses would meet these requirements.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are advancing product candidates under governmental policies
that regulate the development and commercialization of medical treatment countermeasures against bioterror and pandemic threats.
&nbsp;While we intend to pursue FDA market clearance to treat infectious bioterror and pandemic threats, it is often not feasible
to conduct human studies against these deadly high threat pathogens. Thus, we may not be able to demonstrate the effectiveness
of our treatment countermeasures through controlled human efficacy studies. Additionally, a change in government policies could
impair our ability to obtain regulatory approval, and we cannot be certain that the FDA will approve any of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The Hemopurifier was used to treat one patient suffering
from Ebola, and we have received a supplement to our investigational device exemption to establish protocols to treat Ebola patients
in the U.S.; however, you should not construe these events as demonstrating that the device is effective in treating Ebola.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In October 2014, physicians at the Frankfurt University Hospital
in Frankfurt, Germany administered Hemopurifier therapy in a 6.5-hour treatment session to a patient infected with Ebola. This
treatment was made on an emergency basis. The patient was administered Hemopurifier therapy through special approval from The Federal
Institute for Drugs and Medical Devices (Bundesinstitut fur Arzneimittel und Medizinprodukte, BfArM), an independent federal higher
authority within the portfolio of the Federal Ministry of Health of Germany. While we believe the results of the treatment of the
Ebola patient in Germany to be positive with respect to the usage of the Hemopurifier to combat Ebola, no medical organization
or regulatory organization, inside or outside the U.S., has cleared the use of the device for Ebola treatment on a commercial basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, although the FDA approved a supplement to our investigational
device exemption to establish a protocol for the treatment of Ebola patients in the U.S., this approval is very limited and we
cannot predict the results of such protocol and potential treatments, if any. The usefulness of the Hemopurifier in treating Ebola
is still unproven in any clinical or regulatory process in the U.S. or elsewhere. Even if we enroll patients in the Ebola protocol,
the results of such treatments may not demonstrate the safety and efficacy of the device, may be equivocal or may otherwise not
be sufficient to obtain approval of the Hemopurifier for any uses associated with Ebola. In addition, the approval of the supplement
to our investigational device exemption does not in any way ensure clearance or approval of the Hemopurifier device for any purpose.
In April 2015, we submitted a Humanitarian Use Device submission to the FDA to support market clearance of the Hemopurifier as
a treatment for Ebola virus. If the application is designated by the FDA, we then may submit a Humanitarian Device Exemption marketing
application to the Center for Devices and Radiological Health for marketing review. We cannot assure you that the Hemopurifier
will prove to be useful in the treatment of Ebola, that U.S. or foreign regulatory agencies will ever approve it for such use,
or if approved, that we will successfully commercialize it for such use. We may never commercialize the Hemopurifier specifically
for use in treating Ebola.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The results of our clinical trials may not support our
product candidate claims or may result in the discovery of adverse side effects.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any research and development, pre-clinical testing and clinical
trial activities involving any products that we are developing or may develop will be subject to extensive regulation and review
by numerous governmental authorities both in the U.S. and abroad. In the future, we may conduct clinical trials to support approval
of new products. We must conduct clinical studies in compliance with FDA regulations, or the FDA may take enforcement action. Ultimately,
we may use the data collected from these clinical studies to support market clearance for these products. Even if our clinical
trials are completed as planned, we cannot be certain that their results will support our product candidate claims or that the
FDA will agree with our conclusions regarding them. Success in pre-clinical studies and early clinical trials does not ensure that
later clinical trials will be successful, and we cannot be sure that the later trials will replicate the results of prior trials
and pre-clinical studies. The clinical trial process may fail to demonstrate that our product candidates are safe and effective
for the proposed indicated uses, which could cause us to abandon a product candidate and may delay development of others. Any delay
or termination of our clinical trials will delay the filing of our product submissions and, ultimately, our ability to commercialize
our product candidates and generate revenues. It is also possible that patients enrolled in clinical trials will experience adverse
side effects that are not currently part of the product candidate&rsquo;s profile.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>U.S. legislative or FDA regulatory reforms may make it
more difficult and costly for us to obtain regulatory approval of our product candidates and to manufacture, market and distribute
our products after approval is obtained.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">From time to time, legislation is drafted and introduced in
Congress that could significantly change the statutory provisions governing the regulatory approval, manufacture and marketing
of regulated products or the reimbursement thereof. In addition, FDA regulations and guidance are often revised or reinterpreted
by the FDA in ways that may significantly affect our business and our products. Any new regulations or revisions or reinterpretations
of existing regulations may impose additional costs or lengthen review times of future products. In addition, FDA regulations and
guidance are often revised or reinterpreted by the agency in ways that may significantly affect our business and our products.
We cannot predict whether legislative changes will be enacted or FDA regulations, guidance or interpretations changed, and what
the impact of such changes, if any, may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Should our products be approved for commercialization,
lack of third-party coverage and reimbursement for our devices could delay or limit their adoption.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In both the U.S. and international markets, the use of medical
devices is dependent in part on the availability of reimbursement from third-party payors, such as government and private insurance
plans. Healthcare providers that use medical devices generally rely on third-party payors to pay for all or part of the costs and
fees associated with the medical procedures being performed or to compensate them for their patient care services. Should the FDA
approve our products for commercialization, we cannot assure you that our future products will be considered cost-effective, that
reimbursement will be available in other sites or in other countries, including the U.S., if approved, or that reimbursement will
be sufficient to allow sales of our future products on a profitable basis. The assessment of our future products by health technology
assessment bodies will significantly influence coverage decisions of third-party payors. Such assessments are outside our control,
and we cannot assure you that such evaluations will be conducted or that they will have a favorable outcome.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If approved for use in the U.S., we expect that any products
that we develop will be purchased primarily by medical institutions, which will in turn bill various third-party payors for the
health care services provided to patients at their facility. Payors may include the Centers for Medicare &amp; Medicaid Services,
which administers the Medicare program and works in partnership with state governments to administer Medicaid, other government
programs and private insurance plans. The process involved in applying for coverage and incremental reimbursement from the Centers
for Medicare &amp; Medicaid Services is lengthy and expensive. Further, Medicare coverage is based on our ability to demonstrate
the treatment is &ldquo;reasonable and necessary&rdquo; for Medicare beneficiaries. Even if products utilizing our Aethlon ADAPT
system receive FDA and other regulatory clearance or approval, they may not be granted coverage and reimbursement by any payor,
including by the Centers for Medicare &amp; Medicaid Services. For some governmental programs, such as Medicaid, coverage and reimbursement
differ from state to state and some state Medicaid programs may not pay adequate amounts for the procedure necessary to utilize
products utilizing our Aethlon ADAPT system, or any payment at all. Moreover, many private payors use coverage decisions and payment
amounts determined by the Centers for Medicare &amp; Medicaid Services as guidelines in setting their coverage and reimbursement
policies and amounts. If the Centers for Medicare &amp; Medicaid Services or other agencies limit coverage or decrease or limit
reimbursement payments for doctors and hospitals, this may affect coverage and reimbursement determinations by many private payors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Should our products be approved for commercialization,
adverse changes in reimbursement policies and procedures by payors may impact our ability to market and sell our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Healthcare costs have risen significantly over the past decade,
and there have been and continue to be proposals by legislators, regulators and third-party payors to decrease costs. Third-party
payors are increasingly challenging the prices charged for medical products and services and instituting cost containment measures
to control or significantly influence the purchase of medical products and services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For example, in the U.S., the Patient Protection and Affordable
Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, as amended, 42 U.S.C. &sect; 18001 et seq., among
other things, reduced and/or limited Medicare reimbursement to certain providers. The Budget Control Act of 2011, Pub. L. 112-25,
as amended by subsequent legislation, further reduces Medicare&rsquo;s payments to providers by two percent through fiscal year
2024. These reductions may reduce providers&rsquo; revenues or profits, which could affect their ability to purchase new technologies.
Furthermore, the healthcare industry in the U.S. has experienced a trend toward cost containment as government and private insurers
seek to control healthcare costs by imposing lower payment rates and negotiating reduced contract rates with service providers.
Legislation could be adopted in the future that limits payments for our products from governmental payors. In addition, commercial
payors such as insurance companies, could adopt similar policies that limit reimbursement for medical device manufacturers&rsquo;
products. Therefore, we cannot be certain that payors will reimburse our product or the procedures or patient care performed using
our product at a cost-effective level. We face similar risks relating to adverse changes in reimbursement procedures and policies
in other countries where we may market our products. Reimbursement and healthcare payment systems vary significantly among international
markets. Our inability to obtain international reimbursement approval, or any adverse changes in the reimbursement policies of
foreign payors, could negatively affect our ability to sell our products and have a material adverse effect on our business and
financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Should our products be approved for commercialization,
our financial performance may be adversely affected by medical device tax provisions in the healthcare reform laws.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Patient Protection and Affordable Care Act, as amended by
the Health Care and Education Reconciliation Act of 2010, as amended, 42 U.S.C. &sect;18001 et seq., currently imposes, among other
things, an excise tax of 2.3% on any entity that manufactures or imports medical devices offered for sale in the U.S. Under these
provisions, the Congressional Research Service predicts that the total cost to the medical device industry may be up to $20 billion
over the next decade. The Internal Revenue Service issued final regulations implementing the tax in December 2012, which requires,
among other things, bi-monthly payments and quarterly reporting. Once we market products, we will be subject to this or any future
excise tax on our sales of certain medical devices in the U.S. We anticipate that primarily all of our future sales of medical
devices in the U.S. will be subject to this 2.3% excise tax.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Our Intellectual Property and Related Litigation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We rely upon licenses and patent rights from third parties,
which are subject to termination or expiration.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We rely upon third party licenses and ownership rights assigned
from third parties for the development of specific uses for our Hemopurifier devices. For example, we are researching, developing
and testing cancer-related applications for our devices under patents assigned from the London Health Science Center Research,
Inc. Should any of our licenses be prematurely terminated for any reason, or if the patents and intellectual property assigned
to us or owned by such entities that we have licensed should be challenged or defeated by third parties, our research efforts could
be materially and adversely affected. We cannot assure you that any of our licenses or patents assigned to us will continue in
force for as long as we require for our research, development and testing of cancer treatments. We cannot assure you that, should
our licenses terminate, should third parties challenge or defeat the underlying patents and intellectual property, or should third
parties challenge or defeat patents and intellectual property assigned to us, we can obtain suitable replacements or develop suitable
replacements on terms acceptable to us, if at all. There is also the related risk that we may not be able to make the required
payments under any patent license or assignment agreement, in which case we may lose our ability to use one or more of the licensed
or assigned patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We could become subject to intellectual property litigation
that could be costly, result in the diversion of management&rsquo;s time and efforts, require us to pay damages, prevent us from
selling our commercially available products and/or reduce the margins we may realize from our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The medical devices industry is characterized by extensive litigation
and administrative proceedings over patent and other intellectual property rights. Whether a product infringes a patent involves
complex legal and factual issues, and the determination is often uncertain. We may be unaware of existing third-party patents that
our products under development may inadvertently infringe. The likelihood that patent infringement claims may be brought against
us increases as the number of participants in the infectious disease market increases and as we achieve more visibility in the
market place and introduce products to market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any infringement claim against us, even if without merit, may
cause us to incur substantial costs and would place a significant strain on our financial resources, divert the attention of management
from our core business, and harm our reputation. In some cases, a patent holding company or other adverse patent owner that has
no relevant product revenues and against which our patents may provide little or no deterrence may threaten or bring litigation.
If a court were to find that we infringed any of these patents, it could require us to pay substantial damages, including triple
damages if it were to find a willful infringement. A court could require us to pay royalties and could prevent us from selling
our products unless we obtain a license or are able to redesign our products to avoid infringement. We may not be able to obtain
a license enabling us to sell our products on reasonable terms, or at all, and we cannot assure you that we would be able to redesign
our products in a way that would not infringe those patents. If we fail to obtain any required licenses or make any necessary changes
to our technologies or the products that incorporate them, we may be unable to commercialize one or more of our products or may
have to withdraw products from the market, all of which would have a material adverse effect on our business, financial condition
and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If the combination of patents, trade secrets and contractual
provisions upon which we rely to protect our intellectual property is inadequate, our ability to commercialize our products successfully
will be harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our success depends significantly on our ability to protect
our proprietary rights to the technologies incorporated in our products. We currently have three issued U.S. patents and eight
pending U.S. patent applications. We also have fourteen issued foreign patents, have applied for five additional foreign patents
and have two pending international patent applications. Our issued patents begin to expire in 2019, with the last of these patents
expiring in 2029, although terminal disclaimers, patent term extension or patent term adjustment can shorten or lengthen the patent
term. We rely on a combination of patent protection, trade secret laws and nondisclosure, confidentiality and other contractual
restrictions to protect our proprietary technology. However, these may not adequately protect our rights or permit us to gain or
keep any competitive advantage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The issuance of a patent is not conclusive as to its scope,
validity or enforceability. Third parties can challenge the scope, validity or enforceability of our issued patents in litigation
or proceedings before the U.S. Patent and Trademark Office or foreign patent offices where our applications are pending. The U.S.
Patent and Trademark Office or foreign offices may deny or require significant narrowing of claims in our pending patent applications.
Patents issued as a result of the pending patent applications, if any, may not provide us with significant commercial protection
or be issued in a form that is advantageous to us. Proceedings before the U.S. Patent and Trademark Office or foreign offices could
result in adverse decisions as to the priority of our inventions and the narrowing or invalidation of claims in issued patents.
The laws of some foreign countries may not protect our intellectual property rights to the same extent as the laws of the U.S.,
if at all. Some of our patents may expire before we receive FDA approval to market our products in the U.S. or we receive approval
to market our products in a foreign country. Although we believe that certain patent applications and/or other patents issued more
recently will help protect the proprietary nature of the Hemopurifier treatment technology, we cannot assure you that this protection
will be sufficient to protect us during the development of that technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our competitors may successfully challenge and invalidate or
render unenforceable our issued patents, including any patents that may issue in the future, which could prevent or limit our ability
to market our products and could limit our ability to stop competitors from marketing products that are substantially equivalent
to ours. In addition, competitors may be able to design around our patents or develop products that provide outcomes that are comparable
to our products but that are not covered by our patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have also entered into confidentiality and assignment of
intellectual property agreements with all of our employees, consultants and advisors directly involved in the development of our
technology as one of the ways we seek to protect our intellectual property and other proprietary technology. However, we may not
be able to enforce these agreements, or they may not provide meaningful protection for our trade secrets or other proprietary information
in the event of unauthorized use or disclosure or other breaches of the agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the event a competitor infringes upon any of our patents
or other intellectual property rights, enforcing our rights may be difficult, time consuming and expensive, and would divert management&rsquo;s
attention from managing our business. We cannot assure you that we will be successful on the merits in any enforcement effort.
In addition, we may not have sufficient resources to litigate, enforce or defend our intellectual property rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may need to rely on licenses for new technology, and
any inability to obtain licenses or integrate those licenses could have a material adverse effect on our continued operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As we develop our technology, we may need to license additional
technologies to optimize the performance of our products and/or to develop new products. We may not be able to license these technologies
on commercially reasonable terms or at all. In addition, we may fail to successfully integrate any licensed technology into our
proposed products. Our inability to obtain any necessary licenses could delay our product development and testing until alternative
technologies can be identified, licensed and integrated. The inability to obtain any necessary third-party licenses could cause
us to abandon a particular development path, which could seriously harm our business, financial position and results of our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>New technology may lead to our competitors developing
superior products, which would reduce demand for our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research into technologies similar to ours is proceeding at
a rapid pace, and many private and public companies and research institutions are actively engaged in the development of products
similar to ours. These new technologies may, if successfully developed, offer significant performance or price advantages when
compared with our technologies. We cannot provide assurances that our existing patents or our pending and proposed patent applications
will offer meaningful protection if a competitor develops a novel product based on a new technology.<B>&nbsp;</B>If our competitors
develop new technology that is competitive with our products, the demand for our products could decline and adversely affect the
results of our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If we are unable to protect our proprietary technology
and preserve our trade secrets, we will increase our vulnerability to competitors, which could materially adversely impact our
ability to remain in business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our ability to successfully commercialize our products will
depend on our ability to protect those products and our technology with domestic and foreign patents. We will also need to continue
to preserve our trade secrets. The issuance of a patent is not conclusive as to its validity or as to the enforceable scope of
the claims of the patent. The patent positions of technology companies, including us, are uncertain and involve complex legal and
factual issues.&nbsp;We cannot assure you that our patents will prevent other companies from developing similar products or products
that produce benefits substantially the same as our products, or that other companies will not be issued patents that may prevent
the sale of our products or require us to pay significant licensing fees in order to market our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">From time to time, we may need to obtain licenses to patents
and other proprietary rights held by third parties in order to develop, manufacture and market our products. If we are unable to
timely obtain these licenses on commercially reasonable terms, our ability to commercially exploit such products may be inhibited
or prevented. Additionally, we cannot assure investors that any of our products or technology will be patentable or that any future
patents we obtain will give us an exclusive position in the subject matter claimed by those patents. Furthermore, we cannot assure
investors that our pending patent applications will result in issued patents, that patent protection will be secured for any particular
technology, or that our issued patents will be valid or enforceable or provide us with meaningful protection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If we are required to engage in expensive and lengthy
litigation to enforce our intellectual property rights, such litigation could be very costly and the results of such litigation
may not be satisfactory.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Although we have entered into invention assignment agreements
with our employees and with certain advisors, and we routinely enter into confidentiality agreements with our contract partners,
if those employees, advisors or contract partners develop inventions or processes independently that may relate to products or
technology under development by us, disputes may arise about the ownership of those inventions or processes. We may be required
to engage in time-consuming and costly litigation to enforce and determine the scope of our rights under these agreements. In addition,
we may be required to commence litigation to enforce such agreements if they are violated, and it is certainly possible that we
will not have adequate remedies for breaches of our confidentiality agreements as monetary damages may not be sufficient to compensate
us. In addition, we may be unable to fund the costs of such litigation to a satisfactory conclusion, which could leave us without
recourse to enforce contracts that protect our intellectual property rights.<B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Other companies may claim that our technology infringes
on their intellectual property or proprietary rights and commence legal proceedings against us, which could be time-consuming and
expensive and could result in our being prohibited from developing, marketing, selling or distributing our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Because of the complex and difficult legal and factual questions
that relate to patent positions in our industry, we cannot assure you that a court will not find our products or technology to
infringe upon the intellectual property or proprietary rights of others. Third parties may claim that our products or technology
infringe on their patents, copyrights, trademarks or other proprietary rights and demand that we cease development or marketing
of those products or technology or pay license fees. We may not be able to avoid costly patent infringement litigation, which will
divert the attention of management away from the development of new products and the operation of our business. We cannot assure
investors that we would prevail in any such litigation. If a court finds us to have infringed on a third party&rsquo;s intellectual
property rights, we may be liable for money damages, encounter significant delays in bringing products to market or be precluded
from manufacturing particular products or using particular technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other parties may challenge certain of our foreign patent applications.
If such parties are successful in opposing our foreign patent applications, we may not gain the protection afforded by those patent
applications in particular jurisdictions and may face additional proceedings with respect to similar patents in other jurisdictions,
as well as related patents. The loss of patent protection in one jurisdiction may influence our ability to maintain patent protection
for the same technology in other jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to U.S. Government Contracts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our revenues are almost entirely derived from one U.S.
Government contract.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have derived and expect for the near future to continue to
derive substantially all of our revenue under our DARPA contract. If DARPA chooses not to continue our contract in year five (commencing
October 1, 2015 through September 30, 2016) of the contract, our revenues could be substantially reduced. In addition, if we are
unable to meet any of the DARPA contract milestones to the satisfaction of DARPA, if at all, we may not earn payments under the
contract. Any reduction in our revenues, or the termination of the DARPA contract for any reason, could have a material and adverse
effect on our business and operations. In addition, DARPA has the right to unilaterally cancel the contract at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may not obtain additional U.S. Government contracts
to further develop our technology.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We can give no assurances that we will be successful in obtaining
additional government grants or contracts. The process of applying for government contracts is lengthy, and we cannot be certain
that we will be successful in obtaining announced grants or contracts for therapeutics as a medical device technology. Accordingly,
we cannot be certain that we will be awarded any additional U.S. Government grants or contracts utilizing our Hemopurifier<SUP>
</SUP>platform technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>U.S. Government agencies have special contracting requirements,
including a right to audit us, which create additional risks.</I></B> A<B><I> negative audit would be detrimental to us.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our business plan to utilize the Aethlon ADAPT system is likely
to involve contracts with the U.S. Government. Such contracts typically contain unfavorable termination provisions and are subject
to audit and modification by the government at its sole discretion, which subjects us to additional risks. These risks include
the ability of the U.S. Government to unilaterally:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</td>
    <TD STYLE="width: 0.5in"><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend or prevent us for a period of time from receiving new contracts or extending existing contracts based on violations or suspected violations of laws or regulations;</font></td></tr>

<tr style="vertical-align: top">
    <td style="width: 150px">&nbsp;</td>
    <td style="width: 75px"><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">audit and object to our contract-related costs and fees, including allocated indirect costs;</font></td></tr>

<tr style="vertical-align: top">
    <td style="width: 150px">&nbsp;</td>
    <td style="width: 75px"><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">control and potentially prohibit the export of our products; and</font></td></tr>

<tr style="vertical-align: top">
    <td style="width: 150px">&nbsp;</td>
    <td style="width: 75px"><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">change certain terms and conditions in our contracts.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a U.S. Government contractor, we are required to comply with
applicable laws, regulations and standards relating to our accounting practices and would be subject to periodic audits and reviews.
As part of any such audit or review, the U.S. Government may review the adequacy of, and our compliance with, our internal control
systems and policies, including those relating to our purchasing, property, estimating, compensation and management information
systems. Based on the results of its audits, the U.S. Government may adjust our contract-related costs and fees, including allocated
indirect costs. In addition, if an audit or review uncovers any improper or illegal activity, we would possibly be subject to civil
and criminal penalties and administrative sanctions, including termination of our contracts, forfeiture of profits, suspension
of payments, fines and suspension or prohibition from doing business with the U.S. Government. We could also suffer serious harm
to our reputation if anyone were to make allegations of impropriety against us. Although we have not had any government audits
and reviews to date, future audits and reviews could cause adverse effects. In addition, under U.S. Government purchasing regulations,
some of our costs, including most financing costs, amortization of intangible assets, portions of our research and development
costs, and some marketing expenses, would possibly not be reimbursable or allowed under such contracts. Further, as a U.S. Government
contractor, we would be subject to an increased risk of investigations, criminal prosecution, civil fraud, whistleblower lawsuits
and other legal actions and liabilities to which purely private sector companies are not.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our DARPA contract is a fixed price contract, which may
not adequately cover our costs in performance should those costs increase.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our contract with DARPA is on a firm fixed price basis, which
means that we are required to deliver our products at a fixed price regardless of the actual costs we incur and to absorb any costs
in excess of the fixed price.&nbsp; If we have not accurately estimated the costs of expenses to perform the contract, we may not
have positive revenue and we may incur losses to cover our costs.&nbsp;We expect that our future contracts, if any, with the U.S.
Government also may be fixed price contracts. Estimating costs that are related to performance in accordance with contract specifications
is difficult, particularly where the period of performance is over several years. Our failure to anticipate technical problems,
estimate costs accurately or control costs during performance of a fixed price contract could reduce the profitability of a fixed
price contract or cause a loss, which could in turn harm our operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>As a U.S. Government contractor, we are subject to a number
of procurement rules and regulations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Government contractors must comply with numerous procurement
regulations. These regulations, although customary in government contracts, impact our performance and compliance costs. In addition,
current U.S. Government budgetary constraints could lead to changes in the procurement environment, including the Department of
Defense&rsquo;s recent initiative focused on efficiencies, affordability and cost growth and other changes to its procurement practices.
If and to the extent such changes occur, they could impact our results of operations and liquidity, and could affect whether and,
if so, how we pursue certain opportunities and the terms under which we are able to do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, failure to comply with these regulations
could result in reductions of the value of contracts, contract modifications or termination, and the assessment of penalties
and fines, which could negatively impact our results of operations and financial condition. Our failure to comply with these
regulations could also lead to suspension or debarment, for cause, from government contracting or subcontracting for a period
of time. Among the causes for debarment are violations of various statutes, including those related to procurement integrity,
export control, government security regulations, employment practices, protection of the environment, accuracy of records and
the recording of costs, and foreign corruption. The termination of our government contract as a result of any of these acts
could have a negative impact on our results of operations and financial condition and could have a negative impact on our
reputation and ability to procure other government contracts in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>In fulfilling our DARPA contract, we depend on a predictable
supply of raw materials and components.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are dependent upon the delivery by suppliers of materials
and the assembly by subcontractors of major components and subsystems used in our products in a timely and satisfactory manner
and in full compliance with applicable terms and conditions. Some products require relatively scarce raw materials. We are generally
subject to specific procurement requirements, which may, in effect, limit the suppliers and subcontractors we may utilize. In some
instances, we are dependent on sole-source suppliers. If any of these suppliers or subcontractors fails to meet our needs, we may
not have readily available alternatives. In addition, the recent global financial crisis may impact some of our suppliers or subcontractors,
which could impair their ability to meet their obligations to us. If we experience a material supplier or subcontractor problem,
our ability to satisfactorily and timely complete our clinical trial or delivery obligations could be negatively impacted which
could result in reduced sales, termination of contracts and damage to our reputation and relationships with clinical trial providers
and if applicable, the U.S. Government. We could also incur additional costs in addressing such a problem. Any of these events
could have a negative impact on our results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Relating to Our Common Stock, This Offering and Our
Corporate Governance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Historically we have not paid dividends
on our common stock, and we do not anticipate paying any cash dividends in the foreseeable future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have never paid cash dividends on our common stock. We intend
to retain our future earnings, if any, to fund operational and capital expenditure needs of our business, and we do not anticipate
paying any cash dividends in the foreseeable future. Furthermore, future financing instruments may do the same. As a result, capital
appreciation, if any, of our common stock will be the sole source of gain for our common stockholders in the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>Our stock price is speculative,
and there is a risk of litigation.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The trading price of our common stock
in the past has been and in the future may be subject to wide fluctuations in response to factors such as the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</td>
    <TD STYLE="width: 0.5in"><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">revenue or results of operations in any quarter failing to meet the expectations, published or otherwise, of the investment community;</font></td></tr>

<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced investor confidence in equity markets, due in part to corporate collapses in recent years;</font></td></tr>

<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">speculation in the press or analyst community;</font></td></tr>

<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">wide fluctuations in stock prices, particularly with respect to the stock prices for other medical device companies;</font></td></tr>

<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements of technological innovations by us or our competitors;</font></td></tr>

<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">new products or the acquisition of significant customers by us or our competitors;</font></td></tr>

<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in interest rates;</font></td></tr>

<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in investors&rsquo; beliefs as to the appropriate price-earnings ratios for us and our competitors;</font></td></tr>

<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in recommendations or financial estimates by securities analysts who track our common stock or the stock of other medical device companies;</font></td></tr>

<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in management;</font></td></tr>

<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales of common stock by directors and executive officers;</font></td></tr>

<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">rumors or dissemination of false or misleading information, particularly through Internet chat rooms, instant messaging, and other rapid-dissemination methods;</font></td></tr>

<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">conditions and trends in the medical device industry generally;</font></td></tr>

<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the announcement of acquisitions or other significant transactions by us or our competitors;</font></td></tr>

<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adoption of new accounting standards affecting our industry;</font></td></tr>

<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general market conditions;</font></td></tr>

<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">domestic or international terrorism and other factors; and</font></td></tr>

<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the other factors described in this section.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fluctuations in the price of our common stock may expose us
to the risk of securities class action lawsuits. Although no such lawsuits are currently pending against us and we are not aware
that any such lawsuit is threatened to be filed in the future, third parties could sue us based on fluctuations in the price of
our common stock. Defending against such suits could result in substantial cost and divert management&rsquo;s attention and resources.
In addition, any settlement or adverse determination of such lawsuits could subject us to significant liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If at any time our common stock is subject to the Commission&rsquo;s
penny stock rules, broker-dealers may experience difficulty in completing customer transactions and trading activity in our securities
may be adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If at any time our common stock is not listed on a national
securities exchange or we have net tangible assets of $5,000,000 or less and our common stock has a market price per share of less
than $5.00, transactions in our common stock will be subject to the Commission&rsquo;s &ldquo;penny stock&rdquo; rules. If our
common stock is subject to the &ldquo;penny stock&rdquo; rules promulgated under the Exchange Act, broker-dealers may find it difficult
to effectuate customer transactions and trading activity in our securities may be adversely affected. For any transaction involving
a penny stock, unless exempt, the rules require:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</td>
    <TD STYLE="width: 0.5in"><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">that a broker or dealer approve a person&rsquo;s account for transactions in penny stocks; and</font></td></tr>

<tr style="vertical-align: top">
    <td style="width: 150px">&nbsp;</td>
    <td style="width: 75px"><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">that the broker or dealer receive from the investor a written agreement to the transaction, setting forth the identity and quantity of the penny stock to be purchased.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In order to approve a person&rsquo;s account for transactions
in penny stocks, the broker or dealer must:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</td>
    <TD STYLE="width: 0.5in"><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain financial information and investment experience objectives of the person; and</font></td></tr>

<tr style="vertical-align: top">
    <td style="width: 150px">&nbsp;</td>
    <td style="width: 75px"><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">make a reasonable determination that the transactions in penny stocks are suitable for that person and the person has sufficient knowledge and experience in financial matters to be capable of evaluating the risks of transactions in penny stocks.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The broker or dealer must also deliver, prior to any transaction
in a penny stock, a disclosure schedule prescribed by the Commission relating to the penny stock market, which, in highlight form
sets forth:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 150px">&nbsp;</td>
    <td style="width: 75px"><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the basis on which the broker or dealer made the suitability determination; and</font></td></tr>

<tr style="vertical-align: top">
    <td style="width: 150px">&nbsp;</td>
    <td style="width: 75px"><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">that the broker or dealer received a signed, written agreement from the investor prior to the transaction.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Generally, brokers may be less willing to execute transactions
in securities subject to the &ldquo;penny stock&rdquo; rules. This may make it more difficult for investors to dispose of our common
stock and cause a decline in the market value of our stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Disclosure also has to be made about the risks of investing
in penny stocks in both public offerings and in secondary trading and about the commissions payable to both the broker-dealer and
the registered representative, current quotations for the securities and the rights and remedies available to an investor in cases
of fraud in penny stock transactions. Finally, monthly statements have to be sent disclosing recent price information for the penny
stock held in the account and information on the limited market in penny stocks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our common stock has had an unpredictable trading volume,
which means you may not be able to sell our shares at or near asking prices or at all.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Trading in our common shares historically has been volatile
and often has been thin, meaning that the number of persons interested in purchasing our common shares at or near ask prices at
any given time may be relatively small or non-existent. This situation is attributable to a number of factors, including the fact
that we are a small company which is relatively unknown to stock analysts, stock brokers, institutional investors and others in
the investment community that generate or influence sales volume, and that even if we came to the attention of such persons, they
tend to be risk-averse and would be reluctant to follow an unproven company such as ours or purchase or recommend the purchase
of our shares until such time as we became more seasoned and viable. As a consequence, there may be periods of several days or
more when trading activity in our shares is minimal, as compared to a seasoned issuer that has a large and steady volume of trading
activity that will generally support continuous sales without an adverse effect on share price. We cannot give you any assurance
that a broader or more active public trading market for our common shares will develop or be sustained, or that current trading
levels will be sustained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The market price for our common stock is volatile; you
may not be able to sell our common stock at or above the price you have paid for it, which may result in losses to you.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The market for our common shares is characterized by significant
price volatility when compared to seasoned issuers, and we expect that our share price will continue to be more volatile than a
seasoned issuer for the indefinite future. In fact, during the 52-week period ended March 31, 2016, the high and low closing sale
prices of a share of our common stock were $14.00 and $4.34, respectively. The volatility in our share price is attributable to
a number of factors. First, as noted above, trading in our common shares often has been thin. As a consequence of this lack of
liquidity, the trading of relatively small quantities of shares by our stockholders may disproportionately influence the price
of those shares in either direction. The price for our shares could, for example, decline precipitously in the event that a large
number of our common shares are sold on the market without commensurate demand, as compared to a seasoned issuer which could better
absorb those sales without adverse impact on its share price. Secondly, we are a speculative investment due to our limited operating
history, limited amount of revenue, lack of profit to date, and the uncertainty of future market acceptance for our potential products.
As a consequence of this enhanced risk, more risk-adverse investors may, under the fear of losing all or most of their investment
in the event of negative news or lack of progress, be more inclined to sell their shares on the market more quickly and at greater
discounts than would be the case with the stock of a seasoned issuer. The following factors may add to the volatility in the price
of our common shares: actual or anticipated variations in our quarterly or annual operating results; acceptance of our proprietary
technology as a viable method of augmenting the immune response of clearing viruses and toxins from human blood; government regulations;
announcements of significant acquisitions, strategic partnerships or joint ventures; our capital commitments; and additions or
departures of our key personnel. Many of these factors are beyond our control and may decrease the market price of our common shares
regardless of our operating performance. We cannot predict or project the prevailing market price for our common shares at any
time, including whether our common shares will sustain their current market prices, or what effect the sale of shares or the availability
of common shares for sale at any time will have on the prevailing market price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Although our common stock trades on the Nasdaq Capital
Market, we cannot assure you that we will be able to comply with the continued listing standards of the Nasdaq Capital Market.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Although our common stock trades on the Nasdaq Capital Market,
we cannot assure you that we will be able to comply with the continued listing standards that we are required to meet in order
to maintain that listing. Our failure to meet the listing maintenance requirements may result in our common stock being delisted
from the Nasdaq Capital Market. If the Nasdaq Capital Market were to delist our common stock, we could face significant material
adverse consequences, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</td>
    <TD STYLE="width: 0.5in"><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a limited availability of market quotations for our securities;</font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced liquidity with respect to our securities;</font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a limited amount of news and analyst coverage for our company; and</font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a decreased ability to issue additional securities or obtain additional financing in the future.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The National Securities Markets Improvement Act of 1996, which
is a federal statute, prevents or preempts the states from regulating the sale of certain securities, which are referred to as
&ldquo;covered securities.&rdquo; While our common stock is listed on the Nasdaq Capital Market, such securities will be covered
securities. Although the states would be preempted from regulating the sale of our securities, in that event, the federal statute
does allow the states to investigate companies if there is a suspicion of fraud, and, if there is a finding of fraudulent activity,
then the states can regulate or bar the sale of covered securities in a particular case. Further, if the Nasdaq Capital Market
were to delist our common stock, our common stock would not be a covered security and we would be subject to regulation in each
state in which we offer our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The Depository Trust Company imposed restrictions upon
electronic trading of our common stock, which negatively affected liquidity of the stock and our ability to raise capital.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In September 2011, The Depository Trust Company placed a &quot;chill&quot;
on the electronic clearing of trades in our shares, which led to some brokerage firms being unwilling to accept certificates and/or
electronic deposits of our stock. We have since been successful in lifting the restrictions and our shares now clear electronically,
making more brokers willing to trade in our common stock. We cannot assure you that The Depository Trust Company will not again
place a chill on our common stock. A chill, if placed on our common stock, would affect the liquidity of our shares, which may
make it difficult to purchase or sell shares in the open market. It may also have an adverse effect on our ability to raise capital
since investors may be unable to resell shares into the market. Our inability to raise capital on terms acceptable to us, if at
all, could have a material and adverse effect on our business and operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our directors and officers own or control approximately
10% of our outstanding common shares, which may limit your ability to propose new management or influence the overall direction
of the business. This concentration of control may also discourage potential takeovers that could otherwise provide a premium to
you.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of May 3, 2016, our officers and directors beneficially own
or control approximately 10% of our outstanding common shares (assuming the exercise of all outstanding options and warrants exercisable
within the next 60 days held by our officers and directors). These persons will have the ability to substantially influence all
matters submitted to our stockholders for approval and to control our management and affairs, including extraordinary transactions
such as mergers and other changes of corporate control, and going private transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>A large number of our common shares are issuable upon
exercise of outstanding convertible securities, which, if exercised or converted, would be dilutive to your holdings.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2015, there were outstanding purchase options
and warrants entitling the holders to purchase 2,659,782 common shares at a weighted average exercise price of $7.46 per share.
This includes 26,105 warrants that are conditional upon the exercise of other warrants. As of December 31, 2015, there were 105,112
shares underlying promissory notes convertible into common stock at a weighted average exercise price of $5.60.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of May 3, 2016, there were outstanding purchase options and
warrants entitling the holders to purchase 2,602,639 common shares at a weighted average exercise price of $7.40 per share. This
includes 26,105 warrants that are conditional upon the exercise of other warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The exercise price for all of our outstanding options and warrants,
or the conversion price of our convertible notes, may be less than your cost to acquire our common shares. If holders exercise
or convert these securities, you could suffer substantial dilution of your investment in terms of your percentage ownership in
us as well as the book value of your common shares. In addition, the holders of the convertible notes, common share purchase options
or warrants may sell common shares in tandem with their exercise or conversion of those securities to finance that exercise or
conversion, or may resell the shares purchased in order to cover any income tax liabilities that may arise from their exercise
of the options or warrants or conversion of the notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our issuance of additional common shares, or convertible
securities, would be dilutive to your holdings.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are entitled under our Articles of Incorporation to issue
up to 30,000,000 shares of common stock. We have reserved for issuance 2,710,107 shares of common stock for existing options, warrants
and convertible notes. As of March 31, 2016, we had issued and outstanding 7,622,393 shares of common stock. As a result, as of
March 31, 2016, we had 19,667,500 common shares available for issuance to new investors or for use to satisfy indebtedness or pay
service providers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our Board of Directors may generally issue shares of common
stock, or options or warrants to purchase those shares, without further approval by our stockholders based upon such factors as
our Board of Directors may deem relevant at that time. It is likely that we will be required to issue a large amount of additional
securities to raise capital to further our development. It is also likely that we will be required to issue a large amount of additional
securities to directors, officers, employees and consultants as compensatory grants in connection with their services, both in
the form of stand-alone grants or under our stock plans. We cannot give you any assurance that we will not issue additional shares
of common stock, or options or warrants to purchase those shares, under circumstances we may deem appropriate at the time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our issuance of additional shares of common stock in satisfaction
of services, or to repay indebtedness, would be dilutive to your holdings.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our Board of Directors may generally issue shares of common
stock to pay for debt or services, without further approval by our stockholders based upon such factors that our Board of Directors
may deem relevant at that time. For the past four fiscal years (ending March 31, 2015), we issued a total of 2,602,909 shares for
debt to reduce our obligations. The average price discount of common stock issued for debt in this period, weighted by the number
of shares issued for debt in such period, was 76% and 43% for the years ended March 31, 2015 and 2014, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For the past four fiscal years (ending March 31, 2015), we issued
a total of 216,032 shares as payment for services. The average price discount (premium) of common stock issued for services during
this period, weighted by the number of shares issued, was (6.6)% and 16.0% for the years ended March 31, 2015 and 2014, respectively.
It is likely that we will issue additional securities to pay for services and reduce debt in the future. We cannot give you any
assurance that we will not issue additional shares of common stock at various discounts under circumstances we may deem appropriate
at the time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our officers and directors are entitled to indemnification
from us for liabilities under our Articles of Incorporation, which could be costly to us and may discourage the exercise of stockholder
rights.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our Articles of Incorporation contain provisions that eliminate
the liability of our directors for monetary damages to our company and stockholders. Our by-laws also require us to indemnify our
officers and directors. We may also have contractual indemnification obligations under our agreements with our directors, officers
and employees. As a result of these obligations, we could incur substantial expenditures to cover settlement or damage awards against
directors, officers and employees that we may be unable to recoup. These provisions and resultant costs may also discourage us
from bringing a lawsuit against directors, officers and employees for breaches of their fiduciary duties, and may similarly discourage
stockholders from filing derivative litigation against our directors, officers and employees even though such actions, if successful,
might otherwise benefit our company and stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our by-laws and Nevada law may discourage, delay or prevent
a change of control of our company or changes in our management, which may depress the trading price of our common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Provisions of Nevada anti-takeover law (NRS 78.378 <I>et seq.</I>)
could delay or prevent a third party from acquiring us, even if the acquisition arguably could benefit our stockholders. Our by-laws
may be adopted, amended or repealed by the affirmative vote of the holders of at least a majority of our outstanding shares of
capital stock entitled to vote for the election of directors, and except as provided by Nevada law, our Board of Directors has
the power to adopt, amend or repeal the by-laws by a vote of not less than a majority of our directors. The interests of these
stockholders and directors may not be consistent with your interests, and they may make changes to the by-laws that are not in
line with your concerns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our authorized but unissued shares of common stock are available
for our Board or Directors to issue without stockholder approval. We may use these additional shares for a variety of corporate
purposes; however, faced with an attempt to obtain control of us by means of a proxy contest, tender offer, merger or other transaction,
our Board of Directors acting alone and without approval of our stockholders can issue large amounts of capital stock as part of
a defense to a take-over challenge.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The foregoing provisions and other potential anti-takeover measures
could limit the price that investors might be willing to pay in the future for shares of our common stock. They could also deter
potential acquirers of our company, thereby reducing the likelihood that you could receive a premium for your common stock in an
acquisition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We incur substantial costs as a result of being a public
company, and our management expects to devote substantial time to public company compliance programs.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a public company, we incur significant legal, insurance,
accounting and other expenses, including costs associated with public company reporting. We intend to invest resources to comply
with evolving laws, regulations and standards, and this investment will result in increased general and administrative expenses
and may divert management&rsquo;s time and attention from product development and commercialization activities. If our efforts
to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to
ambiguities related to practice, regulatory authorities may initiate legal proceedings against us, and our business may be harmed.
These laws and regulations could make it more difficult and costly for us to obtain director and officer liability insurance for
our directors and officers, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage.
These factors could also make it more difficult for us to attract and retain qualified executive officers and qualified members
of our Board of Directors, particularly to serve on our audit and compensation committees. In addition, if we are unable to continue
to meet the legal, regulatory and other requirements related to being a public company, we may not be able to maintain the listing
of our common stock on the <FONT STYLE="background-color: white">Nasdaq Capital Market,</FONT> which would likely have a material
adverse effect on the trading price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If securities or industry analysts do not publish research
or reports about our business, or if they change their recommendations regarding our stock adversely, our stock price and trading
volume could decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The research and reports that industry or securities analysts
publish about us or our business will influence the trading market for our common stock. Our research coverage by industry and
financial analysts is currently limited. Even if our analyst coverage increases, if one or more of the analysts who cover us downgrade
our stock, our stock price would likely decline. If one or more of these analysts cease coverage of our company or fail to regularly
publish reports on us, we could lose visibility in the financial markets, which in turn could cause our stock price or trading
volume to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Except as described in any prospectus supplement, we currently
intend to use the net proceeds from the sale of the securities for general corporate purposes, including for research and development,
sales and marketing initiatives and general administrative expenses, working capital and capital expenditures. In addition, our
use of proceeds may include the repayment of debt or refinancing of indebtedness or the acquisition of complementary products or
companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have not determined the amount of net proceeds to be used
specifically for the foregoing purposes. As a result, our management will have broad discretion in the allocation of the net proceeds
and investors will be relying on the judgment of our management regarding the application of the proceeds of any sale of the securities.
Pending use of the net proceeds, we intend to invest the proceeds in a variety of capital preservation instruments, including short-term,
investment-grade, interest-bearing instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">When we offer a particular series of securities, we will describe
the intended use of the net proceeds from that offering in a prospectus supplement. The actual amount of net proceeds we spend
on a particular use will depend on many factors, including our future revenue growth, if any, our future capital expenditures and
the amount of cash required by our operations. Many of these factors are beyond our control. Therefore, we will retain broad discretion
in the use of the net proceeds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DILUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If you purchase shares of our common stock in this offering,
you will experience dilution to the extent of the difference between the price per share you pay in this offering and the net tangible
book value per share of our common stock immediately after this offering. Our net tangible book value as of December 31, 2015 was
approximately $2,612,522, or approximately $0.34 per share. Net tangible book value per share represents our total tangible assets
less total tangible liabilities, divided by the number of shares of common stock outstanding as of December 31, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">After giving effect to the assumed sale by us of $12,500,000
of our common stock in this offering at an assumed public offering price of $5.16 per share of our common stock (the last reported
sale price of our common stock on the Nasdaq Capital Market on May 2, 2016), and after deducting the estimated fees and commissions
and estimated offering expenses payable by us, our as adjusted net tangible book value as of December 31, 2015 would have been
approximately $14,637,522 or approximately $1.46 per share of common stock. This represents an immediate increase in net tangible
book value of approximately $1.12 per share to existing shareholders and an immediate dilution of approximately $3.70 per share
to new investors. The following table illustrates this per share dilution:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>Assumed public offering price per share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>$</TD><TD STYLE="text-align: right">5.16</TD>
    <TD>&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>Net tangible book value per share as of December 31, 2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.34</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>Increase in net tangible book value per share attributable to new investors</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">1.12</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; width: 68%">As adjusted net tangible book value per share as of December 31, 2015, after giving effect to this offering</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 13%">&nbsp;</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">$</TD><TD STYLE="width: 13%; border-bottom: Black 1pt solid; text-align: right">1.46</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Dilution per share to new investors in the offering</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3.70</TD>
    <TD>&nbsp;</TD>
    </TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have calculated the dilution discussed above in accordance
with Item 506 of Regulation S-K using the last reported sale price of our common stock on a date within five days of the date of
this prospectus. However, we are unable to issue common stock or securities convertible into or exchangeable for common stock at
a price per share below $6.30 absent the consent of certain of our investors. That price is higher than the price we used to calculate
the dilution information presented above. If you purchase shares of our common stock in this offering at a price of $6.30 per share
or more, you would experience more dilution than discussed above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The above discussion and table are based on 7,622,393 shares
of our common stock outstanding as of December 31, 2015 and excludes the following, as of that date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</td>
    <TD STYLE="width: 0.5in"><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">445,557 shares of common stock issuable upon exercise of outstanding stock options under our stock incentive plans at a weighted average exercise price of $10.89 per share;</font></td></tr>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,164,093 shares of common stock reserved for issuance under outstanding warrants with a weighted average exercise price of $6.68 per share;</font></td></tr>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">105,112 shares of common stock reserved for
    issuance under outstanding convertible notes, including accrued interest through  December 31, 2015, with a fixed conversion
    price of $5.60 per share;</font></td></tr>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,845 additional shares of common stock reserved for future issuance under our stock incentive plans.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES WE MAY OFFER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may offer shares of common stock, debt securities, or warrants
to purchase common stock or debt securities, or any combination of the foregoing, either individually or as units comprised of
one or more of the other securities. We may offer up to $12,500,000 of securities under this prospectus. If securities are offered
as units, we will describe the terms of the units in a prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DESCRIPTION OF CAPITAL STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our authorized capital consists of 30,000,000 shares of common
stock, par value $0.001 per share. As of May 3, 2016, there were issued and outstanding 7,622,393 shares of common stock. On April
14, 2015, we completed a 1-for-50 reverse stock split. Accordingly, our authorized common stock was reduced from 500,000,000 shares
to 10,000,000 shares, and each 50 shares of outstanding common stock held by stockholders were combined into one share of common
stock. All shares and per share amounts have been revised accordingly. On March 31, 2016, we amended our Articles of Incorporation
to increase our authorized common stock to 30,000,000 shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Common Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The holders of our common stock are entitled to one vote (or
consent) per share on all matters to be voted on by the stockholders. Holders of common stock are entitled to receive ratably such
dividends as may be declared by the Board of Directors out of funds legally available therefor. If we liquidate, dissolve or wind
up, holders of common stock are entitled to share ratably in all assets remaining after payment of all debts and other liabilities.
Holders of common stock have no preemptive, conversion or subscription rights. There are no redemption or sinking fund provisions
applicable to the common stock. All outstanding shares of common stock are, and all shares of common stock to be outstanding upon
completion of this offering will be, validly issued, fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Except as otherwise required by Nevada law, all stockholder
action is taken by the vote of a majority of common stock voting as a single class present at a meeting of stockholders at which
a quorum is present in person or by proxy. Stockholders representing a majority of the stock issued and outstanding, either in
person or by proxy, shall constitute a quorum at a meeting of stockholders; <I>provided</I>, <I>however</I>, that at any time during
which shares of our capital stock are listed for trading on The NASDAQ Stock Market LLC, stockholders representing not less than
thirty-three and one-third percent (33 1/3%) of the common voting stock issued and outstanding, either in person or by proxy, shall
constitute a quorum at a meeting of the holders of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Options and Warrants Convertible into Common Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of May 3, 2016, there were outstanding common share purchase
options and warrants entitling the holders to purchase 2,602,639 common shares at a weighted average exercise price of $7.40 per
share. This includes 26,105 warrants that are conditional upon the exercise of other warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth certain information relating
to the options outstanding and exercisable as of May 3, 2016:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD COLSPAN="9" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Options Outstanding</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD COLSPAN="5" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Options Exercisable</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Range of</font><br> <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise Prices</font></TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Number</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Outstanding</P></TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Weighted Average</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Remaining</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Life (Years)</P></TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Weighted Average</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Exercise</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Price</P></TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Number</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Outstanding</P></TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Weighted Average</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Exercise</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Price</P></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$3.80 - $9.50</font></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">190,547</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.70 years</font></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">6.03</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">140,414</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">5.91</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$10.50 - $12.50</font></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">163,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.39 years</font></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">12.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">163,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">12.50</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$18.00 - $20.50</font></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">85,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.02 years</font></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1pt; text-align: right">19.03</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">85,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1pt; text-align: right">19.03</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">438,547</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">388,414</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth certain information relating
to the warrants outstanding and exercisable as of May 3, 2016:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD COLSPAN="9" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Warrants Outstanding</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD COLSPAN="5" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Warrants Exercisable</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">Range of <BR>Exercise Prices</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Number</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Outstanding</P></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Weighted Average</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Remaining</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Life (Years)</P></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Weighted Average</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exercise Price</P></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Number</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Outstanding</P></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Weighted Average</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exercise Price</P></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 13%; text-align: center">$5.00 or Below</TD>
    <TD STYLE="width: 1%">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">515,533</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">2.78</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">2.63</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">515,533</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">2.63</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$5.20 - $9.00</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,351,632</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.85</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.46</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,351,632</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.46</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">$9.65 - $15.00</TD>
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">296,929</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">3.71</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1pt; text-align: right">14.70</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">296,929</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1pt; text-align: right">14.70</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,164,094</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,164,094</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Anti-Takeover Effects of Certain Provisions of Nevada Law
and Our Articles of Incorporation and Bylaws</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nevada Revised Statutes (&ldquo;NRS&rdquo;) 78.378 to 78.3793
contain anti-takeover provisions in certain circumstances whereby a person acquires a controlling interest in a Nevada corporation
(the &ldquo;Controlling Interest Law&rdquo;). This law generally provides that any person or entity that acquires 20% or more of
the outstanding voting shares of a publicly held Nevada corporation in the secondary public or private market will be denied voting
rights with respect to the acquired shares, unless a majority of the disinterested stockholders of the corporation elects to grant
such voting rights in whole or in part to the investor. Under the law, a person or entity acquires &quot;control shares&quot; whenever
it acquires shares that, but for the operation of the law, would bring its voting power to elect directors within any of the following
three ranges: (1) one-fifth or more but less than one-third, (2) one-third or more but less than a majority, or (3) a majority
or more.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This law defines an &quot;acquisition&quot; as the direct or
indirect acquisition of either ownership or voting power associated with issued and outstanding voting shares. A corporation's
articles of incorporation or bylaws may provide that the Controlling Interest Law does not apply to the corporation. Neither our
Articles of Incorporation nor our Bylaws exclude us from the application of the Controlling Interest Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">However, this law is applicable only to a Nevada corporation
(1) with 200 or more stockholders (100 of whom are both stockholders of record and residents of Nevada), and (2) that does business
in Nevada directly or through an affiliated corporation. At this time, we do not have 100 stockholders of record who are residents
of Nevada. Therefore, the provisions of the Controlling Interest Law do not currently apply to acquisitions of our shares and will
not until the number of our stockholders of record who are residents of Nevada exceeds 100. If the Controlling Interest Law becomes
applicable to us, its application may discourage companies or persons interested in acquiring a significant interest in or control
of us, regardless of whether such acquisition may be in the interest of our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, our authorized but unissued shares of common stock
are available for our Board of Directors to issue without stockholder approval. We may use these additional shares for a variety
of corporate purposes, including future public or private offerings to raise additional capital, corporate acquisitions and employee
benefit plans. The existence of our authorized but unissued shares of common stock could render more difficult or discourage an
attempt to obtain control of our company by means of a proxy contest, tender offer, merger or other transaction. Our authorized
but unissued shares may be used to delay, defer or prevent a tender offer or takeover attempt that a stockholder might consider
in its best interest, including those attempts that might result in a premium over the market price for the shares held by our
stockholders. The Board of Directors is also authorized to adopt, amend or repeal our Bylaws which could delay, defer or prevent
a change in control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Transfer Agent, Warrant Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our transfer agent and registrar for our common stock is Computershare
Investor Services, located at 350 Indiana Street, Suite 800, Golden, Colorado 80401.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DESCRIPTION OF DEBT SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following description, together with the additional information
we include in any applicable prospectus supplements or free writing prospectuses, summarizes the material terms and provisions
of the debt securities that we may offer under this prospectus. We may issue debt securities, in one or more series, as either
senior or subordinated debt or as senior or subordinated convertible debt. While the terms we have summarized below will apply
generally to any future debt securities we may offer under this prospectus, we will describe the particular terms of any debt securities
that we may offer in more detail in the applicable prospectus supplement or free writing prospectus. The terms of any debt securities
we offer under a prospectus supplement may differ from the terms we describe below. However, no prospectus supplement shall fundamentally
change the terms that are set forth in this prospectus or offer a security that is not registered and described in this prospectus
at the time of its effectiveness. As of the date of this prospectus, we have no outstanding registered debt securities. Unless
the context requires otherwise, whenever we refer to the &quot;indentures,&quot; we also are referring to any indenture or supplemental
indentures that specify the terms of a particular series of debt securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will issue any senior debt securities under the senior indenture
that we will enter into with the trustee named in the senior indenture. We will issue any subordinated debt securities under the
subordinated indenture that we will enter into with the trustee named in the subordinated indenture. We will file forms of these
documents, supplemental indentures and forms of debt securities containing the terms of the debt securities as exhibits to the
registration statement, of which this prospectus is a part, or they will be incorporated by reference from reports that we file
with the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The indentures will be qualified under the Trust Indenture Act
of 1939, as amended. We use the term &quot;trustee&quot; to refer to either the trustee under the senior indenture or the trustee
under the subordinated indenture, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following summaries of material provisions of the senior
debt securities, the subordinated debt securities and the indentures are subject to, and qualified in their entirety by reference
to, all of the provisions of the indenture applicable to a particular series of debt securities. We urge you to read the applicable
prospectus supplements and any applicable free writing prospectuses related to the debt securities that we may offer under this
prospectus, as well as the complete indentures that contain the terms of the debt securities. Except as we may otherwise indicate,
the terms of the senior indenture and the subordinated indenture will be identical.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The terms of each series of debt securities will be established
by or pursuant to a resolution of our Board of Directors and set forth or determined in the manner provided in an officers' certificate
or by a supplement indenture. Debt securities may be issued in separate series without limitation as to aggregate principal amount.
We may specify a maximum aggregate principal amount for the debt securities of any series. We will describe in the applicable
prospectus supplement the terms of the series of debt securities being offered, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in; text-align: left"><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>the title;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>the principal amount being offered, and if a series, the total
amount authorized and the total amount outstanding;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>any limit on the amount that may be issued;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>whether or not we will issue the series of debt securities
in global form, and, if so, the terms and who the depositary will be;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>the maturity date;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>whether and under what circumstances, if any, we will pay additional
amounts on any debt securities held by a person who is not a U.S. person for tax purposes, and whether we can redeem the debt securities
if we have to pay such additional amounts;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>the annual interest rate, which may be fixed or variable, or
the method for determining the rate and the date interest will begin to accrue, the dates interest will be payable and the regular
record dates for interest payment dates or the method for determining such dates;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>whether or not the debt securities will be secured or unsecured,
and the terms of any secured debt;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>the terms of the subordination of any series of subordinated
debt;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>the place where payments will be payable;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>restrictions on transfer, sale or other assignment, if any;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>our right, if any, to defer payment of interest and the maximum
length of any such deferral period;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>the date, if any, after which, and the price at which, we may,
at our option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions and the terms
of those redemption provisions;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>the date, if any, on which, and the price at which we are obligated,
pursuant to any mandatory sinking fund or analogous fund provisions or otherwise, to redeem, or at the holder's option, to purchase,
the series of debt securities and the currency or currency unit in which the debt securities are payable;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>whether the indenture will restrict our ability or the ability
of our subsidiaries to:</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#111;</FONT></TD>
    <TD>incur additional indebtedness;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&#111;</FONT></TD>
    <TD>issue additional securities;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&#111;</FONT></TD>
    <TD>create liens;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&#111;</FONT></TD>
    <TD>pay dividends or make distributions in respect of our capital
stock or the capital stock of our subsidiaries;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&#111;</FONT></TD>
    <TD>redeem capital stock;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&#111;</FONT></TD>
    <TD>place restrictions on our subsidiaries' ability to pay dividends,
make distributions or transfer assets;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&#111;</FONT></TD>
    <TD>make investments or other restricted payments;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&#111;</FONT></TD>
    <TD>sell or otherwise dispose of assets;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&#111;</FONT></TD>
    <TD>enter into sale-leaseback transactions;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&#111;</FONT></TD>
    <TD>engage in transactions with stockholders or affiliates;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&#111;</FONT></TD>
    <TD>issue or sell stock of our subsidiaries; or</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&#111;</FONT></TD>
    <TD>effect a consolidation or merger;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>whether the indenture will require us to maintain any interest
coverage, fixed charge, cash flow-based, asset-based or other financial ratios;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>a discussion of certain material or special U.S. federal income
tax considerations applicable to the debt securities;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>information describing any book-entry features;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>provisions for a sinking fund, purchase or other analogous
fund, if any;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>the applicability of the provisions in the indenture on discharge;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>whether the debt securities are to be offered at a price such
that they will be deemed to be offered at an &quot;original issue discount&quot; as defined in paragraph (a) of Section 1273 of
the Internal Revenue Code of 1986, as amended;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>the denominations in which we will issue the series of debt
securities, if other than denominations of $1,000 and any integral multiple thereof;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>the currency of payment of debt securities if other than U.S.
dollars and the manner of determining the equivalent amount in U.S. dollars; and</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>any other specific terms, preferences, rights or limitations
of, or restrictions on, the debt securities, including any additional events of default or covenants provided with respect to the
debt securities, and any terms that may be required by us or advisable under applicable laws or regulations.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Conversion or Exchange Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will set forth in the applicable prospectus supplement the
terms on which a series of debt securities may be convertible into or exchangeable for our common stock or other securities (including
securities of a third party). We will include provisions as to whether conversion or exchange is mandatory, at the option of the
holder or at our option. We may include provisions pursuant to which the number of shares of our common stock or other securities
(including securities of a third party) that the holders of the series of debt securities receive would be subject to adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Consolidation, Merger or Sale</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unless we provide otherwise in the prospectus supplement applicable
to a particular series of debt securities, the indentures will not contain any covenant that restricts our ability to merge or
consolidate, or sell, convey, transfer or otherwise dispose of all or substantially all of our assets. However, any successor to
or acquirer of such assets must assume all of our obligations under the indentures or the debt securities, as appropriate. If the
debt securities are convertible into or exchangeable for our other securities or securities of other entities, the person with
whom we consolidate or merge or to whom we sell all of our property must make provisions for the conversion of the debt securities
into securities that the holders of the debt securities would have received if they had converted the debt securities before the
consolidation, merger or sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Events of Default under the Indenture</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unless we provide otherwise in the prospectus supplement applicable
to a particular series of debt securities, the following will be events of default under the indentures with respect to any series
of debt securities that we may issue:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>if we fail to pay interest when due and payable and our failure
continues for 90 days and the time for payment has not been extended;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>if we fail to pay the principal, premium or sinking fund payment,
if any, when due and payable at maturity, upon redemption or repurchase or otherwise, and the time for payment has not been extended;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>if we fail to observe or perform any other covenant contained
in the debt securities or the indentures, other than a covenant specifically relating to another series of debt securities, and
our failure continues for 90 days after we receive notice from the trustee or we and the trustee receive notice from the holders
of at least 25% in aggregate principal amount of the outstanding debt securities of the applicable series; and</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>if specified events of bankruptcy, insolvency or reorganization
occur.</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will describe in each applicable prospectus supplement any
additional events of default relating to the relevant series of debt securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an event of default with respect to debt securities of any
series occurs and is continuing, other than an event of default specified in the last bullet point above, the trustee or the holders
of at least 25% in aggregate principal amount of the outstanding debt securities of that series, by notice to us in writing, and
to the trustee if notice is given by such holders, may declare the unpaid principal, premium, if any, and accrued interest, if
any, due and payable immediately. If an event of default specified in the last bullet point above occurs with respect to us, the
unpaid principal, premium, if any, and accrued interest, if any, of each issue of debt securities then outstanding shall be due
and payable without any notice or other action on the part of the trustee or any holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The holders of a majority in principal amount of the outstanding
debt securities of an affected series may waive any default or event of default with respect to the series and its consequences,
except defaults or events of default regarding payment of principal, premium, if any, or interest, unless we have cured the default
or event of default in accordance with the indenture. Any waiver shall cure the default or event of default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subject to the terms of the indentures, if an event of default
under an indenture shall occur and be continuing, the trustee will be under no obligation to exercise any of its rights or powers
under such indenture at the request or direction of any of the holders of the applicable series of debt securities, unless such
holders have offered the trustee reasonable indemnity or security satisfactory to it against any loss, liability or expense. The
holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time,
method and place of conducting any proceeding for any remedy available to the trustee, or exercising any trust or power conferred
on the trustee, with respect to the debt securities of that series, provided that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>the direction so given by the holder is not in conflict with
any law or the applicable indenture; and</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>subject to its duties under the Trust Indenture Act of 1939,
as amended, the trustee need not take any action that might involve it in personal liability or might be unduly prejudicial to
the holders not involved in the proceeding.</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The indentures will provide that if an event of default has
occurred and is continuing, the trustee will be required in the exercise of its powers to use the degree of care that a prudent
person would use in the conduct of its own affairs. The trustee, however, may refuse to follow any direction that conflicts with
law or the indenture, or that the trustee determines is unduly prejudicial to the rights of any other holder of the relevant series
of debt securities, or that would involve the trustee in personal liability. Prior to taking any action under the indentures,
the trustee will be entitled to indemnification against all costs, expenses and liabilities that would be incurred by taking or
not taking such action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A holder of the debt securities of any series will have the
right to institute a proceeding under the indentures, appoint a receiver or trustee, or seek other remedies only if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>the holder has given written notice to the trustee of a continuing
event of default with respect to that series;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>the holders of at least 25% in aggregate principal amount of
the outstanding debt securities of that series have made written request, and such holders have offered reasonable indemnity to
the trustee or security satisfactory to it against any loss, liability or expense or to be incurred in compliance with instituting
the proceeding as trustee; and</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>the trustee does not institute the proceeding, and does not
receive from the holders of a majority in aggregate principal amount of the outstanding debt securities of that series other conflicting
directions within 90 days after the notice, request and offer.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These limitations do not apply to a suit instituted by a holder
of debt securities if we default in the payment of the principal, premium, if any, or interest on, the debt securities, or other
defaults that may be specified in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will periodically file statements with the trustee regarding
our compliance with specified covenants in the indentures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The indentures will provide that if a default occurs and is
continuing and is actually known to a responsible officer of the trustee, the trustee must mail to each holder notice of the default
within the earlier of 90 days after it occurs and 30 days after it is known by a responsible officer of the trustee or written
notice of it is received by the trustee, unless such default has been cured or waived. Except in the case of a default in the payment
of principal or premium of or interest on any debt security or certain other defaults specified in an indenture, the trustee shall
be protected in withholding such notice if and so long as the Board of Directors or a trust committee of directors, or responsible
officers of the trustee, in good faith determine that withholding notice is in the best interests of holders of the relevant series
of debt securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Modification of Indenture; Waiver</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subject to the terms of the indenture for any series of debt
securities that we may issue, we and the trustee may change an indenture without the consent of any holders with respect to the
following specific matters:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>to fix any ambiguity, defect or inconsistency in the indenture;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>to comply with the provisions described above under &quot;Description
of Debt Securities - Consolidation, Merger or Sale&quot;;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>to comply with any requirements of the Commission in connection
with the qualification of any indenture under the Trust Indenture Act of 1939, as amended;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>to add to, delete from or revise the conditions, limitations,
and restrictions on the authorized amount, terms, or purposes of issue, authentication and delivery of debt securities, as set
forth in the indenture;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>to provide for the issuance of and establish the form and terms
and conditions of the debt securities of any series as provided under &quot;Description of Debt Securities - General,&quot; to
establish the form of any certifications required to be furnished pursuant to the terms of the indenture or any series of debt
securities, or to add to the rights of the holders of any series of debt securities;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>to evidence and provide for the acceptance of appointment hereunder
by a successor trustee;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>to provide for uncertificated debt securities and to make all
appropriate changes for such purpose;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>to add to our covenants such new covenants, restrictions, conditions
or provisions for the benefit of the holders, to make the occurrence, or the occurrence and the continuance, of a default in any
such additional covenants, restrictions, conditions or provisions an event of default or to surrender any right or power conferred
to us in the indenture; or</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>to change anything that does not adversely affect the interests
of any holder of debt securities of any series in any material respect.</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">In addition, under the indentures, the rights of holders of a series of debt securities
may be changed by us and the trustee with the written consent of the holders of at least a majority in aggregate principal amount
of the outstanding debt securities of each series that is affected. However, subject to the terms of the indenture for any series
of debt securities that we may issue or otherwise provided in the prospectus supplement applicable to a particular series of debt
securities, we and the trustee may only make the following changes with the consent of each holder of any outstanding debt securities
affected:</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>to extend the stated maturity of the series of debt securities;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>to reduce the principal amount, reduce the rate of or extend
the time of payment of interest, or reduce any premium payable upon the redemption or repurchase of any debt securities; or</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>to reduce the percentage of debt securities, the holders of
which are required to consent to any amendment, supplement, modification or waiver.</TD></TR>
</TABLE>

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0"><B></B></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Discharge</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each indenture will provide that, subject to the terms of the
indenture and any limitation otherwise provided in the prospectus supplement applicable to a particular series of debt securities,
we can elect to be discharged from our obligations with respect to one or more series of debt securities, except for specified
obligations, including obligations to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>register the transfer or exchange of debt securities of the
series;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>replace stolen, lost or mutilated debt securities of the series;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>maintain paying agencies;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>hold monies for payment in trust;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>recover excess money held by the trustee;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>compensate and indemnify the trustee; and</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><font style="font-family: Symbol; font-size: 10pt">&middot;</font></TD>
    <TD>appoint any successor trustee.</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>



<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In order to exercise our rights to be discharged, we must deposit
with the trustee money or government obligations sufficient to pay all the principal of and any premium and interest on the debt
securities of the series on the dates payments are due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Denominations, Registrations and Transfer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unless an accompanying prospectus supplement states otherwise,
debt securities will be represented by one or more global certificates registered in the name of a nominee for The Depository Trust
Company, or DTC. In such case, each holder's beneficial interest in the global securities will be shown on the records of DTC and
transfers of beneficial interests will only be effected through DTC's records.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A holder of debt securities may only exchange a beneficial interest
in a global security for certificated securities registered in the holder's name if:</P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD>we deliver to the trustee notice from DTC that it is unwilling
or unable to continue to act as depository or that it is no longer a clearing agency registered under the Exchange Act and, in
either case, a successor depositary is not appointed by us within 120 days after the date of such notice from DTC;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD>we in our sole discretion determine that the debt securities
(in whole but not in part) should be exchanged for definitive debt securities and deliver a written notice to such effect to the
trustee; or</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD>there has occurred and is continuing a default or event of
default with respect to the debt securities.</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If debt securities are issued in certificated form, they will
only be issued in the minimum denomination specified in the accompanying prospectus supplement and integral multiples of such denomination.
Transfers and exchanges of such debt securities will only be permitted in such minimum denomination. Transfers of debt securities
in certificated form may be registered at the trustee's corporate office or at the offices of any paying agent or trustee appointed
by us under the indentures. Exchanges of debt securities for an equal aggregate principal amount of debt securities in different
denominations may also be made at such locations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Information Concerning the Trustee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The trustee or trustees under the indentures will be named in
any applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The trustee, other than during the occurrence and continuance
of an event of default under an indenture, will undertake to perform only those duties as are specifically set forth in the applicable
indenture and will be under no obligation to exercise any of the powers given it by the indentures at the request of any holder
of debt securities unless it is offered reasonable security and indemnity against the costs, expenses and liabilities that it might
incur. However, upon an event of default under an indenture, the trustee must use the same degree of care as a prudent person would
exercise or use in the conduct of his or her own affairs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Payment and Paying Agents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unless we otherwise indicate in the applicable prospectus supplement,
we will make payment of the interest on any debt securities on any interest payment date to the person in whose name the debt securities,
or one or more predecessor securities, are registered at the close of business on the regular record date for the interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will pay principal of and any premium and interest on the
debt securities of a particular series at the office of the paying agents designated by us, except that, unless we otherwise indicate
in the applicable prospectus supplement, we will make interest payments by check that we will mail to the holder or by wire transfer
to certain holders. Unless we otherwise indicate in the applicable prospectus supplement, we will designate the corporate trust
office of the trustee as our sole paying agent for payments with respect to debt securities of each series. We will name in the
applicable prospectus supplement any other paying agents that we initially designate for the debt securities of a particular series.
We will maintain a paying agent in each place of payment for the debt securities of a particular series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All money we pay to a paying agent or the trustee for the payment
of the principal of or any premium or interest on any debt securities that remains unclaimed at the end of two years after such
principal, premium or interest has become due and payable will be repaid to us, and the holder of the debt security thereafter
may look only to us for payment thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Governing Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The indentures and the debt securities will be governed by and
construed in accordance with the laws of the State of California, except to the extent that the Trust Indenture Act of 1939, as
amended, is applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Ranking Debt Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The subordinated debt securities will be unsecured and will
be subordinate and junior in priority of payment to certain other indebtedness to the extent described in a prospectus supplement.
The subordinated indenture will not limit the amount of subordinated debt securities that we may issue. It also will not limit
us from issuing any other secured or unsecured debt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The senior debt securities will be unsecured and will rank equally
in right of payment to all our other senior unsecured debt. The senior indenture will not limit the amount of senior debt securities
that we may issue. It also will not limit us from issuing any other secured or unsecured debt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DESCRIPTION OF WARRANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following description, together with the additional information
we may include in any applicable prospectus supplements and free writing prospectuses, summarizes the material terms and provisions
of the warrants that we may offer under this prospectus, which may consist of warrants to purchase common stock or debt securities
and may be issued in one or more series. Warrants may be offered independently or together with common stock or debt securities
offered by any prospectus supplement, and may be attached to or separate from those securities. While the terms we have summarized
below will apply generally to any warrants that we may offer under this prospectus, we will describe the particular terms of any
series of warrants that we may offer in more detail in the applicable prospectus supplement and any applicable free writing prospectus.
The terms of any warrants offered under a prospectus supplement may differ from the terms described below. However, no prospectus
supplement will fundamentally change the terms that are set forth in this prospectus or offer a security that is not registered
and described in this prospectus at the time of its effectiveness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will issue the warrants under a warrant agreement that we
will enter into with a warrant agent to be selected by us. The warrant agent will act solely as an agent of ours in connection
with the warrants and will not act as an agent for the holders or beneficial owners of the warrants. We will file as exhibits to
the registration statement of which this prospectus is a part, or will incorporate by reference from a current report on Form 8-K
that we file with the Commission, the form of warrant agreement, including a form of warrant certificate, that describes the terms
of the particular series of warrants we are offering before the issuance of the related series of warrants. The following summaries
of material provisions of the warrants and the warrant agreements are subject to, and qualified in their entirety by reference
to, all the provisions of the warrant agreement and warrant certificate applicable to a particular series of warrants. We urge
you to read the applicable prospectus supplement and any applicable free writing prospectus related to the particular series of
warrants that we sell under this prospectus, as well as the complete warrant agreements and warrant certificates that contain the
terms of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will describe in the applicable prospectus supplement the
terms relating to a series of warrants, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD>the offering price and aggregate number of warrants offered;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD>the currency for which the warrants may be purchased;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD>if applicable, the designation and terms of the securities
with which the warrants are issued and the number of warrants issued with each such security or each principal amount of such security;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD>if applicable, the date on and after which the warrants and
the related securities will be separately transferable;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD>in the case of warrants to purchase debt securities, the principal
amount of debt securities purchasable upon exercise of one warrant and the price at, and currency in, which this principal amount
of debt securities may be purchased upon such exercise;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD>in the case of warrants to purchase common stock, the number
of shares of common stock purchasable upon the exercise of one warrant and the price at which these shares may be purchased upon
such exercise;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD>the effect of any merger, consolidation, sale or other disposition
of our business on the warrant agreements and the warrants;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD>the terms of any rights to redeem or call the warrants;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD>any provisions for changes to or adjustments in the exercise
price or number of securities issuable upon exercise of the warrants;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD>the dates on which the right to exercise the warrants will
commence and expire;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD>the manner in which the warrant agreements and warrants may
be modified;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD>U.S. federal income tax consequences of holding or exercising
the warrants;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD>the terms of the securities issuable upon exercise of the warrants;
and</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD>any other specific terms, preferences, rights or limitations of or restrictions on the warrants.</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Before exercising their warrants, holders of warrants will not
have any of the rights of holders of the securities purchasable upon such exercise, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD>in the case of warrants to purchase debt securities, the right
to receive payments of principal of, or premium, if any, or interest on, the debt securities purchasable upon exercise or to enforce
covenants in the applicable indenture; or</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD>in the case of warrants to purchase common stock, the right
to receive dividends, if any, or payments upon our liquidation, dissolution or winding up, or to exercise voting rights, if any.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exercise of Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each warrant will entitle the holder to purchase the securities
that we specify in the applicable prospectus supplement at the exercise price that we describe in the applicable prospectus supplement.
Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants at any time
up to the specified time on the expiration date that we set forth in the applicable prospectus supplement. After the close of business
on the expiration date, unexercised warrants will become void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Holders of the warrants may exercise the warrants by delivering
the warrant certificate representing the warrants to be exercised together with specified information, and paying the required
amount to the warrant agent in immediately available funds, as provided in the applicable prospectus supplement. We will set forth
on the reverse side of the warrant certificate and in the applicable prospectus supplement the information that the holder of the
warrant will be required to deliver to the warrant agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Upon receipt of the required payment and the warrant certificate
properly completed and duly executed at the corporate trust office of the warrant agent or any other office indicated in the applicable
prospectus supplement, we will issue and deliver the securities purchasable upon such exercise. If fewer than all of the warrants
represented by the warrant certificate are exercised, we will issue a new warrant certificate for the remaining amount of warrants.
If we so indicate in the applicable prospectus supplement, holders of the warrants may surrender securities as all or part of the
exercise price for warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Enforceability of Rights by Holders of Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each warrant agent will act solely as our agent under the applicable
warrant agreement and will not assume any obligation or relationship of agency or trust with any holder of any warrant. A single
bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have no duty or responsibility
in case of any default by us under the applicable warrant agreement or warrant, including any duty or responsibility to initiate
any proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may, without the consent of the related
warrant agent or the holder of any other warrant, enforce by appropriate legal action its right to exercise, and receive the securities
purchasable upon exercise of, its warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DESCRIPTION OF UNITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following description, together with the additional information
we may include in any applicable prospectus supplements, summarizes the material terms and provisions of the units that we may
offer under this prospectus. While the terms we have summarized below will apply generally to any units that we may offer under
this prospectus, we will describe the particular terms of any series of units in more detail in the applicable prospectus supplement.
The terms of any units offered under a prospectus supplement may differ from the terms described below. However, no prospectus
supplement will fundamentally change the terms that are set forth in this prospectus or offer a security that is not registered
and described in this prospectus at the time of its effectiveness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will file as exhibits to the registration statement of which
this prospectus is a part, or will incorporate by reference from a current report on Form 8-K that we file with the Commission,
the form of unit agreement that describes the terms of the series of units we are offering, and any supplemental agreements, before
the issuance of the related series of units. The following summaries of material terms and provisions of the units are subject
to, and qualified in their entirety by reference to, all the provisions of the unit agreement and any supplemental agreements applicable
to a particular series of units. We urge you to read the applicable prospectus supplements related to the particular series of
units that we sell under this prospectus, as well as the complete unit agreement and any supplemental agreements that contain the
terms of the units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may issue units comprised of one or more debt securities,
shares of common stock and warrants in any combination. Each unit will be issued so that the holder of the unit is also the holder
of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each included
security. The unit agreement under which a unit is issued may provide that the securities included in the unit may not be held
or transferred separately, at any time or at any time before a specified date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will describe in the applicable prospectus supplement the
terms of the series of units, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD>the designation and terms of the units and of the securities
comprising the units, including whether and under what circumstances those securities may be held or transferred separately;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD>any provisions of the governing unit agreement that differ
from those described below; and</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD>any provisions for the issuance, payment, settlement, transfer
or exchange of the units or of the securities comprising the units.</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">The provisions described in this section, as well as those described under &quot;Description
of Capital Stock,&quot; &quot;Description of Debt Securities&quot; and &quot;Description of Warrants&quot; will apply to each
unit and to any common stock, debt security or warrant included in each unit, respectively.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Issuance in Series</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may issue units in such amounts and in numerous distinct
series as we determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Enforceability of Rights by Holders of Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each unit agent will act solely as our agent under the applicable
unit agreement and will not assume any obligation or relationship of agency or trust with any holder of any unit. A single bank
or trust company may act as unit agent for more than one series of units. A unit agent will have no duty or responsibility in case
of any default by us under the applicable unit agreement or unit, including any duty or responsibility to initiate any proceedings
at law or otherwise, or to make any demand upon us. Any holder of a unit may, without the consent of the related unit agent or
the holder of any other unit, enforce by appropriate legal action its rights as holder under any security included in the unit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We, the unit agents and any of their agents may treat the registered
holder of any unit certificate as an absolute owner of the units evidenced by that certificate for any purpose and as the person
entitled to exercise the rights attaching to the units so requested, despite any notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may sell the securities being offered hereby in one or more
of the following ways from time to time:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD>through agents to the public or to investors;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD>to underwriters for resale to the public or to investors;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD>directly to investors; or</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD>through a combination of any of these methods of sale.</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may sell the securities from time to time in one or more
transactions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD>at a fixed price or prices, which may be changed from time
to time;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD>at market prices prevailing at the times of sale;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD>at prices related to such prevailing market prices; or</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD>at negotiated prices.</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will set forth in a prospectus supplement the terms of that
particular offering of securities, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD>the name or names of any agents or underwriters;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD>the purchase price of the securities being offered and the
proceeds we will receive from the sale;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD>any over-allotment options under which underwriters may purchase
additional securities from us;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD>any agency fees or underwriting discounts and other items constituting
agents' or underwriters' compensation;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD>any initial public offering price;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD>any discounts or concessions allowed or reallowed or paid to
dealers; and</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD>any securities exchanges or markets on which such securities
may be listed.</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Agents, Underwriters, and Direct Sales</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may designate agents who agree to use their reasonable efforts
to solicit purchases of our securities for the period of their appointment or to sell our securities on a continuing basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If we use underwriters for a sale of securities, the underwriters
will acquire the securities for their own account. The underwriters may resell the securities in one or more transactions, including
negotiated transactions, at a fixed public offering price or at varying prices determined at the time of sale. The obligations
of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable underwriting agreement.
The underwriters will be obligated to purchase all the securities of the series offered if they purchase any of the securities
of that series. We may change from time to time any initial public offering price and any discounts or concessions the underwriters
allow or re-allow or pay to dealers. We may use underwriters with whom we have a material relationship. We will describe the nature
of any such relationship in any prospectus supplement naming any such underwriter. Only underwriters we name in the prospectus
supplement are underwriters of the securities offered by the prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Underwriters, dealers and agents that participate in the distribution
of the securities may be underwriters as defined in the Securities Act, and any discounts or commissions they receive from us and
any profit on their resale of the securities may be treated as underwriting discounts and commissions under the Securities Act.
We will identify in the applicable prospectus supplement any underwriters, dealers or agents and will describe their compensation.
We may have agreements with the underwriters, dealers and agents to indemnify them against specified civil liabilities, including
liabilities under the Securities Act. Underwriters, dealers and agents may engage in transactions with or perform services for
us in the ordinary course of their businesses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may also sell securities directly to one or more purchasers
without using underwriters or agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Trading Markets and Listing of Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unless otherwise specified in the applicable prospectus supplement,
each class or series of securities will be a new issue with no established trading market, other than our common stock, which is
listed on the Nasdaq Capital Market. We may elect to list any other class or series of securities on any exchange or market, but
we are not obligated to do so. The listing of our common stock on the Nasdaq Capital Market does not ensure the listing of any
other class of our securities on that or any other exchange or market in the future. It is possible that one or more underwriters
may make a market in a class or series of securities, but the underwriters will not be obligated to do so and may discontinue any
market making at any time without notice. We cannot give any assurance as to the liquidity of the trading market for any of the
securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Stabilization Activities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any underwriter may engage in overallotment, stabilizing transactions,
short covering transactions and penalty bids in accordance with Regulation M under the Exchange Act. Overallotment involves sales
in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying
security so long as the stabilizing bids do not exceed a specified maximum. Short covering transactions involve purchases of the
securities in the open market after the distribution is completed to cover short positions. Penalty bids permit the underwriters
to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a covering transaction
to cover short positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced,
the underwriters may discontinue any of these activities at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Passive Market Making</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any underwriters who are qualified market makers on the Nasdaq
Capital Market may engage in passive market making transactions in the securities on the Nasdaq Capital Market in accordance with
Rule 103 of Regulation M, during the business day prior to the pricing of the offering, before the commencement of offers or sales
of the securities. Passive market makers must comply with applicable volume and price limitations and must be identified as passive
market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid
for such security. If all independent bids are lowered below the passive market maker's bid, however, the passive market maker's
bid must then be lowered when certain purchase limits are exceeded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left">The consolidated financial statements of Aethlon
Medical, Inc. as of March 31, 2015 and 2014 and for each of the years in the two-year period ended March 31, 2015 have been audited
by Squar Milner LLP (formerly Squar, Milner, Peterson, Miranda &amp; Williamson, LLP), an independent registered public accounting
firm, as stated in their report thereon and incorporated by reference in this prospectus and registration statement in reliance
upon such report and upon the authority of such firm as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Raines Feldman LLP has passed upon the validity of the securities
offered by this prospectus. Jennifer A. Post, Esq., a partner of the firm, owns approximately 16,000 shares of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION INCORPORATED BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus is part of a registration statement on Form
S-3. The Commission allows this filing to &quot;incorporate by reference&quot; information that we previously have filed with the
Commission. This means we can disclose important information to you by referring you to other documents that we have filed with
the Commission. The information that is incorporated by reference is considered part of this prospectus, and information that we
file later will automatically update and may supersede this information. For further information about our company and the securities
being offered, you should refer to the registration statement and the following documents that are incorporated by reference:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr>
    <TD STYLE="width: 0.5in">&nbsp;</td>
    <TD STYLE="vertical-align: top; width: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT> </font></td>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our Annual Report on Form 10-K for the fiscal year ended March
        31, 2015, filed with the Commission on June 26, 2015, as amended on July 13, 2015;</P></td></tr>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<tr>
    <TD>&nbsp;</td>
    <TD STYLE="vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></font></td>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our Quarterly Reports on Form 10-Q for the quarter ended June
        30, 2015, filed with the Commission on August 13, 2015, for the quarter ended September 30, 2015, filed with the Commission on
        November 16, 2015, and for the quarter ended December 31, 2015, filed with the Commission on February 4, 2016, respectively;</P></td></tr>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<tr>
    <TD>&nbsp;</td>
    <TD STYLE="vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT> </font></td>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our Current Reports on Form 8-K filed with the Commission on
        April 7, 2015, April 9, 2015, April 14, 2015, April 15, 2015, June 9, 2015, June 15, 2015, June 16, 2015, June 18, 2015, June 24,
        2015, June 26, 2015, July 8, 2015, September 10, 2015, September 28, 2015, October 22, 2015, October 29, 2015, November 12, 2015,
        February 16, 2016, and March 30, 2016, respectively;</P></td></tr>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<tr>
    <TD>&nbsp;</td>
    <TD STYLE="vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></font></td>
    <TD STYLE="vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Definitive Proxy Statement on Schedule 14A filed with the Commission on February 23, 2016;</font></td></tr>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<tr>
    <TD>&nbsp;</td>
    <TD STYLE="vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT> </font></td>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All other reports filed by us pursuant to Section 13(a) or 15(d)
        of the Exchange Act since the end of the fiscal year covered by the annual report referred to above; and</P></td></tr>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<tr>
    <TD>&nbsp;</td>
    <TD STYLE="vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></font></td>
    <TD STYLE="vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The description of our common stock contained in our registration statement on Form 8-A filed with the Commission on July 8, 2015, including any amendments or reports filed for the purpose of updating such description.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All documents filed by us subsequent to those listed above with
the Commission pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act following the date of filing of the registration
statement of which this prospectus is a part and prior to the termination of the offering, shall be deemed to be incorporated by
reference into this prospectus and to be a part hereof from the date of filing of such documents (all of such documents, and the
documents enumerated above. The information relating to our company contained in this prospectus does not purport to be comprehensive
and should be read together with the information contained in the incorporated documents. Any statement contained in a document
incorporated by reference herein shall be deemed to be modified or superseded for purposes of this prospectus to the extent that
a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference
herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified
or superseded, to constitute a part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You may request a copy of all documents that are incorporated
by reference in this prospectus by writing or telephoning us at the following address and number: Aethlon Medical, Inc., 9635 Granite
Ridge Drive, Suite 100 San Diego, California 92123, (858) 459-7800. We will provide copies of all documents requested (not including
exhibits to those documents, unless the exhibits are specifically incorporated by reference into those documents or this prospectus)
without charge.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>You should rely only on the information provided in and incorporated
by reference into this prospectus or any prospectus supplement. We have not authorized anyone else to provide you with different
information. You should not assume that the information in this prospectus or any prospectus supplement is accurate as of any date
other than the date on the front cover of these documents.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus is part of a registration statement on Form
S-3 filed with the Commission under the Securities Act. This prospectus does not contain all the information set forth in the registration
statement because certain information has been incorporated into the registration statement by reference in accordance with the
rules and regulations of the Commission. Please review the documents incorporated by reference for a more complete description
of the matters to which such documents relate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are a reporting company under the Exchange Act, and we file
annual, quarterly and current reports and other information with the Commission. The public may read and copy any materials that
we file with the Commission at its Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. The public may obtain information
on the operation of the Public Reference Room by calling the Commission at 1-800-SEC-0330. The Commission maintains an Internet
site at http://www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers that
file electronically with the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our website address is www.aethlonmedical.com. Our website and
the information contained on our website are not incorporated into this prospectus or the registration statement of which it forms
a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Aethlon Medical, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>$12,500,000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock<BR>
Debt Securities<BR>
Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>__________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>_________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>, 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 14. Other Expenses of Issuance and Distribution</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth the estimated expenses, other
than the underwriting discounts and commissions, we expect to incur in connection with this offering. All amounts shown are estimates
except for the Securities and Exchange Commission registration fee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nature of Expense</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 83%; text-align: left">Securities and Exchange Commission registration fee</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">1,258.75</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Legal fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</font></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Accounting fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</font></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Transfer agent and trustee fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</font></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Printing expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</font></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Miscellaneous expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</font></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* The amount of securities and number of offerings are indeterminable
at this time. Accordingly, the expenses cannot be estimated at this time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 15. Indemnification of Directors and Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Nevada Law.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are incorporated in Nevada. Subsection 1 of Section 78.7502
of the Nevada Revised Statutes empowers a corporation to indemnify any person who was or is a party or is threatened to be made
a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative
(other than an action by or in the right of the corporation) by reason of the fact that he is or was a director, officer, employee
or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of
another corporation or other enterprise, against expenses (including attorneys&rsquo; fees), judgments, fines and amounts paid
in settlement actually and reasonably incurred by him in connection with such action, suit or proceeding if he is not liable pursuant
to Section 78.138 of the Nevada Revised Statutes or if he acted in good faith and in a manner he reasonably believed to be in or
not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable
cause to believe his conduct was unlawful. Subsection 7 of Section 78.138 provides that, with certain exceptions, a director or
officer is not individually liable to the corporation or its stockholders or creditors for any damages as a result of any act or
failure to act in his capacity as a director or officer unless it is proven that (i) his act or failure to act constituted a breach
of his fiduciary duties as a director or officer, and (ii) his breach of those duties involved intentional misconduct, fraud or
a knowing violation of the law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subsection 2 of Section 78.7502 empowers
a corporation to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed
action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that such person
acted in any of the capacities set forth above against expenses, including amounts paid in settlement and attorneys&rsquo; fees
actually and reasonably incurred by him in connection with the defense or settlement of such action or suit if he acted under similar
standards, except that no indemnification may be made in respect of any claim, issue or matter as to which such person shall have
been adjudged by a court of competent jurisdiction to be liable to the corporation or for amounts paid in settlement to the corporation,
unless and only to the extent that the court in which such action or suit was brought or other court of competent jurisdiction
determines that, in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such
expenses as the court deems proper.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Section 78.7502 further provides that to the extent a director
or officer of a corporation has been successful in the defense of any action, suit or proceeding referred to in subsections (1)
and (2) thereof, or in the defense of any claim, issue or matter therein, he shall be indemnified against expenses (including attorneys&rsquo;
fees) actually and reasonably incurred by him in connection therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subsection 1 of Section 78.751 provides that any discretionary
indemnification pursuant to Section 78.7502, unless ordered by a court or advanced pursuant to Subsection 2 of Section 78.751,
may be made by a corporation only as authorized in the specific case upon a determination that indemnification of the indemnified
person is proper in the circumstances. Such determination must be made (a) by the stockholders, (b) by the board of directors by
majority vote of a quorum consisting of directors who were not parties to the action, suit or proceeding, (c) if a majority vote
of a quorum of such disinterested directors so orders, by independent legal counsel in a written opinion, or (d) by independent
legal counsel in a written opinion if a quorum of such disinterested directors cannot be obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 42; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subsection 2 of Section 78.751 provides that a corporation's
articles of incorporation or bylaws or an agreement made by the corporation may require the corporation to pay the expenses of
officers and directors incurred in defending a civil or criminal action, suit or proceeding as such expenses are incurred and in
advance of the final disposition, upon receipt by the corporation of an undertaking by or on behalf of the officer or director
to repay the amount if it is ultimately determined by a court of competent jurisdiction that he is not entitled to be indemnified
by the corporation. The provisions of that subsection do not affect any rights to advancement of expenses to which corporate personnel
other than officers and directors may be entitled under contract or otherwise by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subsection 3 of Section 78.751 of the Nevada Revised Statutes
provides that the indemnification provided for by Section 78.7502 and advancement of expenses authorized in or ordered by a court
pursuant to Section 78.751 shall not be deemed exclusive or exclude any other rights to which the indemnified party may be entitled
for either an action in his official capacity or in another capacity while holding his office (except that indemnification will
generally not be available to a person if a final adjudication establishes that his acts or omissions involved intentional misconduct,
fraud or a knowing violation of the law and were material to the cause of action) and that the indemnification shall continue as
to directors, officers, employees or agents who have ceased to hold such positions, and to their heirs, executors and administrators.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Section 78.752 empowers the corporation to purchase and maintain
insurance on behalf of a director, officer, employee or agent of the corporation against any liability asserted against him or
incurred by him in any such capacity or arising out of his status as such whether or not the corporation would have the power to
indemnify him against such liabilities under Section 78.7502.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>By-Laws.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;<I> </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our by-laws provide for the elimination of the personal liability
of our officers, directors, corporate employees and agents to the fullest extent permitted by the provisions of the Nevada Law.
Under such provisions, we shall indemnify a director or officer (and may indemnify a corporate employee or agent) who in his capacity
as such is made, or threatened to be made, party to any suit or proceeding, if it is determined that such person acted in good
faith and in a manner he reasonably believed to be in or not opposed to the best interests of our company and, with respect to
any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Liability Insurance.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;<I> </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We maintain directors&rsquo; and officers&rsquo; liability insurance
covering our directors and officers against expenses and liabilities arising from certain actions to which they may become subject
by reason of having served in such role, including insurance for claims against these persons brought under securities laws. Such
insurance is subject to the coverage amounts, exceptions, deductibles and other conditions set forth in the policy as in effect
at the time of a claim, if any. We can give no assurance that we will maintain liability insurance for our directors and officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Public Policy Limitations.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;<I> </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Insofar as indemnification for liabilities arising under the
Securities Act of 1933, as amended, may be permitted to our directors, officers and controlling persons pursuant to the foregoing
provisions, or otherwise, we have been advised that in the opinion of the Securities and Exchange Commission such indemnification
is against public policy as expressed in the Securities Act of 1933, as amended, and is, therefore, unenforceable. In the event
that a claim for indemnification against such liabilities (other than the payment by us of expenses incurred or paid by one of
our directors, officers or controlling persons in the successful defense of any action, suit or proceeding) is asserted by such
director, officer or controlling person in connection with the securities being registered, we will, unless in the opinion of our
counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether
such indemnification by us is against public policy as expressed in the Securities Act of 1933, as amended, and will be governed
by the final adjudication of such issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 16. Exhibits and Financial Statement Schedules</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Reference is made to the Exhibit Index attached to this registration
statement, which is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 17. Undertakings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a) The undersigned registrant hereby undertakes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(1) To file, during any period in which offers or
sales are being made, a post-effective amendment to this registration statement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">(i) To include any prospectus required by Section 10(a)(3)
of the Securities Act of 1933;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">(ii) To reflect in the prospectus any facts or events
arising after the effective date of the registration statement (or the most recent post- effective amendment thereof) which, individually
or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding
the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would
not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be
reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume
and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the &quot;Calculation of
Registration Fee&quot; table in the effective registration statement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">(iii) To include any material information with respect
to the plan of distribution not previously disclosed in the registration statement or any material change to such information in
the registration statement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Provided, however,</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">that paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii)
do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports
filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange
Act of 1934 that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant
to Rule 424(b) that is part of the registration statement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(2) That, for the purpose of determining any liability
under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating
to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial <I>bona fide</I>
offering thereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(3) To remove from registration by means of a post-effective
amendment any of the securities being registered which remain unsold at the termination of the offering;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(4) That, for the purpose of determining liability
under the Securities Act of 1933 to any purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">(A) Each prospectus filed by the registrant pursuant
to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part
of and included in the registration statement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">(B) Each prospectus required to be filed
pursuant to Rule 424(b)(2), (b)(5) or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an
offering made pursuant to Rule 415(a)(1)(i), (vii) or (x) for the purpose of providing the information required by Section
10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the
earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of
securities in the offering described in prospectus. As provided in Rule 430B, for liability purposes of the issuer and any
person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration
statement relating to the securities in the registration statement to which the prospectus relates, and the offering of such
securities at that time shall be deemed to be the initial bona fide offering thereof. <I>Provided, however</I>, that no
statement made in a registration statement or prospectus that is part of the registration statement or made in a document
incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the
registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or
modify any statement that was made in the registration statement or prospectus that was part of the registration statement or
made in any such document immediately prior to such effective date; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(5) That, for the purpose of determining liability
of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned
registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement,
regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such
purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will
be considered to offer or sell such securities to such purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">(i) Any preliminary prospectus or prospectus of the
undersigned registrant relating to the offering required to be filed pursuant to Rule 424;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">(ii) Any free writing prospectus relating to the offering
prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">(iii) The portion of any other free writing prospectus
relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf
of the undersigned registrant; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">(iv) Any other communication that is an offer in the
offering made by the undersigned registrant to the purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(b) The undersigned registrant hereby undertakes that, for purposes
of determining any liability under the Securities Act of 1933, each filing of the registrant's annual report pursuant to Section
13(a) or Section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan's
annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration
statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such
securities at that time shall be deemed to be the initial bona fide offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(c) Insofar as indemnification for liabilities arising under
the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing
provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification
is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling
person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or
controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel
the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) The undersigned registrant hereby undertakes that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(1) For purposes of determining any liability under
the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in
reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h)
under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(2) For the purpose of determining any liability under
the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration
statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the
initial bona fide offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(e) The undersigned registrant hereby undertakes to file an
application for the purpose of determining the eligibility of the trustee to act under subsection (a) of Section 310 of the Trust
Indenture Act in accordance with the rules and regulations prescribed by the Commission under Section 305(b)(2) of the Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Act of 1933,
the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3
and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the
City of San Diego, State of California, on May 5, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">AETHLON MEDICAL, INC.,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">a Nevada corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><U>/s/ James A. Joyce&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">By: James A. Joyce</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">Its: Chief Executive Officer</P>

</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4in"></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>POWER OF ATTORNEY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">KNOW ALL MEN BY THESE PRESENTS, that each person whose signature
appears below constitutes and appoints James A. Joyce and James B. Frakes, or either of them, as his true and lawful attorneys-in-fact
and agents, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities,
to file and sign any and all amendments, including post-effective amendments and any registration statement for the same offering
that is to be effective under Rule 462(b) of the Securities Act of 1933, to this registration statement, with the Securities and
Exchange Commission, granting unto said attorneys-in-fact and agents, full power and authority to do and perform each and every
act and thing requisite and necessary to be done in connection therewith as fully to all intents and purposes as he might or could
do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes may
lawfully do or cause to be done by virtue hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Act of 1933,
this registration statement has been signed by the following persons in the capacities and on the dates indicated:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 25%; text-decoration: underline; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><u>Signature</u></b></font></td>
    <td style="width: 50%; text-decoration: underline; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><u>Title</u></b></font></td>
    <td style="width: 25%; text-decoration: underline; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><u>Date</u></b></font></td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><u>/s/ James A. Joyce&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">James A. Joyce</P></td>
    <td>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Chairman, Chief Executive Officer, Principal
        Executive Officer</P></td>
    <td>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">May 5, 2016</P></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><u>/s/ James B. Frakes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">James B. Frakes</P></td>
    <td>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Chief Financial Officer, Principal Accounting
        Officer</P></td>
    <td>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">May 5, 2016</P></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><u>/s/ Franklyn S. Barry, Jr.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Franklyn S. Barry, Jr.</P></td>
    <td>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Director</P></td>
    <td>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">May 5, 2016</P></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><u>/s/ Edward G. Broenniman&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Edward G. Broenniman</P></td>
    <td>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Director</P></td>
    <td>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">May 5, 2016</P></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><u>/s/ Rodney S. Kenley&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Rodney S. Kenley</P></td>
    <td>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Director</P></td>
    <td>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">May 5, 2016</P></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><u>/s/ Chetan S. Shah&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chetan S. Shah, MD</P></td>
    <td>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Director</P></td>
    <td>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">May 5, 2016</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INDEX TO EXHIBITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Underwriting Agreement *</font></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement and Plan of Reorganization Between Aethlon Medical, Inc. (formerly, Bishop Equities, Inc.) and Aethlon, Inc. dated March 10, 1999 (1)</font></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement and Plan of Reorganization Between Aethlon Medical, Inc. (formerly, Bishop Equities, Inc.) and Hemex, Inc. dated March 10, 1999 (1)</font></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Articles of Incorporation of Aethlon Medical, Inc., as amended **</font></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bylaws of Aethlon Medical, Inc., as amended (2)</font></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Common Stock Certificate (3)</font></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Indenture *</font></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Debt Security *</font></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant Certificate *</font></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant Agreement *</font></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Unit Agreement *</font></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</font></td>
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Raines Feldman LLP **</font></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td>&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</font></td>
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Independent Registered Public Accounting Firm (Squar Milner LLP) **</font></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td>&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2</font></td>
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Raines Feldman LLP (included in Exhibit 5.1) **</font></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td>&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1</font></td>
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power of Attorney (included on signature page hereto) **</font></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td>&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25.1</font></td>
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statement of Eligibility of Trustee on Form T-1 ***</font></td></tr>
<TR STYLE="background-color: White">
    <td>&nbsp;</td>
    <td style="width: 1px">&nbsp;</td>
    <td>&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* To the extent applicable, to be filed by an amendment or as
an exhibit to a document filed under the Securities Exchange Act of 1934, as amended, and incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">** Filed herewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*** To the extent applicable, to be filed by amendment or pursuant
to Trust Indenture Act Section 305(b)(2).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(1) Filed with the Company's Current Report on Form 8-K/A dated
March 26, 1999 and incorporated by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(2) Filed with the Company&rsquo;s Annual Report on Form 10-K
filed on June 26, 2015 for the year ended March 31, 2015 and incorporated by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(3) Filed with the Company&rsquo;s Registration Statement on
Form S-1 (File No. 333-201334) filed on December 31, 2014 and incorporated by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 48; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>aethlon_s1-ex0301.htm
<DESCRIPTION>ARTICLES OF INCORPORATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: left"><B>EXHIBIT 3.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>ARTICLES OF INCORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>BISHOP EQUITIES, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Article I - The Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The name of the corporation is Bishop Equities,
Inc. (the &quot;Corporation&quot;) and it is hereby incorporated pursuant to the laws of the State of Nevada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Article II - Duration of Existence</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Corporation shall have perpetual existence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Article IV - Purposes and Powers of Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Corporation shall have unlimited power to
engage in and do any lawful act concerning any or all lawful business for which corporations may be organized under the corporation
statutes and codes of the State of Nevada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Article V - Common Stock and Voting</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Corporation shall have the authority to
issue an aggregate of twenty-five million (25,000,000) shares, with a par value of $.001 per share. All shares will be of the same
class, designated &quot;common&quot; shares, with the same rights. Shares may only be issued as fully-paid and non-assessable,
and may be issued at such times, upon such terms and conditions and for such consideration as the Board of Directors shall determine.
Each common share shall be entitled to one vote concerning all matters as to which the Corporation's shareholders shall be entitled
to vote. The Corporation's common stock shall not be subject to assessment to pay any debts of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Article VI - Capitalization</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Corporation will commence its official business
upon its receipt of consideration of at least $1,000 for the issuance of shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Article VII - No Preemptive Rights</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Corporation's shareholders shall have no
preemptive rights to acquire, purchase or subscribe for any unissued shares of the Corporation's securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Article VIII - Registered Agent</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The name of the Corporation's initial registered
agent in the State of Nevada is Laughlin Associates, and the address of its initial registered office is c/o Laughlin Associates,
1000 East William, Carson City, Nevada 89701.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Article IX - Board of Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Corporation's initial Board of Directors
shall be composed of two members, who need not be shareholders of the Corporation nor residents of the State of Nevada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Directors shall be elected by a vote of such
majority of a quorum of the Corporation's shareholders present at any meeting held for the election of directors. Cumulative voting
is not authorized and shall not be allowed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The names and addresses of the persons who are
to serve as the Corporation's directors until the first annual meeting of its shareholders and until their successors shall be
elected and shall qualify, are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Deborah A. Salerno, 355 South End Ave., New
York NY 10280</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Maureen Abato, 19 Union Square West, New York
NY 10003.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Article X - Powers of Board of Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Corporation's Board of Directors shall have
and may exercise all of the powers now or hereafter conferred upon the Board by its Articles of Incorporation and By-Laws, and
by Nevada law, and the following powers:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">To make distributions to the Corporation's stockholders
of assets or cash belonging to the Corporation, in partial liquidation of its assets, and to make distributions in cash or kind,
out of the Corporation's capital surplus; to cause the Corporation to purchase, take, receive or otherwise acquire its own shares
out of its capital surplus, subject to limitations contained in the Nevada corporate codes; and to sell or acquire the stock or
assets of the Corporation without the approval of the stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Article XI - Common Directors; Corporate Transactions</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">No contract or other transaction between the
Corporation and any one or more of its directors or any other entity in which one or more of its directors or officers may be financially
interested, shall be either void or voidable because of such relationship or interest, or because such director(s) may be present
at a meeting of the Board of Directors which authorizes, approves or ratifies such contract or transaction, or because the vote
of such director(s) was counted for such purpose, so long as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">(a) the fact of such relationship or interest
is disclosed or known to the Board of Directors which authorizes, approves or ratifies the contract or transaction by vote or consent
sufficient for the purpose, without including the votes or consents of such interested director(s); OR</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">(b) the fact of such relationship or interest
is disclosed or known to the stockholders entitled to vote on the transaction, and the stockholders grant their authorization.
approval or ratification, by oral or written consent; OR</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">(c) the contract or transaction is deemed to
be fair and reasonable to the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Common or interested directors may be counted
in determining the presence of a quorum at any meeting of the Board of Directors or committee thereof, which authorizes, approves
or ratifies such contract or transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Article XII - Indemnification</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Without limiting the powers or authority now
or hereafter conferred upon the Corporation by its Articles of Incorporation or By-Laws, or by Nevada law, the Corporation shall
possess and may exercise all powers of indemnification of its officers, directors, employees, agents and other persons, and all
powers and authority incidental thereto (including, without limitation, to advance expenses and to purchase and maintain insurance
in that connection), without regard to whether or not such powers and authority are specifically provided for by Nevada corporation
law. The Corporation's Board of Directors is hereby authorized and empowered on behalf of the Corporation and without shareholder
action, to exercise all of the Corporation's powers of indemnification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Article XIII - Change, Amendment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Corporation reserves the right to amend,
alter, change or repeal any provisions hereof, or to add any provision hereto, at any time and in any manner as may be now or hereafter
prescribed or permitted by Nevada corporation codes. All of the rights and powers conferred upon the Corporation's directors and
shareholders hereby are so granted subject to the reservation contained in this Article.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Article XIV - By-Laws</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Corporation's initial By-Laws shall be adopted
by its Board of Directors. The Board may amend, alter or repeal the By-Laws, or replace them by the adoption of new By-Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Article XV - Incorporator</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Corporation's incorporator is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Maureen Abato, 19 Union Square West, New York
NY 10003</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">IN WITNESS WHEREOF, the undersigned, a natural
person over the age of twenty-one years and the incorporator designated in Article XIV of the annexed and foregoing Articles of
Incorporation of Avalon Enterprises, Inc., has executed said Articles of Incorporation as of April 10, 1991.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in"><U>/s/ Maureen Abato</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">Maureen Abato</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">(As incorporator)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">STATE OF NEW YORK &nbsp;&nbsp;&nbsp;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) ss.:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">COUNTY OF NEW YORK )</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On April 10, 1991, before me, the undersigned,
a Notary Public in and for the above County and State, personally appeared Maureen Abato, known to me to be the person whose name
is subscribed above, and who duly acknowledged that she executed the foregoing Articles of Incorporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in"><U>/s/ Margery Heitbrink</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">Notary Public</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate date commission expires:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">[notary stamp here]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">STATE OF NEVADA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">SECRETARY OF STATE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">CERTIFICATE OF ACCEPTANCE OF APPOINTMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">BY RESIDENT AGENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>IN THE MATTER OF BISHOP EQUITIES, INC.,</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">(Name of Corporation)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>I, LAUGHLIN ASSOCIATES, INC., with address at Suite 100,</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Name of Resident Agent</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Street 1000 E. WILLIAM STREET</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Town of CARSON CITY, County of CARSON CITY, State of Nevada, hereby
accept the appointment as Resident Agent of the above-entitled corporation in accordance with NRS 78.090.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">FURTHERMORE, that the principal office in this
state is located at Suite 100, Street 1000 E. WILLIAM STREET, Town of CARSON CITY, County of CARSON CITY, State of Nevada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">IN WITNESS WHEREOF, I have hereunto set my hand
this 11th day of April, 1991.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in"><U>/s/ Irma D. Butler</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">Sales/Service Advisor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">CERTIFICATE OF AMENDMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">OF</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">ARTICLES OF INCORPORATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">FRANKLYN S. BARRY, JR., and JAMES A. JOYCE certify that</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;They are President and Secretary, respectively,
of BISHOP EQUITIES, INC., a Nevada corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Article FIRST of the Articles of Incorporation
of this corporation is amended to read as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&quot;FIRST: The name of this corporation is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">AETHLON MEDICAL, INC.&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The foregoing Amendment of Articles of Incorporation
has been duly approved by the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The foregoing Amendment of Articles of Incorporation
has been duly approved by the required vote of shareholders in accordance with the Corporations Code. The total number of outstanding
shares of the corporation is 2,660,000. The number of shares voting in favor of the Amendment equaled or exceeded the vote required.
The percentage vote required was more than 50%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We further declare under penalty of perjury
under the laws of the State of Nevada that the matters set forth in this certificate are true and correct of our own knowledge.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date: March 28, 2000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in"><U>/s/ Franklyn S. Barry</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">FRANKLYN S. BARRY, JR., President</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in"><U>/s/ James A. Joyce</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">JAMES A. JOYCE, Secretary</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">-------------------------------</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">Document Number</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">20050234786-67</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">-------------------------------</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">Filing Date and Time</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">06/15/2005 8:56 AM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">-------------------------------</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">Entity Number</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">C3159-1991</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">-------------------------------</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">-------------------------------------------------------------------</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">Certificate of Amendment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">(PURSUANT TO NRS 78.385 and 78.390)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">-------------------------------------------------------------------</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">Certificate of Amendment to Articles of Incorporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">For Nevada Profit Corporations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">(Pursuant to NRS 78.385 and 78.390 - After Issuance
of Stock)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">1. Name of corporation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Aethlon Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">2. The articles have been amended as follows (provide article numbers,
if</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">available):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Article V. Common Stock and Voting</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The Corporation shall have the authority to issue an aggregate of
fifty million (50,000,000) shares, with a par value of $.001 per share. All shares will be of the same class, designated 'common'
shares, with the same rights. Shares may only be issued as fully-paid and non-assessable, and may be issued at such times, upon
such terms and conditions and for such consideration as the Board of Directors shall determine. Each common share shall be entitled
to one vote concerning all matters as to which the Corporation's shareholders shall be entitled to vote. The Corporation's common
stock shall not be subject to assessment to pay any debts of the Corporation.&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">3. The vote by which the stockholders holding shares in the corporation
entitling them to exercise at least a majority of the voting power, or such greater proportion of the voting power as may be required
in the case of a vote by classes or series, or as may be required by the provisions of the * articles of incorporation have voted
in favor of the amendment is: 10,238,794</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">4. Effective date of filing (optional):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">5. Officer Signature (required): /s/ James A. Joyce</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">* If any proposed amendment would alter or change any preference
or any relative or other right given to any class or series of outstanding shares, then the amendment must be approved by the vote,
in addition to the affirmative vote otherwise required, of the holders of shares representing a majority of the voting power of
each class or series affected by the amendment regardless of limitations or restrictions on the voting power thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">IMPORTANT: Failure to include any of the above information and submit
the proper fees may cause this filing to be rejected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">-------------------------------</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">Document Number</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">20070165791-08</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">-------------------------------</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">Filing Date and Time</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">03/07/2007 8:04 AM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">-------------------------------</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">Entity Number</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">C3159-1991</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">-------------------------------</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">-------------------------------------------------------------------</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">Certificate of Amendment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">(PURSUANT TO NRS 78.385 and 78.390)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">-------------------------------------------------------------------</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">Certificate of Amendment to Articles of incorporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">For Nevada Profit Corporations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">(Pursuant to NRS 78.385 and 78.390 - After issuance
of Stock)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">1. Name of corporation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Aethlon Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">2. The articles have been amended as follows (provide article numbers,
if available):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Article V. Common Stock and Voting. The Corporation shall have the
authority to issue an aggregate of one hundred million (100,000,000) shares, with a par value of $.001 per share. All shares will
be of the same class, designated 'common' shares, with the same rights. Shares may only be issued as fully-paid and non-assessable,
and may be issued at such times, upon such terms and conditions and for such consideration as the Board of Directors shall determine.
Each common share shall be entitled to one vote concerning all matters as to which the Corporation's shareholders shall be entitled
to vote. The Corporation's common stock shall not be subject to assessment to pay any debts of the Corporation.&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">3. The vote by which the stockholders holding shares in the corporation
entitling them to exercise at least a majority of the voting power, or such greater proportion of the voting power as may be required
in the case of a vote by classes or series, or as may be required by the provisions of the * articles of incorporation have voted
in favor of the amendment is: 8,628,045</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">4. Effective date of filing (optional):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">5. Officer Signature (required): /s/ [signature]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">* If any proposed amendment would alter or change any preference
or any relative or other right given to any class or series of outstanding shares, then the amendment must be approved by the vote,
in addition to the affirmative vote otherwise required, of the holders of shares representing a majority of the voting power of
each class or series affected by the amendment regardless of limitations or restrictions on the voting power thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">IMPORTANT: Failure to include any of the above information and submit
the proper fees may cause this filing to be rejected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">-------------------------------</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">Document Number</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">20090692683-05</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">-------------------------------</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">Filing Date and Time</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">09/21/2009 4:45 PM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">-------------------------------</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">Entity Number</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">C3159-1991</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">-------------------------------</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">-------------------------------------------------------------------</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">Certificate of Amendment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">(PURSUANT TO NRS 78.385 and 78.390)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">-------------------------------------------------------------------</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">Certificate of Amendment to Articles of Incorporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">For Nevada Profit Corporations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">(Pursuant to NRS 78.385 and 78.390 - After Issuance
of Stock)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">1. Name of corporation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Aethlon Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">2. The articles have been amended as follows: (provide article numbers,
if</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">available)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&quot;Article V. Common Stock and Voting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The Corporation shall have the authority to issue an aggregate of
two hundred fifty million (250,000,000) shares, with a par value of $.001 per share. All shares will be of the same class, designated
'common' shares, with the same rights. Shares may only be issued as fully paid and non-assessable, and may be issued at such times,
upon such terms and conditions and for such consideration as the Board of Directors shall determine. Each common share shall be
entitled to one vote concerning all matters as to which the Corporation's stockholders shall be entitled to vote. The Corporation's
common stock shall not be subject to assessment to pay any debts of the Corporation.&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">3. The vote by which the stockholders holding shares in the corporation
entitling them to exercise at least a majority of the voting power, or such greater proportion of the voting power as may be required
in the case of a vote by classes or series, or as may be required by the provisions of the articles of incorporation* have voted
in favor of the amendment is: 41,840,130</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">4. Effective date of filing: (optional)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">5. Signature: (required) /s/ James A. Joyce</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">* If any proposed amendment would alter or change any preference
or any relative or other right given to any class or series of outstanding shares, then the amendment must be approved by the vote,
in addition to the affirmative vote otherwise required, of the holders of shares representing a majority of the voting power of
each class or series affected by the amendment regardless to limitations or restrictions on the voting power thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">IMPORTANT: Failure to include any of the above information and submit
the proper fees may cause this filing to be rejected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">ROSS MILLER</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Secretary of State</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">204 North Carson Street, Suite 1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Carson City, Nevada 89701-4520</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(775) 984-5708</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">website: www.nvsos.gov</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">-------------------------------</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">Document Number</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">20120397920-95</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">-------------------------------</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">Filing Date and Time</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">06/04/2012 3:30 PM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">-------------------------------</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">Entity Number</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">C3159-1991</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 4in">-------------------------------</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">Certificate of Amendment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">Certificate of Amendment to Articles of Incorporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">For Nevada Profit Corporations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">(Pursuant to NRS 78,385 and 78.390 - After Issuance
of Stock)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">1. Name of corporation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Aethlon Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">2. The articles have been amended as follows: (provide article numbers,
if available)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&quot;Article V. Common Stock and Voting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Corporation shall have the authority to
issue an aggregate of five hundred million (500,000,000) shares, with a par value of $.001 per share. All shares will be of the
same class, designated &quot;common&quot; shares, with the same rights. Shares may only be issued as fully paid and non-assessable,
and may be issued at such times, upon such terms and conditions and for such consideration as the Board of Directors shall determine.
Each common share shall be entitled to one vote concerning all matters as to which the Corporation's stockholders shall be entitled
to vote. The Corporation's common stock shall not be subject to assessment to pay any debts of the Corporation.&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">3. The vote by which the stockholders holding shares in the corporation
entitling them to exercise a least a majority of the voting power, or such greater proportion of the voting power as may be required
in the case of a vote by classes of series, or as may be required by the provisions of the articles of incorporation* have voted
in favor of the amendment is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">89,118,817 shares voted in favor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">4. Effective date and time of filing: (optional)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">5. Signature: (required)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>/s/ James A. Joyce</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Signature of Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">*if any proposed amendment would alter or change any preference
or any relative or other right given to any class or series of outstanding shares, then the amendment must be approved by the vote,
in addition to the affirmative vote otherwise required, of the holders of shares representing a majority of the voting power of
each class or series affected by the amendment regardless to limitations or restrictions on the voting power thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">IMPORTANT: Failure to include any of the above information and submit
with the proper fees may cause this filing to be rejected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="ex0301stamp.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><B>Certificate of Change filed Pursuant to NRS 78.209</B></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><B>For Nevada Profit Corporations</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">1. Name of corporation:</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">Aethlon Medical, Inc.</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">2. The board of directors have adopted a resolution pursuant to NRS 78.209 and have obtained any
required approval of the stockholders.</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">3. The current number of authorized shares and the par value, if any, of each class or series, if any,
of shares before the change:</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">500,000,000 shares of common stock, par value $0.001.</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">4. The number of authorized shares and the par value, if any, of each class or series, if any, of shares
after the change:</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">10,000,000 shares of common stock, par value $0.001.</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">5. The number of shares of each affected class or series, if any, to be issued after the change in
exchange for each issued share of the same class or series:</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">6,570,574 shares of common stock, par value $0.001.</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">6. The provisions, if any, for the issuance of fractional shares, or for the payment of money or
the issuance of scrip to stockholders otherwise entitled to a fraction of a share and the percentage of outstanding shares
affected thereby:</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">No fractional shares will be issued. If the reverse stock split would result in the issuance of any fractional
shares, the corporation will issue one whole share in lieu of the fractional share on a holder-by-holder basis.</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">7. Effective date and time
of filing:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Date:
04/08/2015&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Time: _____________</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">8. Signature</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><U>/s/ James A. Joyce&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief
Executive Officer</U></P>

<P STYLE="margin: 0">Signature of Officer&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Title</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="ex0302.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><B><U>Certificate of Correction</U></B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">1. The name of the entity for which correction is being made:</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">Aethlon Medical, Inc.</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">2. Description of the original document for which correction is being made:</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">Certificate of Change Pursuant to NRS 78.209 filed for a reverse stock split of corporation&rsquo;s
outstanding and issued common stock.</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">3. Filing date of the original document for which correction is being made: 04/01/2015</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">4. Description of the inaccuracy or defect:</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">Article 5 of the Certificate of Change filed April 1, 2015 incorrectly stated the shares to be issued
after the reverse stock split as an aggregate number of shares rather than on a per share basis.</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">Additionally, the effective date for the Certificate of Change filed April 1, 2015 was April 8, 2015 and
the corporation wants the effective date to be April 10, 2015.</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">5. Correction of the inaccuracy or defect:</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">Section 5 to the Certificate of Change filed on April 1, 2015 is hereby changed to &ldquo;After
the change 1/50th share of the company&rsquo;s common stock, par value $0.001, will be issued for each issued share of common stock.&rdquo;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">Section 7 (Effective Date) to the Certificate of Change filed April 1, 2015 is hereby changed to: April
10, 2015.</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">6. Signature:</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><U>/s/ James B. Frakes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief
Financial
Officer&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4-7-15</U></P>

<P STYLE="margin: 0">Authorized Signature&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Title&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Date</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>



<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="ex31sig.jpg" ALT="">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>




<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;<IMG SRC="ex0301.jpg" ALT=""></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">1.
Name of corporation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Aethlon
Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">2.
The articles have been amended as follows: <FONT STYLE="font-size: 10pt">(provide article numbers. if available)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&ldquo;Article
V. Common Stock and Voting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">'The
Corporation shall have the authority to issue an aggregate of thirty million (30,000,000) shares, with a par value of $.001 per
share. All shares will be of the same class, designated 'common' shares, with the same rights. Shares may be issued only as fully
paid and non-assessable, and may be issued at such times, upon such terms and conditions and for such consideration as the Board
of Directors shall determine. Each common share shall be entitled to one vote concerning all matters as to which the Corporation's
stockholders shall be entitled to vote. The Corporation's common stock shall not be subject to assessment to pay any debts of
the Corporation.&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">3.
The vote by which the stockholders holding shares in the corporation entitling them to exercise at least a majority of the voting
power, or such greater proportion of the voting power as may be required in the case of a vote by classes or series, or as may
be required by the provisions of the articles of incorporation* have voted in favor of the amendment is: 5,624,821 shares voted
in favor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">4. Effective date and time of filing: (optional) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Date:&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Time:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 262.5pt">(must not be later than 90 days after the certificate
is filed)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 430.7pt; margin-bottom: 0pt; text-align: left">5.
Signature: (required)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 430.7pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 430.7pt; margin-bottom: 0pt; text-align: left"><IMG SRC="image_001.jpg" ALT="" STYLE="width: 270px; height: 61px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 46.1pt; margin-bottom: 0pt; text-align: left">*If
any proposed amendment would alter or change any preference or any relative or other right given to any class or series of outstanding
shares, then the amendment must be approved by the vote, in addition to the affirmative vote otherwise required, of the holders
of shares representing a majority of the voting power of each class or series affected by the amendment regardless to limitations
or restrictions on the voting power thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 46.1pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 46.1pt; margin-bottom: 0pt; text-align: left">IMPORTANT: Failure to include any of the above information and submit with the proper
fees may cause this filing to be rejected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 46.1pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 46.1pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 46.1pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 14; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 46.1pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>aethlon_ex0501.htm
<DESCRIPTION>OPINION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>EXHIBIT&nbsp;5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%"><IMG SRC="raines_logo.jpg" ALT="">&nbsp;</TD>
    <TD STYLE="width: 50%"><P STYLE="font: 10pt Century Gothic; margin: 0; text-align: right; color: #E36C0A"><B>Beverly Hills</B></P>

<P STYLE="font: 10pt Century Gothic; margin: 0; text-align: right">9720 Wilshire Boulevard, 5<SUP>th</SUP> Floor</P>

<P STYLE="font: 10pt Century Gothic; margin: 0; text-align: right">Beverly Hills, California 90212</P>

<P STYLE="font: 10pt Century Gothic; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Century Gothic; margin: 0; text-align: right; color: #E36C0A"><B>Irvine</B></P>

<P STYLE="font: 10pt Century Gothic; margin: 0; text-align: right">18401 Von Karman Avenue, Suite 270</P>

<P STYLE="font: 10pt Century Gothic; margin: 0; text-align: right">Irvine, California 92612</P>

<P STYLE="font: 10pt Century Gothic; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Century Gothic; margin: 0; text-align: right">Main: 310.440.4100</P>

<P STYLE="font: 10pt Century Gothic; margin: 0; text-align: right"><U>www.raineslaw.com</U></P>



</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">May 5, 2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aethlon Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">9635 Granite Ridge Drive, Suite 100</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">San Diego, California 92123</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have acted as counsel to Aethlon Medical,
Inc., a Nevada corporation (the &ldquo;<B><I>Company</I></B>&rdquo;), in connection with the Registration Statement on Form&nbsp;S-3
(the &ldquo;<B><I>Registration Statement</I></B>&rdquo;) filed by the Company with the Securities and Exchange Commission (the
&ldquo;<B><I>Commission</I></B>&rdquo;) under the Securities Act of 1933, as amended (the &ldquo;<B><I>Act</I></B>&rdquo;), on
May 5, 2016. The Company has provided us with a prospectus (the &ldquo;<B><I>Prospectus</I></B>&rdquo;), which forms a part of
the Registration Statement and which provides that it may be supplemented in the future by one or more prospectus supplements
(each, a &ldquo;<B><I>Prospectus Supplement</I></B>&rdquo;). The Registration Statement, including the Prospectus as supplemented
from time to time by one or more Prospectus Supplements, will provide for the registration of the offer and sale by the Company
of up to $12,500,000 of the Company&rsquo;s (i)&nbsp;common stock, par value $0.001 per share (the &ldquo;<B><I>Common Stock</I></B>&rdquo;),
(ii)&nbsp;debt securities in one or more series (the &ldquo;<B><I>Debt Securities</I></B>&rdquo;), which may be issued pursuant
to an indenture to be dated on or about the date of the first issuance of Debt Securities thereunder, by and between a trustee
to be selected by the Company (the &ldquo;<B><I>Trustee</I></B>&rdquo;) and the Company, in the form filed as Exhibit&nbsp;4.2
to the Registration Statement (the &ldquo;<B><I>Indenture</I></B>&rdquo;), (iii)&nbsp;warrants to purchase shares of Common Stock
or Debt Securities (the &ldquo;<B><I>Warrants</I></B>&rdquo;), which may be issued under warrant agreements to be dated on or
about the date of the first issuance of the applicable Warrants thereunder, by and between a warrant agent to be selected by the
Company (the &ldquo;<B><I>Warrant Agent</I></B>&rdquo;) and the Company (each, a &ldquo;<B><I>Warrant Agreement</I></B>&rdquo;),
and (iv)&nbsp;units comprised of one or more shares of Common Stock, Debt Securities or Warrants (&ldquo;<B><I>Units</I></B>&rdquo;),
which may be issued under unit agreements to be dated on or about the date of the first issuance of the applicable Units thereunder,
by and between a unit agent to be selected by the Company (the &ldquo;<B><I>Unit Agent</I></B>&rdquo;) and the Company (each,
a &ldquo;<B><I>Unit Agreement</I></B>&rdquo;). The Common Stock, Debt Securities, Warrants and Units are collectively referred
to herein as the &ldquo;<B><I>Securities</I></B>.&rdquo; The Securities are being registered for offer and sale from time to time
at prices and on terms to be determined at the time of an offering pursuant to Rule&nbsp;415 under the Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with this opinion, we have
examined and relied upon originals or copies certified to our satisfaction of such documents, records, certificates, memoranda
and other instruments as we deem necessary or appropriate to enable us to render the opinions expressed below. As to certain factual
matters, we have relied upon certificates of the officers of the Company and have not independently sought to verify such matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have assumed the genuineness and authenticity
of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as copies thereof and
the due execution and delivery of all documents where due execution and delivery are a prerequisite to the effectiveness thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With respect to our opinion as to the Common
Stock, we have assumed that, at the time of issuance and sale, a sufficient number of shares of Common Stock will be authorized
and available for issuance and that the consideration for the issuance and sale of the Common Stock (or Debt Securities convertible
into Common Stock or Warrants exercisable for Common Stock) will be in an amount that is not less than the par value of the Common
Stock.<FONT STYLE="color: red"> </FONT>We have also assumed that any Debt Securities and Warrants offered under the Registration
Statement, and the related Indenture and Warrant Agreement, as applicable, will be executed in the forms filed as exhibits to the
Registration Statement or incorporated by reference therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our opinion is limited to the matters stated
herein and no opinion is implied or may be inferred beyond the matters expressly stated. Our opinion herein is expressed solely
with respect to the federal laws of the United States and the Nevada Revised Statutes and, as to the Debt Securities constituting
valid and legally binding obligations of the Company in paragraph 2 below, solely with respect to the laws of the State of California.&nbsp;
We express no opinion with respect to the applicability thereto, or the effect thereon, of the laws of any other jurisdiction or,
in the case of the State of Nevada, any other laws, or as to any matters of municipal law or the laws of any local agencies within
any state.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our opinion is based on these laws as in
effect on the date hereof, and we disclaim any obligation to advise you of facts, circumstances, events or developments which hereafter
may be brought to our attention and which may alter, affect or modify the opinion expressed herein. We are not rendering any opinion
as to compliance with any federal or state antifraud law, rule&nbsp;or regulation relating to securities, or to the sale or issuance
thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On the basis of the foregoing, and in reliance
thereon, and provided that the Registration Statement and any required post-effective amendment thereto have all become effective
under the Securities Act and the Prospectus and any and all Prospectus Supplement(s)&nbsp;and any related free writing prospectuses
required by applicable laws have been delivered and filed as required by such laws, we are of the opinion that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 44pt; text-align: left">1.</TD><TD STYLE="text-align: justify">With respect to the Company Common Stock offered under
the Registration Statement, provided that (i)&nbsp;the issuance of the Company Common Stock has been duly authorized by all necessary
corporate action on the part of the Company (including, without limitation, by the adoption by the Board of Directors of the Company
of a resolution duly authorizing the issuance and delivery of the Common Stock); (ii)&nbsp;the issuance and sale of the Company
Common Stock do not violate any applicable law, are in conformity with the Company&rsquo;s then operative Articles of Incorporation,
as amended (the &ldquo;<B><I>Articles of Incorporation</I></B>&rdquo;), and Amended and Restated Bylaws (the &ldquo;<B><I>Bylaws</I></B>&rdquo;),
do not result in a default under or breach of any agreement or instrument binding upon the Company and comply with any applicable
requirement or restriction imposed by any court or governmental body having jurisdiction over the Company; and (iii)&nbsp;the
certificates for the Company Common Stock have been duly executed by the Company, countersigned by the transfer agent therefor
and duly delivered to the purchasers thereof against payment therefor; then the Company Common Stock, when issued and sold as
contemplated in the Registration Statement, the Prospectus and the related Prospectus Supplement(s)&nbsp;and in accordance with
any applicable duly authorized, executed and delivered purchase, underwriting or similar agreement, or upon conversion of any
convertible Debt Securities in accordance with their terms, or upon exercise of any Warrants in accordance with their terms, will
be validly issued, and the Common Stock will be fully paid and nonassessable.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 44pt; text-align: left">2.</TD><TD STYLE="text-align: justify">With respect to any series of the Debt Securities issued
under the Indenture and offered under the Registration Statement, provided that (i)&nbsp;the Indenture has been duly authorized
by the Company and the Trustee by all necessary corporate action (including, without limitation, by the adoption by the Board
of Directors of the Company of a resolution duly authorizing the execution and delivery of the Indenture); (ii)&nbsp;the Indenture,
in substantially the form filed as an exhibit to the Registration Statement, has been duly executed and delivered by the Company
and the Trustee; (iii)&nbsp;the terms of the Debt Securities and of their issuance and sale have been duly authorized by the Company
by all necessary corporate action (including, without limitation, by the adoption by the Board of Directors of the Company of
a resolution duly authorizing the issuance and delivery of the Debt Securities); (iv)&nbsp;the terms of the Debt Securities and
of their issuance and sale have been duly established in conformity with the Indenture so as not to violate any applicable law
or result in a default under or breach of any agreement or instrument binding upon the Company, so as to be in conformity with
the Articles of Incorporation and the Bylaws, and so as to comply with any requirement or restriction imposed by any court or
governmental body having jurisdiction over the Company; and (v)&nbsp;the Debt Securities have been duly executed and delivered
by the Company and authenticated by the Trustee pursuant to the Indenture and delivered against payment therefor, then the Debt
Securities, when issued and sold in accordance with the Indenture and a duly authorized, executed and delivered purchase, underwriting
or similar agreement, or upon exercise of any Warrants in accordance with their terms, will be valid and legally binding obligations
of the Company, enforceable against the Company in accordance with their terms, except as enforcement thereof may be limited by
applicable bankruptcy, insolvency, reorganization, arrangement, moratorium or other similar laws affecting creditors&rsquo; rights,
and subject to general equity principles and to limitations on availability of equitable relief, including specific performance.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 44pt; text-align: left">3.</TD><TD STYLE="text-align: justify">With respect to the Warrants issued under a Warrant Agreement
and offered under the Registration Statement, provided that (i)&nbsp;the Warrant Agreement has been duly authorized by the Company
and the Warrant Agent by all necessary corporate action (including, without limitation, by the adoption by the Board of Directors
of the Company of a resolution duly authorizing the execution and delivery of the Warrant Agreement); (ii)&nbsp;the Warrant Agreement
has been duly executed and delivered by the Company and the Warrant Agent; (iii)&nbsp;the issuance and terms of the Warrants have
been duly authorized by the Company by all necessary corporate action (including, without limitation, by the adoption by the Board
of Directors of the Company of a resolution duly authorizing the issuance and delivery of the Warrants); (iv)&nbsp;the terms of
the Warrants and of their issuance and sale have been duly established in conformity with the Warrant Agreement and as described
in the Registration Statement, the Prospectus and the related Prospectus Supplement(s), so as not to violate any applicable law
or result in a default under or breach of any agreement or instrument binding upon the Company, so as to be in conformity with
the Articles of Incorporation and the Bylaws, and so as to comply with any requirement or restriction imposed by any court or
governmental body having jurisdiction over the Company; and (v)&nbsp;the Warrants have been duly executed and delivered by the
Company and authenticated by the Warrant Agent pursuant to the Warrant Agreement and delivered against payment therefor, then
the Warrants, when issued and sold in accordance with the Warrant Agreement and a duly authorized, executed and delivered purchase,
underwriting or similar agreement, will be valid and legally binding obligations of the Company, enforceable against the Company
in accordance with their terms, except as enforcement thereof may be limited by applicable bankruptcy, insolvency, reorganization,
arrangement, moratorium or other similar laws affecting creditors&rsquo; rights, and subject to general equity principles and
to limitations on availability of equitable relief, including specific performance.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 44pt; text-align: left">4.</TD><TD STYLE="text-align: justify">With respect to the Units issued under the Unit Agreement
and offered under the Registration Statement, provided that (i)&nbsp;the Unit Agreement has been duly authorized by the Company
and the Unit Agent by all necessary corporate action (including, without limitation, by the adoption by the Board of Directors
of the Company of a resolution duly authorizing the execution and delivery of the Unit Agreement); (ii)&nbsp;the Unit Agreement
has been duly executed and delivered by the Company and the Unit Agent; (iii)&nbsp;the issuance and terms of the Units have been
duly authorized by the Company by all necessary corporate action (including, without limitation, by the adoption by the Board
of Directors of the Company of a resolution duly authorizing the issuance and delivery of the Units); (iv)&nbsp;the terms of the
Units and of their issuance and sale have been duly established in conformity with the Unit Agreement and as described in the
Registration Statement, the Prospectus and the related Prospectus Supplement(s), so as not to violate any applicable law or result
in a default under or breach of any agreement or instrument binding upon the Company, so as to be in conformity with the Articles
of Incorporation and Bylaws, and so as to comply with any requirement or restriction imposed by any court or governmental body
having jurisdiction over the Company; and (v)&nbsp;the Units have been duly executed and delivered by the Company and authenticated
by the Unit Agent pursuant to the Unit Agreement and delivered against payment therefor, then the Units, when issued and sold
in accordance with the Unit Agreement and a duly authorized, executed and delivered purchase, underwriting or similar agreement,
will be valid and legally binding obligations of the Company, enforceable against the Company in accordance with their terms,
except as enforcement thereof may be limited by applicable bankruptcy, insolvency, reorganization, arrangement, moratorium or
other similar laws affecting creditors&rsquo; rights, and subject to general equity principles and to limitations on availability
of equitable relief, including specific performance.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The opinions set forth in paragraphs 2
and 3 relating to the enforceability of the Debt Securities, the Indenture, the Warrant Agreement and the Warrants, respectively,
are subject to the following exceptions, limitations and qualifications: (i)&nbsp;the effect of bankruptcy, insolvency, reorganization,
preference, fraudulent transfer, moratorium or other similar laws relating to or affecting the rights and remedies of creditors;
(ii)&nbsp;the effect of general principles of equity, whether enforcement is considered in a proceeding in equity or at law (including
the possible unavailability of specific performance or injunctive relief), concepts of materiality, reasonableness, good faith
and fair dealing, and the discretion of the court before which any proceeding therefor may be brought; (iii)&nbsp;the unenforceability
under certain circumstances under law or court decisions of provisions providing for the indemnification of, or contribution to,
a party with respect to a liability where such indemnification or contribution is contrary to public policy; (iv)&nbsp;&nbsp;the
unenforceability of any provision requiring the payment of attorneys&rsquo; fees, where such payment is contrary to law or public
policy; (v)&nbsp;we express no opinion with respect to whether acceleration of the Debt Securities may affect the collectability
of that portion of the stated principal amount thereof which might be determined to constitute unearned interest thereon; and (vi)&nbsp;we
express no opinion as to the enforceability of any provision to the extent it requires any party to indemnify any other person
against loss in obtaining the currency due following a court judgment rendered in another currency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The opinions expressed herein as to Debt
Securities do not include (i)&nbsp;any opinion with respect to the creation, validity, perfection or priority of any security interest
or lien, or (ii)&nbsp;any opinion with respect to compliance with laws relating to permissible rates of interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have not been requested to express and,
with your consent, do not render any opinion as to the applicability to the obligations of the Company under the Indenture or the
Debt Securities of Sections 547 and 548 of the United States Bankruptcy Code or applicable state law relating to preferences and
fraudulent transfers and obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With your consent, we have assumed for
purposes of this opinion that (i)&nbsp;each of the parties to the Indenture, any Warrant Agreement and any Unit Agreement (collectively,
the &ldquo;Operative Documents&rdquo;) other than the Company (a)&nbsp;is and at all relevant times will be duly organized, validly
existing and in good standing under the laws of its jurisdiction of organization; (b)&nbsp;has and at all relevant times will have
the requisite power and authority to execute and deliver and to perform its obligations under each of the Operative Documents to
which it is a party; and (c)&nbsp;has duly authorized, executed and delivered each such Operative Document and has never revoked
such authorization; (ii)&nbsp;with respect to each of the parties to the Operative Documents other than the Company, each Operative
Document to which it is a party constitutes and will at all relevant times constitute its legally valid and binding agreement,
enforceable against it in accordance with its terms; (iii)&nbsp;the Trustee is and at all relevant times will be in compliance,
generally and with respect to acting as Trustee under the Indenture, with all applicable laws and regulations; (iv)&nbsp;the Warrant
Agent is and at all relevant times will be in compliance, generally and with respect to acting as warrant agent under the Warrant
Agreement, with all applicable laws and regulations; and (v) the Unit Agent is and at all relevant times will be in compliance,
generally and with respect to acting as unit agent under the Unit Agreement, with all applicable laws and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We hereby consent to the filing of this
opinion letter as Exhibit&nbsp;5.1 to the Registration Statement and to the reference to our firm under the caption &ldquo;Legal
Matters&rdquo; in the Prospectus. In giving this consent, we do not thereby admit that we are an &ldquo;expert&rdquo; within the
meaning of the Securities Act of 1933, as amended. In addition, we give such consent on the condition and understanding that (i)&nbsp;this
letter speaks only as of the date hereof and (ii)&nbsp;we have no responsibility or obligation to update this letter, to consider
its applicability or correctness to other than its addressee, or to take into account changes in law, facts or any other developments
of which we may later become aware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Very truly yours,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Raines Feldman LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Raines Feldman LLP</B>&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>aethlon_ex2301.htm
<DESCRIPTION>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>EXHIBIT 23.1</B></P>

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0">We consent to the incorporation by reference in this Registration
Statement on Form S-3 of Aethlon Medical, Inc. of our report dated June 25, 2015, relating to our audit of the consolidated financial
statements, appearing in the Annual Report on Form 10-K of Aethlon Medical, Inc. for the year ended March 31, 2015.<BR>
<BR>
We also consent to the reference to our firm under the captions &quot;Experts&quot; in the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0">/s/ SQUAR MILNER LLP (FORMERLY SQUAR, MILNER, PETERSON,
MIRANDA &amp; WILLIAMSON, LLP)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify">San Diego, California</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify">May 5, 2016</P>



<P STYLE="margin: 0pt 0 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ex0301stamp.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex0301stamp.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" #F K$# 2(  A$! Q$!_\0
M'0 !  (# 0$! 0            8'! 4( P(!"?_$ % 0  $# P," P,'" 8(
M! 4%  $" P0 !1$&$B$',1,B011180@5%C)6<9,C0E2!E-'2U!<S4I&A\"0W
M56)R<[&R&*+!X24F-$.2)V1UL_'_Q  4 0$                     _\0
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M_C5@T"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*_%*2A)4LA*0,DDX
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M2V4J()&0ZM(P,':<X(R:P+7U<U YK9RQW*V6>,KVB3%:96X^TZYX*2?%0M:
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MZ+:CM]H1>+-?YK-KB/)1(:F+2X7$NA:/*$I]"C<<D?FCGM5<,W)]^6ZJ5(>
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M+S_BAU]QIQLK;P$)V*;*B03DXXX& L_VWIO8[D%KG:5@W!F9(<WN26$/(DN
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M5J*^B(T),=LEAMN,AM"#C:"%$)4#@8['X5>0&.U I2E I2E I2E I2E I2E
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M*4H%*4H%*4H%*4H%*4H('UT2MWI5J1E#+3H<@2"H.$@ (96YN!VGD% (SC)
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M0 Q:VVTK/@J 2GSGA(_.4<<=S4=Z=V2>KKUI&_,:<UDU:BRXV]/OB%NNNN^
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M4''EK5M0$I(!.X\@]L<YQS0:?J APNZ6N(ARID"!=$R9;,=A3K@08[R$+\,
MJ5M<6VK !(QG'%:S7,M3K,1ZWQ[Y%@W!3C,N9;[?(]J:<#1+*U-H =V @C.,
M9V ^7->]PUH[=9=DM^DGF&IEQ5+"GIT1QQ,=44I2XTXV%(4E6Y6W.>,$C.17
MU?=638&NF+,[(@VR,Z&?95SXZ_#N"EJ(6VV^%!*7$@##925*R,<'@--\Y7-.
MHI"'[A=GE1I("%-1GDH>'L2$ADE*#'"B^HKR5<*\F,8%>5K7J.':WIN+_)3
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MA[>VM 4@I"RHJ0V1@<E/P-;/3=RT'/M2]26X0&X]K68[LN6R67(BVPH%"RZ
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+2E*!2E*!2E*#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ex0302.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex0302.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" #O K,# 2(  A$! Q$!_\0
M'  !  (# 0$!              8' 00% P@"_\0 7A   00" 0(#! 0'"0D,
M!@L  0 " P0%$082(0<3,10B05$5%C)A"!<C<971TB0S0D92@861P28H5E=B
M<G6AL2<T-C=5=H*2HK3"X1@E-3A#A$5'4V1E9I26I++$_\0 &0$! 0 # 0
M              $" P0%_\0 +A$!  $# @0$!@,  P        $" Q$A,002
M4? 306'1(G&!D:&Q!13!,N'Q_]H # ,!  (1 Q$ /P#ZI1$0$1$!$1 1$0$1
M$!$/=$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MF'N/\W:[B B(@(?1$/H@PB(JQ91$49"(B B(@(B("(B B(3I 1-H@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M\;&'_E.%P[?++2_K7IBI&,N^+S2]A,>6B?T[[Z;E7%:MB0&7QM8U[06V9'N
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M0]\G;7#UWO8\MH('8;:?DKQSV"K\CH-@R'DQPML,FC<Z1@DKR@GID:QXT>X
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M'&(IAW#]AH+G;[[<23M2;A!GRMQV)KOM?161G=DXH+\S8[.0E9T-G[QM(T'
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M(B(991$0$1$!$1 1$0$1$&" ?4+( 'HB)@-+'2-+*(&D1$!$1 1$0$1$!$1
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M!9R;58_B:Q0[CDO,P?G]-RK'XFL5O_A+S/\ -]-2H+/VFU6#?!K$M_C+S/\
M34JS^)O%$]^2\S/Y\W*@L[?W%-_G59?B:Q'^$7,?TU*GXFL1K_A%S'\_TU*@
MLW:;59?B;Q&_^$/,/TW,GXFL/O?UAY@?Z:E06:BK+\3>(UKZP\P_3<JR/!O#
M@?\ M_E_Z;F_6@LS?YT59_B;P_\ R_R_]-S?K61X.X<?_3_+S_3<WZT3*RTV
MJS_$YA_\(.8?IN;]:S^)W$=_[H.8?IN;]:&5E[_.F_SJM/Q/8C6OK!S _?\
M3<WZT'@[B!_&'F!_/FYOUHJR]HJT_$[B.W]T',/TW-W_ -:?B=P__+_+Q_3<
MWZT%E[3:K0>#N('\8.8?IN;]:'P=Q&_^$/,!]WTW-^M!9>TW^=5F/!S$?X1<
MQ_3<WZT_$YB>_P#='S+]-RH+,3:K'\3>*ZB1R7F8W\LW*N%Q?$GBWX0,6"J9
M3-W*#^..NN&0R$EC\H;'1O3CKT9_K*"ZT1$!$1 1$0$1$!$1 1$0$1$!$1 1
M$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!#Z(A]$&$1$1E$1%$1$!5AXYG
M3O#WX?W74/\ 9*K/57>.OKX>GY<OQ_\ LE3S2=EH#U65@>JRBB(B B%5%G?%
M;+W^17\+X:<6EY+/C7]%ZU)8;7KQNV06-<[74[8(]1Z'6T%NHH%X7^)%3G#\
MG1EQ]G$9W%O$=W'V2"Z,G8VTCU&P1Z CY=P3/4!$4:RW+Z&.YK@^+R16GY'+
M,EEC<QGY.-D;'.)<XGX].@!L]QO2"2HHSC<SG+'-LKB[?'GU<)6B:^KE?: X
M67$,VWR];;KJ=W_R5!>)>)/,>48?*9W&<)9+AA'*<9^[FMFLR,E;'T.:?L['
MF'>M#H(^()"X$6A@+5R[A*%K)T30O30L?/4,@D\EY&RSJ'8Z/;:WT!$46R/-
ML?2\0<5P]T%N3*7ZS[8D8P>5%$T/[N<3O9+"  #]^D$I1$0$1?B:40POD<'$
M,:7$-&SV&T'[15IX1\YY)SL/RMWCM?'<9GCD?1M"V'RO<V3HZ7L^'H_OV^S\
M=[77\3O$"GP2C1\RG9R.4R,WL]"A6UUSR=OB?0;<T;[G;AV*":(J7K>+N=X_
MDZ<7BAQ0\=QM^015K\5D3QL>?A+K[/;X]M:/;0)%T;[$_) 1$0$3?W(@(A.A
MM:6:R5?#XFWD;OF"M5B=-)Y;2YW2!LZ ]4&ZBA61Y;EY^"8WD'%>-V<I9O>7
M(VA+,R"1D;@3U..R-@:[;^*F<9<8V%[>EQ );O>C\D'Z1 B B(@(B("J><_W
MT=8;_BGV_P#U3U;"J>4G_P!**L-=OJD-GY?NIZ"V$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$0^B#"(B(RB(BB(B
M JN\=P/+X 3\.7XX_P"MX5HJKO'?O'P ; _NOQO\_=Z$K0'JLK ]5E 1$0%0
MWX)TT4.'Y9BK9:S.5LQ(ZU$[7F =+6[(]==;9/YRKY5><P\(.*\HS3\O-#<Q
MV5D;TS6L;9=7?,/D_78_GUL]MGL$&CE>>X X[Q#?Q%L3^182C+-:FBJ@!\C8
MW=+C(!I_201HG?NGMV5,5^,9.7@>'Y%Q7!<CK\PG9#;/(9LU7:RVYW=P<'3]
MV'X-+0?@?COZ,X=X?<:XA@[6)PF,CCIV]BUYCC*ZQMO3I[G;)&B>WH-G0[E1
M./P(XL#!6FN\@LX2O-Y\.%GR+GTF.V2-1ZWKN?C\3O>RB(?S_#.Y?X]<7Q&7
MDO4(;_'"Z]#4L>6XCJE+HB02".K0/KL#U7.Y+X;<:I>-G".,Q5K1QES&3"QN
MY+UO\J%P8>H.'3]D;#= ]^RO*QPO%S<ZH<L)L-R5*F:,,;'@0B,EQ^SK>_>/
MQUZ+0YUX<8SE^7QN5FR&8Q>3Q['QPV\7:\B3H?ZMZM'[_37J455^-P='D?X1
M?B3@\HV=^.GQM4/CCF?&?=95<-.:00=A1/B/'<9'^#+R#DC(I8\K;K3UYI1.
M_I,;;(T S?2/LCN!L]_FOH?$\%Q>+YUEN65Y;KLKDZ[*TXDE!C#6M8T$#6]Z
MC;W)/Q6ACO#'!T?#>SPF&;('#S]?4]TP\X=3^LZ=TZ]?N1/-2D;I.29SP?X-
MEYK'U7N8*.Y9KQR.C%N012N#7N!V0#$SM_E'XZ5G8K#\2\/JO,:F,Y7;ITXZ
MC[,^*BNLE?BV]&S+"QP<]CCU C>P26]CV7;R_A9Q_*<?P6,D=D*\N$C;'C\C
M6LF*W   .T@'Q &^R_."\*^.8O&YNK.+V5GS47D7[V2LF:S.SIZ0TR=B /AK
M7<#Y#5G<B,/G;.4J>)QW%^4<8XYR&F)<I"YO)\MDV^U7>M[CTOA8XDM<!]K0
M[-^.R3..8<1PU[\*+%XVS6>ZKDL=](V )Y&N=.TS@.#@[;1^2;V';MZ=RIJ/
M ?C+L0S'V,ER2S% ]KZ1FR;G>PZ(/Y%NNAN]:)+2=?)2#F'AGBN4<HH<AFR&
M9QV7IPBNR?&V_(+HPYSNDG1_EN!UK8<0H*9;CQSWG'.[/(^,YGD<N.R,F/I.
MJ9"*NW&QL+FM+&OE9ISND/ZM$$]_GNW? QW(_P 7E2'EY?+D:\LD3+#[4=ET
M\6]M<Y['.!(V6^N_=[_-8Y+X2X3-YJ_E(;^=P]G(M:V^W$WW01W- C\HW1![
M$CX>I^))4LXGQO%\3P-;#X&J*M"N#T,#BXDD[))/<DD^I152<BQ5;Q!\>KO&
M>5NL2X#$XJ.U7Q[9G116)7.;N5X:07:ZBW_H_GWPN.82I%SKQ \-A/9N\,BQ
M[;D=9]F0^Q2-,3Q&Q^]M!+W=M_P!OX[MWFOAUB.692GE9Y\GC<Q5B,,61Q=M
MU:<1G9+"X>K>Y_K/S*_?#O#W"<2IY./&BW-:R9+KUZW8,UBP='NYY^/O'T [
MDE!!/P5\!CH/#7&\BB@<W*Y1DL=F3S'%KFQV)0T!I.F]A\ %Y^*]F+$>/?AI
ME<U)'%A0RU V67[$<SF.:"3Z#9?%W/ITD_!6?P3BM'A7%Z> Q+[,E&H7F,V'
MAS_?>YYV0 /5Q^"_7,N)83F>(.-Y'09<J]0D:"XL=&\>CFN:06GO\#]Q[(CE
M^(_+.,<6K8MW*VLE;9M!E6(5_:'B31]\,T3VWK8&]N ^*KCD=<<^_"%M\/Y5
M)*_C.-Q8N08YLSHV6I3Y7OO#2"[7F.UW[='Y]RWBG@IQ'CF9@RL<%V_=KZ-9
MU^R9FP$>A8W0&Q\"0=>OJNWS7P]P_++U7(V)+^-S-5ICAR>,LFO98P@[9UCU
M;W/8_,ZUL["J<!"[BWB%SWA>&L67\:9AI;45*28R-J/,3"0PGNT$R.[?F^2Y
MW@SP3&V?"V+EMF6\_*5:%Z"K&Z<^5%&62,+0SX;+G'\Y5R<8\.,'QVGE8ZOM
MMF[E8W1W,C<L&:U,T@CO([T]?@/ZUN\5X5C>,\,/&:$EQ^/+)6=<\H=)J3?5
M[V@/B==E11?A!Q:O3\)X.?L?>ESV*IWCCHS.710@-D81T'L=N+G'[S]RY>,X
M[D+G"*_(L1Q[-R\L>\6(N3OS5=K7O\WI+2'S@]!&V]);Z]O1?1?#>'XSB?$X
MN.4/.L8V,2#IMN$CGB1Q<X.T "/>/;2B8\$^+B,5/:,V<)YPG^AG9![J9<#L
M#H/?6QOU5RQQ*-<AKR<V\8<+Q_ED=AF*BQ#+DN-$Y;')8()/5T.T[1V/4_8[
M>J]>2\/XWB_#7F6*QF<L9)F.<;K*+[PD^C96@EK &^\&]_LO)!U^=6#RWP^P
M_)KE*],^]CLE39Y<%W&637E8SO[FQVUW/P[?SE>>$\.<#B./9?$1LM6(\N'>
MW6K,Y?8L%P(VY_S&SK^OXE3*XE2/,L)1Q?X.&'N4F2LLY*U4MV7^<]W5)T.&
MP"?=&AZ#04VY;1CYCXQ8KBF>GM#CU;#B^VG%,Z)EN7KZ=/Z2"X #T^X_,J12
M>$&&FXB[CEG+<@L8[VB.Q'YUT.= 6 @-C]W36]^XUZKM<Q\/L-RJ;'VKC[U3
M)T&]%;(T++H+$;3ZCJ'J/CW!^.M;.RP@'$*;.)^,.>X?A)K!XY-A#D32DF=*
MVI-UM;IA<26@M.];^(^2K'B?$<7E?P<,EG[WMDF1QSII*+C9D#:Y:6;Z6 ].
MW$'9()[^O8+Z-XAP#$<7=D)JLE^YD<@-6<A?LF>Q(W78=9] /D!_L"U<-X98
M3$^'MSAM:6^_$V@\/?),#,.O6].Z=#T^2#K>&UN>_P"'?%[ER1\MFQBJLLLC
MSMSWNA:22?F22I&N?Q[%08+!8[$U'2.JT*\=6(R.ZG%C&AK=D ;.@/@N@HHB
M(@*IIQ_?1UO^:8_[T]6RJEL_^]-4/SXG_P#ZGH+:1$0$1$!$1 1$0$1$!$1
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M)LC>QL<$N<+'/K=WCN6P\$-.M;AGF=>B?;R<CY&2RS2;/68XO+< YWS=TZ8
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MUTD!<T.#7AI.CH_S_#:^>ZY @ST^"FQ/TY/C\R^U!6B=[=6<Z8. MO:XN>X
M%K=M80= ;'=6Y3YC@7,Q>4IQV)!GJDEMDK6@Z9!'U%KP7>ZX!Q&A_"WM?OC?
M.8<S:Q\%C"YG$C(P^?2EO,BZ+(Z.OI:Z.1^G='O=+M'0/R*"-^%$V!Q^:Y!6
MP<^!?C9#4$5S%;AK33.;*/):WS'1F5K6-)+-$A[>KN%H^/$&/OVZE/+W,+CX
M'8F^(;.9B\R'SG>2UHC'4W4P&RUPZG %VFG9U,.6<NQ&,RK*=VC?NF@UE^W/
M5B#X\<PES62S>\#HZD.FAQ 8XD :)V:7,JUGD8Q3\;E:S)9IJU>]8A:RO9FB
M!+XV'J+]Z9(07- (C<02-;"(T,9@L]R_BSI>/4X<PS&Q9V[-:J,=<8\!C(&2
M3=(=U=8>2>QW#KT.E+N>W([/AMR>>C(ZPWZ.ML#JDFW=36/:[I<W>G @CL"0
M1Z;[+VQG+J&3MY^I1BMRW,.XMD@\O3IQH@.BV=.:7LDCWL>]&X'YKH\<FHV\
M)4N8II;2N-]KCV""?-)D)(/<$EQ)'S04[AX..5N.<L9#2XSR+'U8JMB 4:;/
MHYULL=$UGE]3P)>H-+G!V^F1@[$=^GR'#>R5</X?X#'Q7G-B?E<B(W,I1_:(
MC?IK2&DV")&M:.WDZ]!HW#K[RL:[>I1,(WPGD8S6(ILR!AK9P,D9;H^:TO9)
M$_RI2 /5G6.SO33F_,*O+#J7XTIK9DQHS#,]%&VGY>\DZ U61%S']6Q![QD+
M>DMT'^]LZ%P&E7-]EUT33;9$Z%LI]0QQ!+1]Q+6_U!;&OO*IA1O@U+C,?;K7
M?;,4)),5/8R7E.#9Z;S,V3IO/)]Z4=;AU.#""V3MH]KR'HO&W5BN5)JUEOF0
M3,,;VG^$TC1"]E%$1$!$1 1$0%4=H_WU%,=M?5/^?_?3U;BJ.V/[ZFF>^OJI
MK_\ DR?J06XB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B'T081$091$0$1$!5GXZ@G'<./P'*<:3]WY0JS%6OCB-X
MOB?W<GQO\WY9062/596!ZE95!$1 1$0$1$!$1 1$0%#_ !(P$_(*.-B92AR-
M6O;\^S1DG,'GM\M[6Z>!V+7.:[7;?3ZJ8(@I6]X;Y:6GC8G4:5F>MCV5*,QO
MO;]$2-F>]KOL_E@UIA&SW)A]!U$J0Y;A.7ORYW+,R;X,O->CN4ZK7,,!%8M]
MG:]Q87@.Z"7!K@/RKQW^-DH@Y+;%W(T,M#%&_'V8WR5Z\SQU GI'3*T:&QL^
MGS:56/'O#R_C,!DJU7$5,>Y]:FT5X<F]QGLP2^9Y[92S<9_D]M$ZZAH=[D1!
M!^*8+.8/CG))PZ&3.Y.U+>ACFG,C62&%D<;7R=(W^]-)TT ;( T N-)X>9+%
M8Z*KB,M->CDPLV%G;<,; &^43%(TL8"XB38]XDZE<=]N]HH@JX^'MZMGZ]JE
M-6%*6A9]I@<=>7<D@CB+X^WV7AFW#YC?JXK>XWA.0R_5"OF:=&C5X\QLA=%<
M,\EB457UP .AH:W4KW;V3L :]2K#1!6OB)P[)Y[(9)F*9##!E\:,=;LMN.A(
M&Y!N2,,/F!K97%H:6DG;7'I(UZV:7+Y>0W<K)C*$]FO%9BQ'F7OW/7VWW'.C
M$?4Y[RUH<[J]T.<&Z!.[%1!7F%XA8XE:PF1.9FN04JL]?(/MB-H\IS?-?(WI
M8"3YK =.)[/=W^?=\-Z\T'#J;[$;H76I)[S87-+70LGF?,V,@^A:V0-(_P E
M29$!$1 1$0$1$!$1 1$0$1$!5%;)_P#2JI#X?5/Y_P#WF16ZJCM'^^GJ?\U!
M_P!YD06XB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(?1$/H@PB(@RB(@(B("K_ ,:,1FLKQW%.XWCFY+(4<O4OBLZ=
MD(>V)_41U.( ^ ^??XJP$052>8>*74>GPMK@?#?(8#_8L_7#Q2_Q75O_ -PP
M?J5JH@JGZW^*G^+&H/Z?A_4@Y=XJ;_XLJ>O]/P_J5K(@JD\M\53K7AI1'W'/
M0G^Q/K=XJZ_XLJ0_/GX?U*UM)H(*I^MOBK_BTHZ_T]%^I9/+/%3_ !:T?T]%
M^RK51!50Y9XJ'U\-: _/GHOV5^QRGQ3/KX=8T?T['^RK21!5GUI\5/\ %UC1
M^?.Q_LH.4^*G?_<YQWZ=C_95IH@JP<H\5?CX=XS].,_93ZT^*NQ_N=8T_P!.
MQ_LJTT059]:?%3>OQ=8T=M[^G8]?F^RL_6GQ3_Q=8W].Q]O^RK21!5HY1XI_
M'P[QOZ=C_93ZT>*F^WAWC /OSD?[*M)-(*M;R?Q4/KX>8P?=].,_90\H\5-C
M_<[QA_IQG[*M)$%6NY1XJ ]O#S&'^G&=O^RL,Y/XJN['P^Q3?O.;9_8U6GH(
M@JX<F\4]'?A_B=_Z<9^RAY-XJ ]N 8D_FS;?V5:*(*N/)O%/7_%_B=_Z<;^R
MLGDWBG_B_P 5^G&=O^PK01!5QY/XI@=O#[%D_=G&?LK/UF\4]?\ %_BOTXW]
MA6@B)A6'UF\4NVO#_%?IQO["?67Q2_Q?XK].-_85GII7)A5_UF\4_P#%]B_T
MXS]A8^L_BGV'XO<7^?Z<9^RK1TFE%5?]9_%(^GA[BQWU_P"W6?U_86/K/XI^
MGXOL6?Z<9^RK11!5XY1XI'_ZO,8/SYUG["Q]:?%+0_W.L;O_ $['^RK11!6'
MUH\4?\7F-_3S/V%^1RGQ2^/AUCOT]'^PK11!5IY5XI]]>'&/_3T?[*Y_%\5S
M'*>,M?E?)>-PX>M'AG8XB+(QV 7"4O:=  ]^HCT^"N)$ +  'H-+*("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("'T1#Z
&(,(B(/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex31sig.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex31sig.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" .H M # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO[Z;6X-7N/"-Q<:XD5Y?H;?6[7S39-82R!_YPOBX]J?^"D7_  <XPDFV8_\
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M?L=?"_Q?\$?V?/@%_P % ?B-_P %._@GX]_:Y\8_%CQE\*OAGI'B/XR_$-]
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MS<S<J;<FFG%*')*-XMR4KZ?RQ^,_VE_CUX[U/XO^*OASXX_:);]DW4OV!?\
M@E+\8?VLOB5K/C?3M-_:Z^%_[.OBA_VD'\>>(/AOX/\ "6A:=X5LOCK\9O"C
MZCXN^-7Q5\"Z9X0LO#G@'X;:Q>_#K16\7ZUX&O?"G0_M&^*OA5K_ .WE\8/#
MC^/_ (1^)O@QX0^!'[ UQ\,8OB)_P6%^./[#6B>&/ GBW0/BG?:KXN^'V@^
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MHO-I-.T:DFK2<>:+YFE=)7E&"2<(NT=.=).[;/V0\;?\$F6^)GPA_;1^&'Q
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M;^\3?$J7P[:_LP_LW_MU?$'PAX'^&=CCQ-HOB#3M0TSP'XCT"36;VXUAM ^
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MKMW7-42CI#17LDG%*7/=7Y+N7OM-6W:5WRH?+2FYJT[IIR:59-:0DFGRJ_\
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MX=U7X27OA.Y\:^//'"W.DK'X:@;XPR:)X4T;XE?#W7_'+^!M.\+^+O"Y,/\
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M.? 7PE\&HOC)\:]>TCPI\"/BI\,]6U3Q=X=\=Z?J&NS7'PQ\1>!%UWQSX?\
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M#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3-$M]0TR'7O#WPVN=:BU[Q3J:61O=:TWPA'J>HS_ -8/_!)S_@FK/^QUX/\
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M32/BUXP_:O\ VR+?XU_"G7/%7QE^!=_XA_:8O+7PU\/)_AAX4^,FC?%;1O\
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M05&Q64AOZ9:*!<J[+[D?S/+\;O\ @ZR)&[]BS_@E.!M.0?B=\5L[L$#I\:W
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MBW>A_#;X]Z7XLNM5T]]2OY-;MM*N?$7AW5M-TR*]COK_ $VQU?2-&U^YT?\
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MTFFK7N_I_9)*LWF6R*!$41I"2S!@R$%8R74, KL,AEW;0&9<G^8_XK?LP_\
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M !7^'.I:7XOTKPWXINK8ZA;:-->ZAI(T5[R*26'1[G4FU&:3R89 ?PJ^$/[
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHOA_X,ZZNHW-I\:]4\8>$;KX7MXGT:^O]3T[^HWQ#KND>&= UCQ'K<_V?1-
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MGB?_ (5JOPR\.?$'6?BAX7M/C))X?L?AX/ 9LM7\66PN8?''B&;Q%'T'B_\
M;@^._P 8/BI:> ?V?_CCX6\)_#3XP?MT?LU?"'X,?&7P[\./"GCS[3^SQ\7?
M^";'BC]L9O$GAR#Q3))H7B67QAXK\/VR:3XCU&SF&G:)>W.GP:?+<6>:^Y?V
M7?B5\?=._:&_:-_9+_:"\;>&?B]K?P8^'G[.7QP\!_&CP]X/M?AYJWC#X9_M
M&ZO\?/!EOX<\?^"='N[_ ,,Z9XU\#^//V<?' 75?#DMAI7B#P;KWA2[?1[+5
M[/6#<.[7;O?6Z]'=+Y[]F#:GJG)..\;KK?E<M'I)+F6NJM=7VI_L2_"[XI?L
MZ_#'X9_LT^-_!FGIIUCX8^.?Q/N?$W@G7=6UCX:_"2Y^(7[1/B?QOX$_99\%
M-KFF6E[?^#?@[\/OB-8?#CX>:BRZ9%'X(^%^GP6'AG1=.>RM++Y:^+_["WQI
M\7_M;>*OBEI/PR^#NOZWXE^,_P  /B3\)/VT]>\4QP?&O]E#X=?"O3] LO&?
MP>\&>#+GPCJ%YK.EZ_:6OQ"TO3-&TKQ'IG@KQK:_%[Q/_P +2L+R$WD.H<;X
M$_;U_:%\1?&&\\,6WQ2^!VJ?%GXH_'_]K[]FWP7^Q)XJ\*:IX4U']GW7_@EI
MWQVN_P!GSQU\6/B'X<?Q+\1)?#7Q@T?X/^$?'_CK6M1\*'2M6\'_ !BTS7?@
MMI6LZ-I6D3^*O:? G[67Q;^ 6C?ML:I^TA\:O ?[17P__9*^$O@CQOK_ ,:O
M"WP[LO@QH6G?';4K#Q])\2/V;86M]>UKPKK2>$UT7X::O::I_:B^(/")^*5C
MX/\ '%[JNOZ=<WD#LW[U_P [VVOHGN[I=V[!K>ZW73Y7_+7_ "/IOP/\,OB?
M\-OB;^W5^TEXLT/3O'GC;XAZOX6TOX!^%M'UR[EO/^&=_@=\#="F^'GPIGD?
M2!%H.K^(OVB_%'[2'CFX:TT[6KB$_%"PBN;C5(M*TZQL6?ME_"'XA_M0?LFI
MX&\,>%M(_M3Q+K?P.\:?$+X'^.-931O#OQ5^'OACXB>"/'OQ<_9K\9^*;72M
M872-(^)W@_2]>^'6O7;:-J.AZQ;7MQH/B;3[KPAK.N6TORK\)/VWOC!XJ_8O
M_:H\9WGBCX3_ !0_:;_8BN]4U;XGR_#0:/<_#CXK:%I7PX\'?M-:9IG@_3M(
M\2>*WT*;Q;\&O&,OPAAU276KN#3?C/X0\5WRR7&DZ8;2;];_  MXIT'QEX:\
M/^*_#-ZNI>'O%.AZ-XAT#4$1XHK_ $77],MM6TF\A2<12".ZT^ZMYU1D651)
MM9%96 )7LF[MIV3\N5))K32SNG;:_6PXI-/1)/6W1W;;>[U;W^[H?DWX#_8O
M^,%I^S5XA^!\/@;X<_!?X<?%C]L7PO\ $S5OV=?!7BI=3\$? K]EM-5^'^N?
M$3X1>#M9M_#MII>I7'Q"\5^"_%/CK6O"V@Z/I'@W3Y_B]XF\(Z'Y/AS3+:.Y
M] ^/?["'BO\ :Q^//Q1\1_%KXL?%/X6?!E?@;:_L]_#CP_\  SQIX2TF\\<^
M"/B?9:KJ/[1Z_$VQ\5_#3Q;)ID'B2\'@_P *^'U\.ZQ9ZI9Z3X8O-3MKZPN=
M1@\C]2,#GCKU]^W/X<5&\22 !AD Y'U'_P"H?D*I59IW5HM<R3CNE/E4M[ZM
M0BF^J36EVR?84G'EG'FB^6Z?]URE'6+@])3DTKI)NZ5M#Y*_9ME^/MAX1\-_
M"G]H/0+2]\9_#SX5?#G^WOB[X?UF[U7PU\3_ !-)XF^)'A'4(HHK_3-.FM?$
M9\(> O _COQB(YI[>'5/B=_9EO;6T.FVUQJ'PY\+?V(OB_X5_:R/Q5U;X=_#
M6T\66?[1_P >_C#XF_;?M?&IU/XR_&CX.?%73/$NF_#W]G?Q7X$/A6RO+32_
MA3X:U#X5?#;2[#4?$NI>"-#\)_L_>%M6\)VMKJGB*\M+#]E_)3T/8=?3./RR
M<>Y)[T]45!A1W+<\\D8)_+BDYNSLHM[VDFTF]WOWU2LUKJM$)4%=.4IWBG&+
M4OL]+JR2:BE%.-FDM'JT_P )_P!CK]DGX\?L@7%Y\2G_ &>O .@^)? /[+NL
M_"_XN7/PS^*UWXN\;?\ !0KX_'XB>$/%VD?M&^/+F]\)Z=-I'BNR_LWXN>(H
MK[QDNO\ C:]U7]H+Q#X9OM1ET#PCI%U/^XL>E6N]'DA4R0S_ &I9%#1AIRN-
M^T.<[0!E26CW$X7C-:)B1B2<C.<X)'7KTZ9QS3P !@# &!^0 'Z #\*4IREV
M7=+F7RWV3OO=VTV+ITXTERPNH[J.ED[)7225KI)/O:[O)RE):***DT"BBB@
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M$/@9XK_:<_:;^,GP3\$>,_@QXST?X5?$FR_93TWPK?W7P2\22>-=)TGQA/\
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MJP&+4O\ P1I_X*NM&4A_X.*_VIXRS89I?V:_!$I\G>^$5D^+L$B3>6RJ;A9
M2ZF3RP"L<?\ 28)8CTDC.<XPZG.!D]^<8)..@Y-*9(P"2Z8 R3N' X.3SZ$?
MF/44 ?S9#_@C9_P5BW,3_P '%O[4)1EBRH_9C\"AA(I!E96_X6^0B.<[(T12
M@(#O,!@S'_@CA_P5?( /_!Q3^U%N)B#D?LR>  #&K9F5 /BP"DDB\1RAB8C\
MSK,/DK^D?S$P"'0YP1\PYW':N#G^)B%'J3@<D4I=!GYER, C<!@G. >>"2"!
MGK0!_-Y_PYQ_X*L'S-__  <2_M3G?#(@V?LU?#Y-L[D8E 'Q1.(U4N/*C\N0
M$HT=Q&(]K20?\$<_^"JL0R__  <1_M4R2;F&1^S9\._+\LAB%\J;XFSCS!(V
M[S-WW (U1<*Z_P!'GG18SYL>WCYO,3'+;1SGN^%'JQ '/%/+*."R@G@ D<GL
M,9R>HZ>O% '\WTO_  1P_P""J<AB(_X.(_VK%"@^:!^SC\/EWNQY*>5\38@B
M[6<*DBS%6*,K#RPI;#_P1N_X*I*0T_\ P<2?M72.)&8F+]G/P!#&8L#RT$3_
M !/N%#K\V^0Y23*_N4*Y;^D0,I (8$'H01@_0]_PH#*> P)Z\$'C)&>/<$?4
M'TH _FQE_P""-7_!5MHPD?\ P<5_M4(P+X=_V;/ [C:0?+#!/BY#(S*QR[-*
M=Z@*%CP")$_X(U?\%4V"BZ_X.)OVKY,PM#,;;]G3P-:;U=0&:$CXJS&WEW%R
MDX,D\8*!)5,>YOZ2MRX+;EVCJ<C ^IZ=Q3?-BY_>1\#)^=>!G&3SP,\<]Z /
MYJ9?^"+O_!5,AOL__!Q9^UI$Q9F4S_L_>%;@ %8@ 0OQCMR<,LK?*R+M=%55
M:.1YV+_P1A_X*PHP"?\ !QC^U-Y1;YU?]FSPG+*R/(SRA)I/C41&Y#E876/;
M;@(%C9$5!_2T'0XPZG/ PP.3SP.>?NG\CZ&C>F2-ZY&=PW#( &3D9XQU.>@H
M _FM;_@C3_P5C"_NO^#B_P#:B63(^:7]F7P5,FW:01Y?_"XXSNR<AM_08*DX
M8:L?_!'?_@JT/*63_@XB_:B9%,?G^7^S+\.4DF".&;RY)/B?/Y#,@V A9$&%
M:2.8^8)/Z//,CP#YB8) !W+@DXP <\DY&/J*3SHNGF1Y[C>N1]>: /YR%_X(
M\_\ !556+?\ $1!^U.=TI9@?V:?AH1Y# AHT5OB,R1R\G;,J[$."L (&)#_P
M1^_X*KHDBP?\'#_[42LRJ$:X_9C^%]SL(;+$AOB(C-E J@*\9!WL2V_:/Z-!
M)&>CITS]Y?;T/N/S'J,GFQ\?.GS?=^=?F.<$#GG&1T]13OZ?<@/YUU_X)!_\
M%2C$D<O_  <+?M5L<GSVB_9M^$\)=-LF!"?^$SDD@8.T;%S++E$>,*N]'BB/
M_!(3_@JL5B'_ !$-?M.[ED=IG_X9@^%H,D9CV1QQ*GQ"2.$HW[QG=)R[=0*_
MHMWIC.]=O&3N'\6-O.<#(Z9Z\8IRL&!(((R1D$$?F*0'\Z,G_!(/_@JD82D7
M_!PO^U LPG\U)Y?V9OAC+A ZLL3Q1_$.".1=H96R KE\E-JA*B?_ ()!_P#!
M5D2;[?\ X.%OVDT5"S0"X_9?^']PRNV0//V_%>W@N416)2.2V $RQNQ:(202
M_P!&E%.]NWW(#^="3_@D)_P52E15?_@X3_::!+2R3&+]F;X=PAY9((8%,7E_
M$X2001^4TZVXE>,7,KR B,M"T#?\$A?^"L #"'_@X7_:*3*"-?-_98\"SX4*
MZJS%OC$K-*O[EQ*&1G>.0SB99W4?T;44^9^7_@,?\A<J\_OE^C/YT(O^"2'_
M  5G@<O'_P '!_QTD&<*MW^R7X.N%*YA(\P#XY1*7 B*[X5MPWF.60EFW:*_
M\$GO^"L*)(4_X+^_&G[2T;)'+)^R5X3E@5B%V2/:/\=S&[QLI8B-H4D+%70I
MA1_0]11SRM;W?_ 8_GRW)<(O?F_\"DORDC^?%?\ @E=_P5B$TDK?\%\?BP0U
MNT$<:?L@>$A'$S.&$P63X\RJ\JKN0,ZEL$'=\BUH/_P2V_X*ILT!7_@O#\6U
M6-HQ,I_9,\)DSPQJJ[-R_'%/+E< B2<!F;.[:)-TC?O]11SR\O\ P&/_ ,B'
MLX_WO_ Y_P#R1_/Y:_\ !+G_ (*R6R.#_P %ZOB;<.<,C7'[''@Z14D)S(Q3
M_A?(9EP2L,1D$4?RF1)R#NH'_@EE_P %<WD9Y/\ @OS\2MA\W"Q?L5^"X6 =
MV9 2OQ],1\M&"@K CED5@RJ6C;^A*BG[27]W_P  A_\ (CY5_>^<I/\ 70_G
MG'_!*[_@KLL*QC_@O]\2O,#29F;]BGP8YD0^8(4=3^T#@-&K1K))$8FF*,_R
M2,KQVK;_ ():?\%<($"R?\%]_B7.PFD?>?V+/! Q"\:A(E$GQYF;?%,&D261
MY%:-A#)"^WS&_H.HI<[_ +O_ (#'_(7LXVM>5K6UG-O[^:_X]^Y_/A=?\$N/
M^"O4TETUO_P7Y^(%K'<S22K&/V'_  /*;<-$4CB@=_C^-D<<A,I"J-_RI\@4
M&LT?\$KO^"PP5T_XB!?'K*2SH6_8:\("02$A4WRI^T<I:%(BVZ&-8?,GVRF1
M54Q-_1#10I-/F5KOO&+7W-67R0<BY>6\K?XY7[[WO][9_.DW_!*;_@L8X:,_
M\'!GCL($58Y!^PSX;6Z5D5@KO(G[3B6TF7;=*K6F)0JJ2O)J+_AU+_P65WQ,
M/^#A'QJ%C<NR']A#PV5F8]/./_#46[:.HCA,,61_J]N5/]&5%)N_1?))?E_2
MZ%**6U]>[;VOW;[_ #ZG\Z)_X)4?\%D?,F9?^#@OQD(Y 52)OV$]"(AR\K!T
M=?VJ$D,@\W!RQC(CB41!451F2_\ !&'_ (*$>/\ XA_L]>)OVE?^"R%Y^T+X
M'_9^_:.^"?[2>E?#O7OV+;?PY%JWBWX+>.=(\7:;'!X@LOVI]2?1+O5+"QU/
MPZ-3_LC58--AUNYU :1?3Q>1-_2#12&U?1G/RZ;K,MW+,-=,-J^X1645A;?N
M00<,;F0-+*X)VX<"'&UA%N0A]:TAFMX$BGN7NY%P#/*J)(XXR7\I$0MUP51>
M H(R"QM44"44G=?F%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J.
M89AE [QN/S4BI*9)]Q^_R-\OKQZ]O3J.M-;KU7YH4OA?H_R'T444AA1110 4
M444 1R[=F&P5+1J0>AW2*N#ZY)QCH<X/%?RUZ5_P5/\ VG_'W[+WP=\6^#/C
MA\!+7XJZG_P3Q^ WQ7^.M]KD_P .?!5EX(_:F^(/[5?P.^$'B_X=ZIKGBVUU
M3P'\'?BUKWAO4OC/\,OA7X8^,>F6'PSTKXX6V@2_$TZ9X0T7Q!<P?U+L 00V
M,=\_7C]:\^3X2_"B*W\8V<7PR^'L=K\1+B2[^(%JG@SPVEOXZNIG>26Y\8P+
MIHC\3W$KRRO)-K:WTCO([,Q+L2+=WU35EY/N)]-;:KYKM\[G\R'AO_@IQ^TU
MXY^-_P"S;\.]-^/VMZ1X!U;X%:!XA^(/B;6=*_X)Y?!7Q3X@^)EI^W+\;OV;
MO&]YXN@^*?QG\:?#_P <^$=&\-_"<:3#J/[&_C+QMIGCS48D\:^ [F#3_'/A
M/0+/W+_@H/\ \%%?VC/V>OVY;WX7>!_B';>'/AMX(^'W[%?CS4/#K:1^S9J?
MAO4],^,'[2WB#P+\;=0\;^'_ !SXZTC]K7XBPVWPF\/:K-\/_"'['_@+X@>.
M[SQO!I6F/I\M[J]EIU_^^%[\$_@UJ,.@VNH?"+X87]MX6L+33/#$%[X!\*W4
M'AS3;"X>ZL=.T**?29(](L;.YDDN;2TT];>"WN'>:&-)&9CMZG\./A[KGB#2
M?%NM^ _!FL>*]"-JVB>)M4\+Z'J'B'1VL9WN;)M*UJ[L9M2T]K.XD>XM6M+F
M$V\[O+"4=BQ=UII>SN]=U:2MVWMOIIML*TKWYM-?=LO+JM=+/[_)'XF/_P %
M2+[1?V"OCA\16^)?PY\;?M>>&OBY\</@QX&^%O@S3K#QSX]TKQ5J7[6WB7]F
MGX /J?P2^'<^K^-=>M='GOO"%]K%O::&U[XH2RGC@1K[4XE/SL?^"F/Q:^)7
MPE^!]CX^_:]\&?L"Z_X5^"/[6*_M*?'/QG\#M,U"YU;]K7]D/QCX1^'MW\.[
MCX+_ !>LM(UWP-H'Q!T+6XOVHXO@1J6A^"OVA_%_P?\ &/P_\/>$IO"6HZI?
MWMI_1CI_PG^%NDZS=^(]*^&O@#3/$-_<)>7VO:?X.\.V6M7EW%?C58[JZU2V
MTZ*^N+F/5%74DGFG>5+\"\5Q< 25H:C\/O 6L>?_ &OX(\(ZI]JU^W\5W/\
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M_P""C_BKXT_%/XL_#KQ1KVI?"OX$?\% E_8KF_9I\5?!_P#9L\%?!;XE> ?
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M<3Z"CZ9*YSC&,I6:44F]KZ.3;MYII)>6K'9ZZ[MM;Z)VLM>WYO1::_)/PO\
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M=2NO$MNMIJ-WJ-CXHU*+0-8CMTK]&[>2_JQ7)'=I7[V\K=7V5CK/$W_!*_\
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MWMY/1>>_3L?BI\;O^"=7[;7[2?@>?X9_M!?M;_L=_&WX=7FIV^M7?@CXI?\
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M]<4I..OL/S.!^M1;G:-"4V2,J,R;@WEL2I92R@J^TD@E<!@"0PX(_$'X)?\
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M,$+SRF&UMHIKFYG$4;&*WMX)YYI=D,4,LDBH?PI^!W_!=KX=?%*QNO&WC/\
M9F^,WPN^#GBO]EC]IC]LWX"_$%?$GPP^)FM_%CX$_LHZF-.^*<VO?#?P)XDN
M_$OPG^($IFMCX4\%^*);Z/5[V2?0;K7-/\2Z??Z+"!==_/Y'[S49ST]Q^1P?
MUK\K?V&?^"FG_#8'Q(U3X0^,OV<?B%^SM\09_P!G3X2?M>> -/U[QM\-OBIX
M?\=?LX?&[5-7T?X?>+9O%7POUC5].\%^,KF^T2X_M/X>>*?LFIQV<O\ :>@7
MWB73;34KO3_H;]N']LWPG^P_\ =:^.7BCP1XT^(L\?C;X=_"_P '^ /!1T&S
MUKQC\2?BSXMTGP-\/_#[^(/%.I:/X4\)Z/J7B37-.@U;Q7XGU2RTC1;-Y)W-
MU=?9K"\+.S?1;^7KV#F2=FU=]/Z1]F @YQV./QI"P&<G&!D_3UK\3[W_ (++
MZ-H_PNOKS7/V6?B_I_[35A^V_P"$O^"=G_#,2^,/A3<QWG[3_C[P=)\1/".G
MVOQW7Q)!\+&^'>H>!H3K-UXQ>ZCU+3;Z:#PY>>%$U^>TTZX]!NO^"MGPYB_X
M)^^./VYC\&OB9::SX*^*'BC]GJ;]G#4[[PC_ ,+)U_\ :/\ "_QF?X!R_"#P
MCXDT#4_$O@?Q7<ZW\1XC8^&O$?A[4M7TS6;%EFCBCU".XTJWF5TKJUK^\W?X
M8WYFK=5Y[ VE>[M;5^2/UO!# $'(/0BE)QU]A^9P/UKYL_9&_:8\$_M??LV?
M!G]I3P#!=Z;X<^+_ (%TSQ4/#FHRV]QK'@OQ );G2O&OP]\02V@%H_B?X<^,
M].U_P-XH%H6MDU_P]J2P.\*H[<!^VO\ MDZ%^QUX-^%&JR_#GQY\8/'_ ,>O
MCIX(_9O^"7PL^']QX6T;5?&WQ<\?:?XBUK0]+U7Q=X[UOPYX,\%^'8-%\)Z_
MJ6K>(_$.KP06\5DMI9VVH:G=V5E*TTTFM4TFFMK/5/Y@I)JZ::TU6VMK??=6
M[W1]I45^+T?_  61\+Z_X%^#W_"M/V4OVC_B;^T?\7_C=^TQ^S_!^RGH-S\'
M]/\ '?@WQW^QYJNM:7^T3>^)OB+K'Q#M?@S>>#O"<^C6T?A_Q9X6\=:]IWB^
M_P#%'A[1-/6WUA]9M-"_0_\ 9=_:H^%W[6G[.7PP_:=^'+Z[HW@#XG^%[CQ'
M:Z=XZTV/PUXI\)W&D7E_I/BSPWXTTQ[N[M=%U_P9KVDZQH?B2./4;W3;>]TN
MZFL]2O=/,%[,_+JW9>MF[>MDWZ*X72ZK17?DNY])45\L>!?VX_V-/B?X;^)?
MC'X<_M4?L_>.O"?P9%P_Q:\2>$_BWX&U[1/AO;VL N)KWQIJ.FZW<6WA[3A$
M25U+49(-/D>.:*.Y:6"9$ZWP'^U/^S/\4[CQ[:_#']H+X*_$6?X5P177Q-3P
M-\4?!/BH?#VSFL)M3BOO&CZ)KE['X:L'L;>YG%_J[6EF%M;L-,K6MPL2YDG:
MZNVDE?K)V2]6]A[7OTO?RMO]W4]ZHK\Y/A-_P4O^ /QZ_;,N/V1O@AK_ (>^
M+VG1?LGS_M5Q_'WX9^/? _CCX3O:6/QNN?@CJWPM:Z\.:OJ%XGC?2=3BM_$%
MZ69+.'2[ZVAE:.X>,3^0?M!?\%AO@W^SO\?OB3\'_$'P=^.'BKX<_L[ZS\ /
M#O[6W[3OA>R\ ?\ "F/V7]<_:9U#2;3X5VGQ!BUKQKI'C_7;<V7B+PSX@\;:
MAX#\&>)K;P=X:\1Z9JUZ9<W=O9/OY6OY75U]Z5_3785U>UU>[6_5.S7JGHUI
M9Z.ST/UZST]^!^1/\@:*_)OQI_P5A\%> OVC(_@OXD_9I_:BT[X7+^TMX-_8
M[NOVL;[P;X0TSX(1_M$>/-&&L^'/"^G:9JWC33OBKXA\)3RS:?X=N_B9X?\
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MXWTZ]^ _@3]F_P#;$M[E/AM\"O!/Q#\6?#OQ!X-U:[_9FUG3?#OB7P[IFL>
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MCP+\6M"U&_TO2;+Q-I'B>#0;+Q;;0?9FTN53+8V]W>V9>YE_G]_9,_X);_\
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M6M;36Y_/'\&-*_:Y_P""3'P6_:W\/>+/ >E?M2?#ZZ_;9^%'C;]FWQ/;^)O
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M+Q4^CB3[:FA2Z[%-I$.I/$MK+J$,UM'(TL4BKU,P8QG:Q4@HV0<?==6(SZ$
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MCN?4_A]J'@'P!X$\0>//BWX)\2>!/A]X TWPE'XO\"_$W]EGP9X0L/BUJ7Q
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MU?6UDW[LM.;X-;6M-:I[+9]12KQ2O:_O3C;FBFU3TJ-)V;Y7]E)RE]G5I/\
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M.&WMK>!'EGN+B>5DBAA@C1Y)I9'5(D5F=@H)'\]W[5?Q[_;#O/VF/VI/@O\
M [XG75OI_A;XU_L(:!I7PN\(>-_V??@[\>?&OP_^(WP ^.OC'XE_#W]EGQ]\
M>-+F^'.I_&/6/$_A#PQX]?0OB7>V\5Y\./!WQ%TKPOXC\+:C<6-ZGZ&?L=?&
M&^^,O[&FN7OB#QC\4?'/CGP-/\9_A3\1;CXT_#GPS\*_C'X>\<> ;_7M*U3P
M3\2O#O@'5_$7PXO_ !CX6LWTW2-3\9?#+7]9\!>-98D\4>&[PVFIB&)6TO\
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M0ROEW?+E50E0[,$7:BC8FU 02%RS$R44 %%%% !1110 4444 %%%% !1110
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MZE97-GJ-E<Z'-=6E]8ZA&UK=V4T3J\5S!<0320W%NR$/ \IDRI85\_\ CO\
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MK^(--B0N\LP16C0E=.U)B&E.(QM2T9OF]0-JCEB!S5A-9T]T+B:0A1EO]$O
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MG69;&_O9-.T72[<W-W,NF:=;7>J7ER%VQ0:?96=Q?7-S)';6]O).ZH9?AO\
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M1I_D9 TJ42;_ .V-4*["GE$:9Y>2<^9_R#?,\P= =^W'!4T2Z=,Z[%U"_3C
ME0::7!(P2/,L'7/ '*$'G((Q6O10)I-69@PZ9<0,Y;4]3N 6=E69=/(^<[@
M8K"$?N\XCR>@&[<14PTR<IM_M;40".24TW><JHY_XEP!Q@]03DG.1@#8(!X-
M%-N_;\NEE?S\]R8P4$U%RU;D[RE+5N[M=M)>2226AS5OH%Y A23Q1X@O29"_
MF72: 9 N%&S-OH5NA4%<Y*%\L26X&$FT*\,*QKXBUTN7R9Q'H1E"88;,'1A%
MMR0>8R<HHSUSTU%(II23B[V:L[-I_)IIKY-?B<C'H6HK+O;Q)X@D7 'ER1Z!
MY8ZC/[K1HY3G()'F#H,=Q4G]B:B9(G_X2?7U6-&5H?*T8I*Q5D$CL-(,@<9#
MCRY(P&'((X/544^9^7W+_(S]C3_O_P#@VJ_SFSD#X?U,R;QXM\1*H#_NE@T+
MRR7<MN.=$+Y4'8N' VJI8,VYC871KY8EC_X2+6V96<M,T&D>;(KDD1N$TA(M
MD8.%VQ*Q &]G/-=/11=^7W(/8P[U/_!E3_Y(YZWTJ^C==^O:M+C)Q)%I8'0C
MGRM.3@DECR,M[8%*VDZBS,RZ]JB*8DB6/R=(?RW12K7*LUB299"0S*Q,:D )
M$BC;7044MRXQ4597M>^LI2?3K)M]-KV.=ETO475%77=3B=,?O$MM+8R<%<N'
MLG12?O?NPGS<\ G-)-"UE1<%O%>MN9G#1%['0,VR[2K)'LT]"^YBK;Y0[ QI
M@[ =W7T4%'._V;J6#_Q/=0!*8R+'3,[OFP__ ![$!\8&T@+]W(!W4'3-3)#+
MK5V!B-61K#3#N* EGR8U.9<XDY*9.41?O#HJ* .<_LK4RRLVM73JNX[#8:4.
M3G;EA'GY<@KMP2$PS#.3 ^D:SO++XBNT4DD(=*TJ7;G;@;C&7.UAN!8G))Y.
M..JHH X\:-X@\W</%5Z(]I'E_P!C:2%+;2-^[8'!SR 0!D =*N'2=0>6)KG5
MIKBWB>*5K06%E$DTUO+:3V[F9"9%"S0%W4-AQ(ZL<11[>DHH !T';BBBB@ H
MHHH *CE.(I#W$;D?4*3Q4E5KI6:VN%! )@F (R""8W (/." 1S@\\XXP6M91
M7>45\G))DR=HR?:,G]T9/\TOO+-%%%(H**** "BBB@"&<$Q-MY;*;><?/O7;
MSV^;%?S=_LU_M]?L<?MS?MZ?"73O#O[2'P.^'/P[_9I^*7QS\._L3?LF^$]1
MMM+^*7QT^.[^"_BG\)O'_P"TYXZT"STRUL?"7@.T^%WB/XU:=\ _AY;*FH^+
M](^(.O?%[QU/::I<^!_#^E_T4^*=8FT/1IM0M].?59A>:190V*7D%@9IM5UB
MPTJ(M=W.88887O1<3L0[F&%TBCDE=$;!DU;QT45(_!FG,K,%D,_C2"-TB,<F
M]V$?A^Y5B)%5-BDAE<N7788RTOM6CI=7?*FNNC;NO7;7STB7;T[_ (VLVO*_
MG;H\#PG\4? ?Q:^%TOQ$^&GBG2?&?@;6M)\3KI'B71)9;G3+]M!N-7T/5%@=
MXHYW:PU;2M0T^XC,2,EU9SHH8;'?^7/PS^U#^SY^U_\ \$7/V%O^"<'[,WQI
M\(_%']LWQY^SM_P3/^%I\ ?#0ZYXZ\3_ +//BKX3Z]^SAK7Q*^+7Q>7P?IFK
M0?"72_V;;?P1X@\?:GJ?CBYT)9?$OA'3/"VD_;_$>MZ)IM__ %7'4O&RKNC\
M'6$LOF!#O\8Q+^Z53^\,@T%V)RS(J%-QP&++DD0-JGQ!,P \$Z1Y1= S2^/&
M7"$L'?R5\*R[MJME4+X=AAMNU6*45S2;TTA;WHM>ZG>5]-6G;XM+7WN*[Y;Z
M-OFN[-)WDW9IN^J=F]M+VU5OY&KG5_&.N_MX>.IO%GQK^$?PH_;]L_\ @H1<
M^%_A_H^J:M^V9XG_ &QG_9V3XQV&L^ /!O@3X,:)XBLOA-XD_8P\9?LY6_E^
M+]=L?#%Y^SO91W>N?$/QYJZ_&+PS?:E:ZG[/GCO5_ G[:'Q8LOV=O$6@?M#_
M +9OQ/UG_@HGI<&KW?Q"^,7@#]KKX=>,]/T_XD^,?A#HW_!2O]ES7VU_X/:S
M\!? ?BK2/A[\(/V>OBU97WPR\/:3X5NOA.OPJ\*/X;\4:W97']:B:AXZ=&:7
MPGI4;[U41#QQ(Z-&S2K(^X>%E V*MNWEE1N,LBJ1Y9,SH[WQO*H2\\*:1$GF
M*<0>-IKI=N\-E_,\*VSD CB,*X(R 1Q5-MIKF^RXI<ZVMIUV3L]>KN#:]Y\R
MU:>D7;1W:M=JW32U[+NK?R#Z!K'[%\'["'QSNOV7?BW^U!K'[5VH?\$Q]5U#
M]NN_B^*'QHU>PT;]H"7QS\%--UWQ!^V-?^+-;U'5/AK_ ,%"T^(Y^+5A\,["
MVU?PY\0[;P19_&JVU/1;OP7X:^&?]C>T?M]^!?!_[,?Q=_:3^#OPKU;XN?"3
MX'>!/V-_^"2.HV^G?"'QU\8I/'WAJV^(G_!8?]HR^^+OB;X=:OX9UK6OBK>_
M%GQ%INJZU<66I^%)]4^(^KZI-9VFA-<Z@FEV+?U+?:_&;+ 6\.:2&5%+ >,[
MDE'VX.6/A0&499AYA +KRR@':/(OCC\%+']H?P1I/@+XA>'KD:'I'Q'^%/Q6
MMH_#_P 0KK1;L>*_@K\3O"_Q7\$*]]#X8DDDTV3Q3X1T>75K$1Q)J%@ESIDT
ML,=U)/3C*:YFY-IJUN=-W4;)]F^BTVZV5B)14W'E:5G%KW6E93<FK-[-6OKJ
ME9)79_+Y\:O"G[&GBKX/_M/7_P &]>T;Q3_P2G^$G[6?_!'GXBZ'XTMOB7\2
M]=_9Z\'_ !>N_P!MSX<^&OVR_$_PV^)M[XLNM-N_"&G?L_\ C6VNOCA=>#_$
M5SX.\*>.-4\3>)]2.E?%FV\6ZM:=7XD\0_#;5_C3KFB_MB_$'4M/_P""9VL?
M\%./V_\ 2_C#K/C3XA>)/"G[/\GQ*L_@K^RW>_L<^%/C)XXAUW2=-T?X#7UM
M<_&W5?#.DZ]KME\'O$7Q7M?A]/K,.H>)[KPRD_\ 5P]WXS.R4>&-),I",R?\
M)A.JQL8LLD3?\(P2RK*3&V1&&4>8 03&52]\7;':3P[81S*S!(E\6F167R]R
ML7;P\@4&0!2&C+!<N X&RESR;;=[MW4N>7-S+E<:C::?M$XQ5[ZQ23]WW310
M2LK*RCR\O+'EY6Y)PY>6W+)2;MI:3OJ]5_,5^S5\+K']IWQ;^PU\&?C</BYX
MU_9.\0:Q_P %=]7_ &?O"_CKXB_'W2;OXN?L6>%_CM\(K#]CMOB\_B3Q;I_C
MGXJ_#V3X;ZR=6^%%O\7[K7T\7_#+3OA7XVU*'5[T6&JO^DW['NO?&:Z_X(^W
MEU\*];\6^+?C5X8^$O[6?A'X)ZIXBUO5/'7C&X\0?#7X@?&CP3\$].FUWQ5+
MK&K>*]6T:T\,^$=%TR^\1SZI>:J]A9/JL]Y)--+)^J:7GBMRBR>&; 1R%3(R
M^*/.* 0Q$.JMH:!V$F]0=XYB67=\X"V1<>(=TP_L&UV! \;-X@#2RR*8P(RI
MTLK'A2S;S*XW1A>CA@FV[=/+IY_?N]7JWJ#C;;7O=[J]^VOW=C^0Z#3_ -DW
MQO\ "7Q?H/[%_C+X@_%OPQXI_P""87[7/B;_ (*>:3??%'XR>+3)\5=#^%VC
M:E\*M2_:EA\3^(GUOX<?MD2_&31?B'97.B)_PAWQIE\(6?BG2?$6BCX?Z/X8
MM--_1KXQ?!GP'<?\&W/B/X;V7@N]OO"L/_!+?1/%MCX0@N?&KW[^(].^"6B?
M$^UNS]CU4^,)KJV\:V=OK;Z9_:$QD:%M(NK:XTU[C3Y?W7^T>(3Y@;0XOE&Z
M,_\ "0+\S[ H4$:<&3@9);/S%CR"<Q_:?$CL[2>';52A=873Q$ID>,A3N;.E
M((F9@!L5F4;5)?' 7S[?@U]^PG#1V2^&45TT=W;31*_6W;HK'\AOQO\ AQ\$
M_'7@?_@JU\:/AOKFO7VD_LG?\$D?^"?'Q>_8T^(7PG^+WQ-L_#W@?XC?#WX,
M?MG>/?AE\6/ VN^$?&,>D^-O&GARZ@\/IH/C;6Y?%>MV'A;5-6\-1ZA#X?\
M&WB_3O$$?[>OB'Q1J?[9/[9\OQ2^-OPM^$?QYT#7_A;8?\$\[[QMXH_:^D_:
M>T/P9XO^"'PLT_P'XO\ ^"?OP&^!NJV?A;X[^(]3_:2U;XC6WQ,\'^%O#GBW
M5?&=_IU_\//VB+6?X.06-I7]=LU]XN0*8/"]K*PF&/-\510E(B$!D8C19L
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M:;3H-*GC-I!92R6MO;"WD963MT_KY_U<?*_Z?]>?_#ZG\T=IXON?'WBWX%_
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MF'X>>#/!7Q(N]1U;XA>%O!_PR^$7AOPGXWU+5X4M]4O/&_AW1Y[#3/%6IZE
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MBSQ7X9\/2>(="TBV7Q]_PM+X6>*8]#\3-JVJ:#I^B^*/"NB2-#K]C]=_$?\
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M$3;ZC+_PDUQ826MY#>0:)]NFMIK.[AF1)()%7\C;G]@3]HRSUWQ7XG\,:O\
M#&VT6W_:)^!GQ^\ ?!KQ)XS\2>(?#VCZW\+_ -ICQ%\6?&=KX.^*UY\,'^(/
MPM\"_$KP7K)U/_A3FH6WQ2\%^!/BN+N^\ 7'AKPQJ>L6.K>>^'?^";_[4&B>
M%/AMX2NT_92O(?"GQCT/XTZCK^GP^-M&\40:UX/_ ."O]Q_P4(T+PQ;^)X/
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MQ^Q++JO@S4?$=\/C=:_"WQ$NJZ5\<_B#!KNGV$FE>*=3L[26_M?#TEYXLO-
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M'_Z4X_=I>ZOHUNKM)2M*UF];7UM?D4O/36UVUJGULG]'^(_VL-(\'?'WPO\
M!3Q?\+?BGX:\/^.M4U/PKX)^.&IZ5H:_"GQ'X[T7P9-X_P!3\+17$.NS>*=-
MA3PU8ZM]B\4:OX<L/"^HZUH6N:/:ZF\UG!-=>;:#_P %#_@3XA\)^&?%MN/$
M=E#\2_#W[//C'X+Z5J%OIMMJ/Q:\)?M8>.HOAS^S[KWAU3?-%I=OXZ\47$"W
MEIXBDT[4/"FD2_VQXDM=/M8;GR*OB;X;_M)_%7XUK#\6/A)\ 9?@3;^'M?\
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M[USX*:EK&D_$G2-;DANY]/>31+S0KYK6\LKV>RUBQDL-0TVXEMM0MI&\A?\
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M?%*TTWXX?M 1?LZ2>$?$/@/Q5KWPI\/OY6L:Q\%[O6/%^L>&O#WPXB\*ZH=
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M;F.SUWP_K%K<Z7K6D7#1ZAIFH6\]I>6\,T3H/Q)TW_@G9^T)H'P;UKX0S2>
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M(G@G7/AUX+\,>*#??!B*\T/R7X9_ S_@HKX7\#?#GQ!XI^!/Q>\4KX,^#?\
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M-\8:>VK6_P "71O 3:,VGZE:GPO=?NTC\57N@&PNO&,(\GQ%-?Q*B+Q6O_\
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MCQ!>3P0:CXYTSX5>']4L_"&BZGI6NRZ:FE:C;O7NWPD_; \(_%KXA6?P_LO
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MOGT]!0!K9 Y)P#C (Z<9QQG/X<=:-RXSGC.,\]:R8O#^BP,7ATVUB<N'+)$
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M#(P>#D]S0!J#!X'L3QCD'Z>H_P XIK[6!!R"5(!(Z8]B"#R?0CU[52BTC3H
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M=9)&\ZZRSH25)_TC P2>  #P"" ,7&\*Z UNUHVG(;=]NZ(S7)5MC*R@_O\
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M3X0_M _\%,]8^%'Q4N?#WB/XP?MK?\$Z='^/%_XE_;!^)GP9\,>$?V5/B/\
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M*^BCTB6+P3?>$+&R^,OVGOBI^UOIGB+]NCXP^"_VSOBU\.[7]G+]NO\ 8[^
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M6=!)+\(%36K!V&05^=E4K",\S,@*N"4(!M4444 %%%% !1110 4444 %%%%
M!1110!%,@>-E.<$KT8H>&4\,I!4C'# @CJ"#7)V?@3P;8^)]7\;67A'PQ9>,
MM?TZVTO7O%UGH.E6OBC6M.L@/L6F:OX@M[2/6-5T^S8;K6TOKVXMX6 ,<:L
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M;\3?VH_C3^U1KOPL^'7BWX2_!2]^,VB_"JRU_P &>$/'EQ\.Y?&GB?QWXM\
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MM/P.%T?X6?#+P]=ZG?>'_AUX%T.]UO7[SQ7K5YHWA+P_I=WJ_BG4+#4-*O\
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MX9ZKX=N_!>CKH[33-I:Z?HEN+!I96M!$TKEO?Z*!679?<>&G]F+]FQO"FB>
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M&H_#=W<>#K;3-,A\)7<NFM=>&H]-TY=$FL18V@A^GZ* LNR/E>\_8<_8RO\
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M=%_9]^'S_##P-XET:VURTC^% N_@A<RV'M?_  4(\9>)_P!E3QO\=_A!X/\
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M0?@SX=\+ZGJ6K>&?A5\!_#>H^(/&%Q\2?$VJ:!X%LM'U76OB9=:?<Z3<>/\
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M]6?RJ_\ !03]JG6O@+XP_:$U[X2_M*_M#>'?$'[&7QD_8]^ 7@O7_C/_ ,%
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MWPR^.GQU^'7@CQ7X2O?"OA[P%\*O!;^-_CAX/\3>.O!NK^!?"=_#XC\?^-/
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MK?,IQDI\UX*.JM*Z1ZS??MB?LSZ5-X\M[_XS>"(D^&6@^.?$GCJ]2_N;G2=
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M\DUJNE[6/V;OCC_PT)\--0^(4G@^_P# 5QI?QA_:.^#]]X:U35].UNZ@U/\
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M#;3\4_M5ZWX%_:/\%_!?QQ\#/&GAWX=?$EO&>D> ?CZ?$_@O4/#6K>+/A_\
M#;4_BMXET_5O ]GJS^./#/AK_A%?#_B:'2?&NI:?_9E]X@T$Z1=VNFKK?AB\
MUOSKP7_P4-^'WC3P-X_\;6G@/QE9GPU^R5H'[;O@7PW=7.B0Z[\4OV>_%EGX
M[N?#6N:*U[=V.EZ%XENG\!R#5/#>OZC;G0;?Q5X-N-1U%#JUU#IW::M\)OV@
M_%GQ^UWQ%XZU#]GC6O@+=:5XG\&^'=,C\(_$ ?&OPOX \6^!X--\0Z98:[=>
M*Y/ J:]XH\:VMAJ/B+7H?#\)F\'Z;8>&HK66YMQ>OX!X&_X)Y:QX-\ ^.]#N
MOB-IFO>*)/\ @GOX._X)X_"G5[C0;JRTK0OA]X#L/B9;:?X[\76$%YYVJ^*?
M%5QXR\)MXKTW23;Z=:6_@. Z$\$FOWWDNR[V:M>^BU[/JUU^]71$N96ERZ2D
MTM6NDFF[JR3Y;+SE%==/;/C-^W5X/^%5E^S#8Z=X:L?$_P 1/VL+[PW%\+?A
MMK?Q1^&?PMU35;+6=/T/4=1_LS7_ (B>(-&\,>)?$NDQ>(=.CL_ OAK4]2\6
M^*IVG3PQIFII;3O']+^.?BYX8\">*_AAX$U&22[\9?&'Q3JGA7P'X?LV1KW4
M9/#GA76?&_BW7+W(":;X<\+^&-#N[G4]8N=MI_;%]X;\-0-)KWBC0K&\^:?B
M=^S-XT^+OP*\._LM^,7^%.J_!C6?@AHGPW^)^K3:-XD;X@:7XV\.VWAVWT/Q
M]\(7>XFT3P[J_A:_T;_A+? &OZ@J^)_ 7C[2?"7B_1[YK[08@=SXS?!CQ1JO
M[5O[)'[2_AR&XU6U^#VD_M"_!SQOX<5(&>W\ ?M):3\,]8E^(&E(]PDEYKG@
MWXB? ;X=:-<Z?#&TP\#>.O'.K0^=/H\6GW\FE[6T>VOEHCV*R_:1_9_O].DU
MBR^./P<OM(C\$>(_B<^J6'Q-\&WFGK\-/!^L3^'O%_Q#:[AUAX!X)\*^(;:Y
MT'Q)XGW_ -B:%K5O-I>J7UK>)Y->._";]MSX6?%*#X[:>VI>#_!GC[X$^/?V
MAO"FN_#CQ1\5/A];>)[WPS^SYXLE\)ZK\4[RV363)X7^'NMS/H]])KOB"WM;
M7PK;Z]IL7B2:SN)/+/@6G?\ !.I]!^*F@^.M#^)S67A+PE\?_C;XR\+^!)?#
M!FL[3]F[]I6U\)?$CX[?LTZD\.KVNEZOH?B3]K#PT_QJ\+:Y=:0W_"'^%H/#
M_P +=-L9-#L[^XU/DM)_X)^_%73/'/B/QM%XT^$]]-XAU_\ X*7ZK-9WGAOQ
M)$(+3]MW5/ASJ_P^T^6Y@G<7LG@I_AOI]A\1)IHF@\06UWYNB6]O-86Z"K*W
MQ+^O+?8.9]K^GYW=DO1Z_-H_0JW^.O@W_A'O"DU]K?@NV^(/C3P)9^,O#OPT
MMOB-X.U#5]?NKSPG?>*X=$\,:K%J,6G>)H;FVTC6O[+\0:6)-)U;2]%U3Q#9
MR2:/IU_<VW,_LK?M1_#?]K+X-_#GXL> ]5T.#4?&GPE^#?Q4\3?#B'Q;X9\2
M^,OA4OQK^&GA_P"*/ACPM\0+7PWJ-^FDZT?#_B&UEMWE$=IK-M$VIZ1)=:?)
M%,?CGX%_L/\ QE^"OB'5],EUO]G[X@_#?Q'H'P1\9&;Q7X \1S?$3X>?'[X,
M_LH_#K]EF+4_AGJS:C>:=I?@G6=)^%F@>)=(UB6.Q\<^#KKQ#X^TZTDU6/Q!
M:3V'HG[$_P"QYXV_9:7P';>(?%7@SQ-9>"_V'?V//V5KJX\.:-JVF:CJWC#]
MFCPYXJT3Q#XNE34)Y5/AO7_[>@?PQIT\MSJ^F10W4=Y<NDRD)I+9W_X;7\?O
M6NFR49-NSA*.DG=V:=IN*2:ZN-I6>U[79]@:?\<_@WJPC;2?BW\+-46;POK/
MCF$Z=\0O"EZ)? _AS7?^$7\0^,T-MJDH?PIH'B?/AS6_$*;M(TO71_8][>0Z
MC_HM:MG\5OAKJ-]K>F:?\0? NH:CX:CN9_$>GV/B_0;N]\/P65[_ &;>RZW:
M6]])<:8EIJ.=/N6NXXA;WVVTEV7#K$?SUTW_ ()Z7WA_XO\ AKXA>'/B-HMG
MX8\-?&SXZZS8>!G\(7QMH?V7?VH-#\/^-OCQ^SG"]KXDM=.6X\3_ +5'@+X9
M?'70/'-OIMM?^&K/P8_@ZQM7L?$GBB36O/=<_P""??Q?\4^)/&&L>+KKX%ZG
MIFM?\-.>']-LO L_Q5^ VL#PK\<?VT?AG^U7X1\4:#KGP?U/P[<?#+XT^#;?
MPKJUYK?Q-\)//XQ\7_'VRTKXWZWXFU'5_$'B2V4T[ZCYGI[CU>]UIYM.SMZ)
MWZ:Z'Z!?&C]I7P5\(OV=OB1^TIIT7_"T_!'PW\'Z_P"-;J'X=ZWX=U*?7=+\
M+W<EIX@AT34[K5+;0I[W2I;34XKJ";4H2E[IMWII(U"-K<='X[_:(^!7PST7
MXA^(/'WQ>^&OA72?A-X=UOQ?\3KK6/&GAZVD\">%_#=OIE[KFM^)[+[<U_I-
MEIEKK6AR7+75LCQ/K>BQ%6DU;3Q<_,7CG]E;XN^+?V!?BG^RC?\ Q1L/'?Q+
M\<^!/BIX%L/BKX\T73=(;4+'QSXK\1:AX=U/Q]!X T3P[I^N^+M'\):QI^G^
M,_%^B^&?#\GQ \8V.I^+[K1],N==NX8OF3XK?\$]_CS\2]7^-UQ_PDG[/'AA
M?B!X%_X*2_#/PEJGA?P1KWA:XCT']M7PY\-Y?AUXG\7>'/#L=CX=UCQ]X0\4
M>"#9?&'Q?J UGQ5\2;2"T\40>(].N+YO#>G%M+]=;);NUO\ @_=?9DN<DTN1
MN[2=G:R:;<M=+*ROKUTVU_5VX^*_PRL9-.MKOXB> ;2ZU;PMJ/CG2[:Y\9>'
M;>;4O!.E6RWNI^,M.CEU&.2]\)Z=9R1WE_XAMTDTJSLY([FYNXXF#&SX9^)7
MPZ\9^'=0\7>$/'G@CQ7X5TN>^L]1\3^&O%>@Z[X>L+S2E5]4M;[6]*O[G3+2
MYTQ9(VU"">YBELUD1KA(E="?S7E_8S^-NL?%_P"+?BWQK:?L_?$+P5\06\0_
M&#P'/XGN?B3>^.?@C^T#XK_9'TW]D[Q+X1\$6EP]SX(G^#VI^'4\3W%MK=UI
M%OX@LM"^('CS1+OPWJ5UKHU2#OM8_8[\>VG[!'PA_9D^'FN> _"7Q4^$?A/]
MFZXM=432K^S^%/C'Q_\  *Y\ ZOJFG>+=,T%=,UVZ\#_ !'U#P9-INLR"*75
M8['4X;J>VU![)K.0:2V=Q0G*4%*45%M724D_M225M[\JC)]N:VK1]OI\5OA?
M)I7A778_B-\/GT;QOJ5MHW@C6%\9^'6TGQCJUYJ<&CV.E^%-1743:^(-1N]8
MN8-*M;'29;NZGU*>&QBB:ZE2$X&L?M!? ;PYJNKZ%XC^-7P?T+6] MKN]US1
M=9^)G@K3-6T6SL;W^SKZZU;3K[6;>ZTVWM-1!LKJ>\BBBM[P-:RND_[L?FG\
M:?\ @G_\7OC-H/Q5TO;\$OAY9_M,?L<_M ?LR?$_P;X$@U:Q\'?!KXB_'SXF
M^+OBCJ_[1_PNMU\.V2^-/'=_XH\;:EXR^)=QK-EX-\0_$'XHZ/HOCG_A)M*N
MFGD6;6_^"=?BW7'\9O>>'_@/>7?BS_@IC\+/VN+C7M7T".^\0W_P1\#ZU\+O
M$&O>']=U#_A%_.U+XE:]=_#EH)();J3P[*-2AN+K5&$$D4KLNKW[6?W]OZ>Q
M7.[VY7M\6T4^W=Z=%M=+5[?J/8?%;X8:IJU_H&E?$7X?ZGKFE^%[/QSJ>AV'
MC'PY>:OIW@K4HH;G3O&%]IMOJ,EW9^%M0M+B"ZL_$-S#'I%U#-%+!=R1RQLV
M#I7Q\^"&M^*? W@G1?BU\--8\5?$SPQXN\:?#K0]&\:>'=6U'QQX2\ ZEI&C
M^-/$7A2*PO[D:YI7AC5]=TRPUBZT]KA+*YN'27'V2\-O^3WC#_@G!\<O&.G?
M'KPM<ZM\%)=1A\;_ !G^(_[*OQXUC5_BYJ_CO3;'XU_M-Z!^U%K7[//Q9^'+
M:DOA'2_@Q<7V@P? CQRW@?5YAXS^!]EH.DV_AC09;74]-N_1/B9^Q#\<?BS!
M:ZWH^E? /]FKQA\3/V>OV^?A3\8;WX(W/B*TU3P9\2_VN+?X!ZKX<^-?A'Q?
MI?AGP=J_C[QO9>)/@+I]O\1/$&H0>"-<UK3O$,&H:=>#4_#T/]H)I)[V]?3Y
M?UZH;<M4DKKO=+\K_,_1_P 6?&OX;^&/AOXH^*EOXJ\*>(/"_AFQ\33?;-(\
M8>$TLM7UOPQ:ZA+>>$[#7M1UJR\-P^(IK[3KG2A9:CJUBEK?K)'?S6B6]RT7
M/>'?VD/A1J?PH^!GQ@\2^(](^&?AW]H2Q^%9^'5C\1-8T;P[J^J>*/C%H%GX
MA\%_#V"*34)K/4?'5_;W3PIH>CWFH23S6%_):RW%K;O.?S:_X8@_:*NKCP)\
M2Y?A[^S-I'CG6]<_:&F_:1^#UA\1/BWXH^%?Q(UGXS_L[?"G]F_P]\9['Q5X
M^\.^(-6/CCP9X%^#FC^#T\(WWA./0KCX4^+_ !1X675!XANM0\1ZW[A=_LF?
M&)_V2_V OA&]_P#"_5_BA^R9XM_8B\3_ ! -^FKVW@+Q3+\ ](\/>&?BH_@>
M\.EW6KZ5>O8G7_$'PTNM0TJ+S-5TS1--UH:;:WE[<VH[723O=VZ>7^>_^1/.
M[/FBXZ+?;;IUZ-]-+=6?HO8^)?#FI:UK/AW3M>T*_P!?\-II\OB'0K'5;"[U
MC08M82XDT>76]+MYY+W2H]5CL;UM.DOH8%O5L[@VIE$$I3RCQW^T3\+OAO\
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MN68NK;._KY?YZ_@*U1..JM=77+JTFVU>^C::5U>S5^ME^/GP0^)GBCQ5\>_
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M_P .Y?B#\(?!$.G>'[#Q#_P3P_;L_:+TKXK:'XJU33?BIX.\?_LY7'P+\/\
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M^/.A'Q]JFN>"])UQ/ 2>.M)\-Q6WC9O#MQ4TO_!,+X1VOC_X9>$]%T>6V_9
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M#QS\4IO"/P^\(WLO[,_[67[2OPC\->,_$FB07_AK2M4A\(?#+X5:#K>O>&=
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M1110 4444 %'_P!?]?\ /\Z** #U]Z",_P">GN/>BB@!,#&#S]>:6BB@+"
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MJ,X!) 4ES**VY9*7K;IZ?U8GE]YROO%1MTT<M?GS?@B2BBBF4%%%% !1110
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MP^WH,UK5EZLQ$-OCR\?VCI0;S%+KAM4LT("AEPY#'RW)*HPRRL,J0#4HHHH
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MD;$')?S @!P30!O@Y /J,T444 %%%% !1110 4444 %%%% !1110 A(4$L0
M.I/05Y!8?M#? +5/B++\'],^.'P@U+XMP7FI:?/\+=/^)7@R]^(T.H:/87.J
MZO8R^![;6I?$\=YI6EV=WJ6HVK:6)[&PM;F\N8XK>"61?7)<;.>07C4C .=T
MBK@@@C!S@^@).1C(_F9_9*\$R_LW?$_]B/XX6^L?L ?M9:%_P4 _; _:WTN/
MXR_LZ?L^:?=_&C2?%/QZTW]KO]JRY^+W@_\ :C/C35]:^(7A?P=I/@O6/@A\
M2](NO"7AY/#_ ( -G;P:K'!X5FT75VMU_7]?UY";_+^O^&/Z9_,0ACN&% +'
M/ !!()/I@9^E>0V/[0WP!U3XK:A\"-,^./P?U'XXZ3:RWNJ_!FP^)?@N\^*^
MF64-C!J<UWJ'P[M]:D\7V5M#IMU;:A+/<Z/%%'8W$%V[B"6.1F_&[4_B)I_P
M/^,^J?!VU&H_%JP^$WQ"O_A98O;17L=[\1K+PAK$W@FT>UFS!=K<>)XM,A-M
M*?*F$AC<;)"3^,/[,OPW_P"">6G?\$F/^"??QP^,UAX;70;'3?V*?CK9_'/P
MKHNOZS\;O$7[:OCWQ#\,;.\\;/XK^&>DZW\7_$?QS^+/[0'B'4/!7QC2S^W>
M)_$K>)O''@[QW$NAS>(;6W3:5KJ3VO9:IO>Z[)[]4N@I/5*+6JNF[V\]NUNO
M^1^_AGA'_+5._P#$,\=>.O'?T[T&>(#)D4#USP><<>O/<9Z@]"*_GQ\=?M6_
MM=:7IOQP_;0TS]HO2M*^&_P3_;VM_P!DBR_8=N/A7\-O^$6\:^!M+^/_ (/_
M &?]7BU;XBW&F7'QQC_:"\:CQ0?B5\/;GP]XLM?!=K V@Z(_PV\2Z5JLNLOS
M&L_&O]O?5?!6F>.](_;7O/#EU^T5_P %>_C?^PGX T*T^ 7P+U#1O@+\"OA3
M^UY^U]\'EU'2I-5\(W>K>.?BYJ7@WX0Z1#IOBCQCJ5YX6LFTSP:^H^!-;U"W
M\:ZKX[;A)VY6E?36,Y7>G\MK:22ZZWML0ZJ2U2TW?/!)VO>U]4M)/WK-)6U9
M_1L)HFP%=23G&#GI@D<=QD9';(]:!+&<X<'!VG'/S<?+QGGD<=:_F'U;]L;_
M (*3K\5OC'XC^',GQA\<_#O]E3]IKPQ^RY?P>*['_@F]\,_V:?B9I'@RX^%W
MA?XB^.?VBO'OQ+^,7PQ_:4\$_%GXGS>,]7\7^";GX2^#?!GPXTW5+GP7I/@_
MX;_$;2M<>VG^P/A%\5_VHOC'XFN/VC]9_;K\!_ _X5^(/VW?VB?V0-!_97\:
M_"WX3:/X=M] ^&GQB^*?[.'@;2_#/C3Q/8K\7KW]L3Q=XC^'^G?%O1-+USQ#
MK'PZU%=:D\#1?!^_TF*#Q!>))VNVGYI277:TO+6Z;73=,KF?6-GT7,G?N[[:
M;6=GI?9H_9,^./!0\2Z=X,/B_P +CQAJ^BZSXDTGPH=?TH>)=4\.^'-1TW1_
M$.OZ;H7VO^U+[1-!U?6-(TK6=5M;66PTO4M4TZQOKB"ZO;:*7I3-&#@N/UK^
M,/\ 94_:L^,_[('_  3Q_9 \>^#O$?A[XB:GH/\ P2'_ &X_CUHUUXZ^%W@!
MK_1/'UI^U#^S+X8\$7VI>(?"^AZ)XNM/A-\/)_B3XB\4>/\ 0K'7],MO%VB:
M1)K?BB\NM2T+1[[1OOO]I7]IG]N;]BZX_:!_9^3]KBP_:.\?W_[(?P]_::^%
M/QZ^('P7^#_A_7O@=XOOOVK/AI^SSK7A?QWX"^%'AKPIX%\1_"CXKV?Q#N_$
M'P=76+&U\<6X^&/QATI_&/C"73K75O#=\L=5=W7^=M+)^7WZ7(]I)-WBK+2R
MDD[Z/=^ZUOMU[:G](0D0G 89ZX[X]<=>XQZ]J/-C'5P.GZD@?F00/H:_,O\
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M$_@?^T]8ZC\/M&T[_@H3^Q%X8T+Q7^T)^SA^S-J6H?'/P3\4-8BN6\,_$_\
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M=]:MLKX=?\$__B_X2UC]D6\U:U^ ,FA? /P/_P %'O"GC#PYIU[XBFTZ\?\
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MGQ9X+^*OQ3_:MUG]H;X3ZM^T9XGU3X#_ !TT+]KW0/AGIGB#XS_#GXQ?#_\
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M1^#?@V3Q5XDT[Q[\-M:\(/XJTBZ\#:OXEC^&FIV=S9W4=O9B#QS!J=R(+?\
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M+]KKPA\3/B+XAO\ ]H#5=-O]3T/5M0TGQ=X?\8?"1IM6\#GQCXBDTWX#Z_\
M#O5/"\7ASXDWQU?]:1%&,811CT7GVP>H P..G QC%*51CDJ"<XR1SD=OT'L<
M#T%"E).Z;OWOT[:=/\QN$7!PV5FD[W:;3LTW>S5]'TLK;(_&KP#^SK^T%X;_
M &TM'^,7_"N_B18^$[C]MK]I_5-7\0WOQIT+5=!B_9D^)'[(?@G3-&U";P?=
M?%_5;L^#O%7[4O@FQUSPY\/+#PK<Z_X'URXO?$J>#?!NB:A?7=UZ#^VC^S'\
M:/VO-3^-'AZREU7X;:#\-?@=;:?^S/XANH/ 'B'2O&_[0OB'6])^**_$S3;
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M +'^\1@MV))(XQ7&>-BIMM#60X0>+/"[#'7>=47:..<,ZH#[$UV47$:#!X4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %4+]4=;<2 $+>6LB9.#YB3(R$=/NL%.,D'N.,&_67JJ.\=F$.,:EI[O\
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M;'W>8,*#XQW@J$5F\Q$!$\00N5F\KJ%0+GDG/4DYX]/8=?SIV!R.Q_P _D*
M.6'B'5BBN?!'B=2TIC,9N_!6^- <"=ROC%HS%WPDC3X(S"#Q5DZUJ/FQQCPG
MKY1S(&G%SX5\J+RXRZF0'Q,)R)F BC\J&4B1U,PBB#2#H?\ /^?RH_S_ )_*
M@#F_[=U3:6_X0SQ+G?MV?:O!^XKOV^8#_P )7LV ?O,%Q)LX$9?Y*E36-1<L
M#X7UV+:/E,EQX8(E.>B>5XDD(R.?W@0 =R>*W_\ /YT4 <\FM:BSRHWA/7T$
M8)5VN?"I68C&T1A/$\DB^9DB/SXX0"C;V7*YI?\ "1ZR4W_\('XK5MVT1&[\
M#&0@NJ[P1XV,6U58R,#('*(P"[RB-UW?/_ZN,_X\_A10!RB^(=7*LS>!O%*$
M,BA&N_!.Y@Y 9U*^,G3;&"2X9U<@'RTD) JU%K6I2,P?PGK]NJM@/-<^%65P
M%#;U\CQ-.P4DE!O5&W*25"%7/0T4 <O'K^JR2,K>"O$T**'(EENO!AC?8ZHH
M7R?%\L@,H8RH7B4"-'$ACD*(TW]MZGE@?"'B$!20'^T^$]KXQ@H/^$H+@-GY
M=ZJ1CY@.,]%UHH P?[7U$[O^*8UH !<!KCPWN8LKL0,>(2!L951BS*"TL93>
M@D>-7U?4$V8\,ZW)N;:WEW'AI?+&TMN<R^(H\J"-F(][[B#MV98;M% &(-4O
MOWV[P]JV8G"IB;02+A<_-- 1KA(C4$';<K;2D$;8SSB$ZUJ6YP/"FOE47<LO
MG^%]DIS@QQJ?$PD#^\J)&>SG(KH:* ,)=6U B,GPUK2%R-P:?PX3%U_UFWQ"
M1V7/EF0Y=0 0&(A_MO4B!CPEX@W%Y%*?:/"FY5C;:)&_XJ@#9.,O"59F"C]Z
MD;$*>CHP/\^QS_.@#FY-<U))8$7PCXAE25E$L\=QX4$5L&=5+3>;XHBE*QJ?
M-?[/#<L8PP0/(-E-.O:D)A%_PB/B)TP^;A9O"JPY497Y7\4K<#S#PH\DX)_>
M&, D=,0#U['/XTTHISD9S]:!.^EOF<T?$&HK!'*?"'B1I&"[K9)?"QG0L,E6
M \4&'*9PS)/)'E6VNW!J0:YJ#*S'PKX@C94W"-W\.,S,5#"(/'XC:$/S@N\J
M0@@@RCC.\(E!!RQP<X)XXZ< #@'D#H/2I:!G.+KE\5);POX@B/E&15=O#S%B
M.L0:+Q#)&)1U^=T1Q]R1B#5)/$^INDKGP/XL0QNR+&[>$A)<!0I#0!?%K*%<
MDA3,T3 HV]5&"W6N@?&21@$<'&0<9!X.>@I!$BYXR2<Y/7ICC  [>E'RO\VO
MR$[VTW,5-8NV#%O#NN1E4WX;^QF+<@;%,.M2JSD<C#;<<ELC;4\6IW$JNS:/
MJL!64Q!94L"T@&,S)Y.HRJ(3GY2[K(<'"$#-:P ';V_G_B:7T]O\".?S_.@9
MCR:I/'C&D:HX(!)2*S;;EPF"OV\,6YWD 8$8+DY&TD6JRR.$_LC5H]V</+!:
MJBX./F(O6/.>./7..E;&,?SHH QWU650N-*U1RX!!6WB^0DX(D5KE<8'S81G
M!'0[OEI9-4ECW8TO5),!2!%;1-DMNS@O<Q@[< L"1C.,GK6O10!B'674(6TG
M6/G$I 6R#LGE$C;*J3-M:7&8"I=) 1N:,F@ZRV_9_96K\X(;["3& REAN<2<
M$<*Z[24<[><9K;ZT?UH YUO$(4JO]C>(&RY4LNDRE5 Q\Y_>#*'/!&2<'"FG
M_P!NC&1I>M'')!TFZ!QV"C!W-V(R!GOCFM^C_/Y4 <X?$:A0W]C^(23Y>%71
MKHL/,)&&R0 4QF7!8(I!R2<4^37_ "_+(T?7I0[;/W6E3;E.2-S"1T*Q@J?G
M8#(*L 58&N@QT]NG\J* ,%-;+IO&F:NN%=RDFEW:R#:RJ$";#ND8N& #!2BR
M-ORH4N;62N__ (EVK?+@C_B6W+%LG&%V!@2,$GD #&"20#N#@8]/7K^-)CD'
MT_KZ^O\ B!0!AC75(RNF:SG)RK:5>J<9P,$Q!3_WU[Y YIBZ^K2F+^S]85@A
MD+MHVJB$JGWE64VFUI#_  1X!<@A<C!/0?Y_S^=% '.OXCA12QTW72%C,A":
M#JSN0N<HJK:'=(V,(F<D$'.?E-B#6HK@.5L]6B"+N(GT74X6;&1M026Z[V)!
MP%).-ORX8&MG'Z9X[<X[?A_/UI: .??Q%;HSJ;#724?RR1X>UEU)(7#*T=E(
MKQY;F2,L  PQE>8/^$JM.^F^)>W/_"+>(!G<[H, :>QR-H9LX C99,\A:Z>@
M#'YD_G_G ]!Q0!S4?B>TD"L-/\0A7N+BW ?PQXAB96MG$;NZRZ:KB&1CFWG*
M+#<Q@R0/*GS4QO%5HJ&0Z?XCP"V%'A3Q(\A"R%#\D>FLV#@LAQET*R!=A!/4
M?THH YV/Q);2@E;'75VY/[WPWX@AW =2HDTX,3Z+MR3WQS4W]N0[%;[)JWSD
M* =#UK<"03ET%B610!DD],A<[CBMSI10!BC6X"ZQBUU;<X)4G0M95.H'S2-9
M!(\<\.5R"".%.6_VY"6""TU7<=__ # ]:V@(Q5LR&Q$?)'RC=EP0RAE.:W*
M,>I^O6@#!3Q!;2^:5M-840KND\W0-=BXVAL1^9IR^<X!!*P[SU R1BJTOBJP
MA9E>UUO*QK*2GAKQ$Z[&.%PZZ85+D\>6#O7!WA<''3=,]3DC^@X]N_YTUD#'
M.2#C'&,=<]P::MU_R)DI->[)1?=QYE;T4H_F8$/B:QG02+:ZTJMNPTWA[7K<
M':2./.TY?O $J/X@,\ @F)/%FF2(TBQ:P%49.[PYXA1L%E4':VF*QR6'"@D
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MWA-=5BN-;TK2=/N+R6V7W^@OI_6X4444 %%%% !1110 4444 %%%% !1110
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MR_\ 7]?\#Y]'T444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MVFU9.RU;NW9']B/[*W[?/[)G[;!^)TG[+'QDT;XRV/P=\0V'A/XA:YX<\/\
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M1][RBU-^MJ<JNGG8[7*VZ:];QWZ>^J:_'[RS14",Q)^8D#&<E3@=^ 2?J<
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MI;>4(R=^RW?0ZBBOG3XM_M+?"WX ^&;?QA\=O&/AKX->'+J]?3;/5_B+XS\
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M+JJ*P%UB]._S/#NMQ%,;4>3P^S2Y4D^5Y.NRAMA&UL[3N(QN4YIPU:Y9 _\
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MPMK9FU:SAU-=0\;V?A?QE-HKV>D27M[:%?#E_P#:[N*VM6$*2M,GXP_M!?\
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M\0:Q-8P^$]?UO2=%T'3IYY?$6IV_/^#?V^M$O?A=\7/B9\*_V:/B1XH_9E^
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MB#P]JVBW%Q87T$5U9RW-N9;2[ACGB9)HT9?S[_:!_8W^&.H?\,E:-^RUX/\
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M\#B\=F7L*.#RRCEF&5&E'+\BH8:>)PU>LGBZ$\8L+AJM2G'$5)Q?"7]I_P"
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M_0KSJ";2X&1U_P!2_3WYXQWIK=>J_-"E\,O\,O\ TF1;HHHI#"BBB@ HHHH
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M_.Y;UOU=VI/UDK-KR;:\M%:C]F<HH.5(.3A^!TY&.I(&>>^1T-2K'(, A0.
M2&.<#(R!P <$CC'4\^EC SGN:6E&$8MM+5I1^2;:2LULV[=.R6MU;N[]KZVW
MZN[]6]9;MMD:Q@$'N,<Y)S\H7G).>_YY.222DBC'.>2!P<'J2?;_ .L#FI::
MPR/ISTSV/3\ZH)*Z:^X_F[E_X*7_ /!4>^F_X* ?'GX>_LU?L7?$O]C_ /8
M_:;_ &DO@SXW\')\5?C9X#_:W\<^"/V;HM(\1^+O$?@:UN_!?BWX-W_B*/P'
MK46LV=AJGB'1/[?UC2]4T33M,MIY-(_M']!O%?\ P5Y_X)]>"U^!R^)/VFO
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ML\4>(M5T_0;K2O!/ASQGX\MY?!6EZWXVOO#VFIXL\OP]>W%KJT\%I(#/L4#
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M;\>M\+_#OCW7/A8-:'C;0_A%XA\>FVT;2?&4OVC4X].OK3Q7K7A;2O"4JZT
M3=OR/TOSTZ8(_'_.*.?I^N>/\?Y>]?E;\/?^"E>J>,M?^%U]KW[+GQ'\#_!O
MXR?M)^._V6_AW\7+WXF_!;6Y-5^(W@;Q[\5?AR\]]\--)\72^.X="U?Q#\(?
M$TJW&EZ?K-]H^@R0^(=;L=-TBQUN\TG[!^,G[7W[-/[/GBCP]X*^,OQB\'>
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M\0O%OPGT;XQ1:/#\<M?^*7PCA?3M2^%GAKX=Z)\!K.V\<^ ;;6/B1)->NS[
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M_@DG96^K?&GQ1#^T1>:;XV^)_C;X9_$&Q\1^$O@C\*_AS8:CXQ^$W[27A/\
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M&8?V;]/UVSO)+62?4+CQ7?6<L=K:Z9:M+X=\5/\ @F9+\3_VA?C)\8S\;9O
M>D?&SP7\2?!OC6Q^&W@./P#XQ\<Z1X\^ ^M_ S2O"?QMU;PAXDT'P'^T1X3^
M&/\ ;T_Q ^%NK_&#X<^*/BCX(U^QT;P_X;^(>F^%[2XLKWT/]ISXG_M!? OP
M9^QU\./#GQ;\(:G\5/C_ /M8>"OV??&'Q@\5_"NTDL_^$;\4_#_XT_$?7M6\
M-?#W1/$^DZ+HOBRUTOX>V^C^"Y]4U/7M%M=6AL;OQ)H_BJWGOM.O_P V['_@
MHM^U)X&^&_@WQG\6OC7\)F3XZ?LX_'WQ3X4U71OV<_+LOA;\1_V;?VT/V<OV
M3;'4=.TF]^.^@Z5XGD^.6F_M&V^KZFOQ'^('@_X>?#3X@^%])UNZU[3_ (<7
MNO>'X%K?7IY;+0J\+-:)2?1O5JZ=VG?I9I6OYW9]L:5_P3@\<?VQ86?BC]HF
M&^^%_C#XI_LA?M'?'[P%HOPKL]-U3Q[^T'^Q[X"^ O@SPEJG@CQ?<>)+Z\^'
MGPO\:ZE^S/\ !7Q3XI\'7&F>)=>LY/!NI:1H?B^SLO&6L75GREU_P2N\2?$G
MX0?"C]F[]H_]HJT^+_[/?P$U3X"V?PD^'6G_  ;\/^#[NW\+? /P=\2_".A:
M]XL\66VN:GKFI_%[5K7QEX.D_P"$IT.?0O"/AG4?A1HFO^'_  /:ZUXAUFXC
M^0_ _P#P4(_;+^*_AOQ-X,\&?%7X4^#/%/PRTS]O77M0^(7C;X2> OB1XG\7
MZ?\ LI)\#/%7PVL=>\/?!?X[ZM\';*_UO3/BK?>%OBI>?#CQMK>EZYIFFV7B
M/P,_P\UG6SI_AVWI_P#P5L^-NK?'/X,:AX0O/"GQ$\#_ !+\0>%_ >K? /1_
M ?A'PK<:+K_B;]B7QK^TM;:!H/CO6/CAK?[07C7XG3?$+1_"_AC3_%FC_LU6
M_P !+WPAKS>%;.\O_'HB\4$N[W^_I_PWW#5MDU&+VUT_/OT^X_875_V9_%7C
M#P)^RQX=^(_QANO&GC/]F_XI?#GXJZY\0KWPE96MY\4]3^'OA?QAX6,NKZ5'
MJ<EEH&I^(K?Q0FI:IJ=E/<^3JUG/<VMHL5RD-M^?WQ;_ ."0OBKXHZ7XB\#G
M]I_6/^%5^-;C]I/5-8\$>(/#GC2Z\/>$/%G[07[2'Q<_:%?XA^$? /A7XI^#
MOAEXM^(6DQ?%*#X=CQ1\:?"'Q)O-%TGPCI7B'P5_PB^IW^L6E_X1\*_^"@?Q
M<^)?QQ_9F^'GBGXU_LP_M":'\0K[]D;XM:G>_"?PAXN\$ZE\'?&7QTU+]I+3
M_$GPEU>XT7XS^)++4KKP5%\-[72/!^C^-K"+Q5%/8^)Y/B9X?OM27198LCP;
M_P %.?VO1\%_@AXI^(WQ)_9JT'5_VI/V4_\ @FU^T9_PM.X^$'B7PS\,OV2=
M+_;)\=7_ (!^(_B#QAHFJ?&_4;OQ[X3\.2VV@Z3X-U;Q!XK\$Z7I?Q+\7Z=J
M'C/4'\"Y\-V9=KY^2?\ 7R*M&:3:3MHK-Z-V\_)::ZJY^FGP&_8=\5_!S]JK
MXI_'U?BOI=GX0^(;?$B\UGX9_#CPGXB^&_ASXD>)_B1XGT+Q.GC[XQ^!+;QQ
MJ?P4USXI^!UTF\T:Q^,_@GX7>#/BI\2+37KZ;XI>+_$1MTLIO ?''_!*;7_B
MG-\9/ GQ"_:&CN/V??BG\7/VR_CE!X,\,_#.VT3XCZ+XX_;!_9_^+G[-.J6%
M[\1)_$E[#JOAGP'\//C;X_U30TC\.:7J^J>(;O1K+4=3;PWH4.F7=[2OVZOC
M;<?\$X/B/^TW8^+/V>?'_P 5?!G[0_C[X'^%_B+X9\*>)[7X >-M+\,?MLO^
MS-X;\=1>%;;XJ^(M?EL=:\(BVUO4H-)^*<EI=>(FNIM$U&UT>6RMX? ;S_@H
M!^V#\$OB%XLLOB)XH^#_ .T/H'@#XZ?M@?LV'P!\-O@MK/PV^(/Q#\2? C]@
MK6?V]O!/B;2=4F^,OCZULO&5]#H,WP6U/P)9>'[K3=<M=3L_'EK=:!?6MQH<
MJ!II66OGK_F=8?\ @CE-<^$X=0NO%/P%C^+&@_&3P+\3],U+PW\(_BGX5\&^
M-;#P'\$OC3\"[7P]\5+ZR^/-Y\6]3EFT3X_?$;Q9X;NO"WQ$\.6'PT\1ZDVG
M^%M)DT;4_$L6O>JS_P#!*/24^"_CWX1:!\1O#G@NS\;_ +-7[.'P&2W\#?"Y
M?#?A#P]K7P+^.7Q'^/'B#QKH7A9_%6K3VUC\0/$WQ&U/S=!N];U&\L91<:E>
MZ]KE_J%S*WR?\$_^"BO[;GQ@'PI^'NG>.OV9;+Q!\<_B_P# +PEH/QB?P/\
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M!_$GBS5OAQ:?#/QKX[\9^'O%_P *4\.2P)-=:RGQ'UR/5-)U:^TM=&\6>&_
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M^$/^*OBEK;P'KQU?6KWPCJ=U9^ O'USI/H7P1_;+_9+^//B?X@_"_P &^/\
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MS2M9^%_[0OC7P7X9\)_ &2.TU'X6?%CP9\*O$_PB\=>,OB5I]QIXM-+U[6/
MWQCTC6/B9?+K,K>);*^M=+B\/(FAV-W VHWW%_ .Z_X)T?M,^%_$G[0/P]^$
M'[/<FI?$F#4-9^*UYXL^&_PIT?XH2-XYM/&'PON+KXQV5U;W6O6L_P 1O#5Y
MXPT&&[\5W,B^.?"&O:I:1SZKINMW5O<>&?\ !,S]B']H/]EGXG?&3X@_&K3?
M@OH%C\1/V=?V2_@QI'A?X/\ Q1OOB)IVAZO^S;XL_:>U2]GTBSA_9&_9+\-^
M%/ &J:!\<_#5AX.\':9X8UJ^\(#PWJFC3:YJ^F/H\MI\&^%/^"/_ .U3=_ )
M_A9XM\'?L+?#OQA\/_V;_C3\*O#/C#X8>-/BEXF3]ICQI\3/VL_@Q^U)I&I?
MM"3ZA^S?\.=5^&V@:7?_  =N-.U.]T:;X\ZD?%OQ:\:^.M'T338-)?PMXK!W
M=VTKJUK::.Z6_P W\NVA^^GC[1?V5=$U^+XJ_%#1/@'I'BC0Y/ WPJA^(GCR
MW^'6G:]I%S:>)M/\;?#+X<+XL\1?9[RPO+?QAJ^E^*_ ?A+^T8KB#Q%JMGK>
M@6$>HZA#<S<!X^^'7[&_CVU\4V7QW^ _P+_X1[X4_&&?7K?4/C?X&^#TGAF\
M^)'BW1O 7BK4?BEX4E\0R:C#!JGB'6/B%H7AO5/$.LP>'_%&L>-()[2ZL[JU
MGT/5-6_)_P"-_P#P3@_;)^->D?%;Q_K?PW_8UB^-?Q!_;%^(/Q]T3PO9?'[X
MF/X,\"^#_'7[!7P@_8[*W7C_ ,<?L5>.O"GQ0U34F^'_ (BL?B7X$\=_LK:A
MH'BOX=>(85\/>,_!GB*RNM+U'U[PA_P2_P#'&L_'Z]^)O[0_AW]E/XO>#]:U
M?XQ>(?$GAV_\'7FJZ)JNO_$O]@G_ ()Y_LM-JVF_"KQ;\.-7\(>&].U/QK^R
MS\8Y=1\+G7M;MM ^%_BGP9I%GJOB6\U?Q/X?\/O3OZ#NW]G[[=[?EK]RW3/U
M!^(7PN_97\;V]]\"?BE\._@1XKMOBOJ^I_$6^^#_ (Z\-^ M93XCZ]H=QI]W
MK/CU_ &NVL[>+-7T>XCT>XU/Q8-)OKS3I$TU[K483#;;'P>$OV6K3P[XL:U\
M*? :T\*>!9O GAKQR]OI/PZA\.^#[CX!7]EXO^&7A[Q6\2+IGAVX^#6I76F>
M)_!&E:T;%_A_>W-EK&B0:3--#<-^$OPH_P""//Q[\$?$3X!ZWXYB^#?CV#P9
MX;_X)[W/BKXC:?\ '3Q?X5\2_#3Q/^QO\%/A7\-->T?P!X7@_9*U/Q_\2M"C
M\4>!O%WBGX:7L/[1'P T_4[+XL^-K3Q]X+TV:+6;;XCXG@G_ ()%?M%^'?@[
MX_\ AIJ'P5_9"M_"::I^SKXC\&?#OPO\9]6M]?U#QC\#_&?CW7%\3:!\<;K]
MBS3M7TOPIX8TKQ3'JWP?^$G[3G@G]KDIXRUCQ18>+OB5IEO%#XZU9!J]/\NO
MR/UJ^)7[/7[#'PH\=6O[77Q9\'_#:'3Q)\!OAGX"FU[P#X,\0?#[P#XZ\9_'
M_P 3?\*W\5?#'3M.\'7=_P"'/B!\4?CC^TM+_;WC.PU)H+_5]:LO$5]<::(M
M:UB?Z/\ B]\'/V9OVB6T_P (?'+X5_!+XX2> ]7@\0Z7X6^*'A+P-\1I/!^M
MZI87\=MJ]IHGB:TU:30KW5=-M-4B6YBM;:34-/M-04M+;07 'Y\^+_V)?C5X
M@_X)I_"/]FG7/A_^S!XE^,GPC^+_ .S3\5K/X;Z!I^D>!?V?;KP[\ ?VTO '
MQ[N?AQX?N-,^"]IX<\/:IKGP,\):I\,)];T?X'^$?!&N^,-<U65/ W@KP+K<
MFDZ5YMX!_P""?GQN_9YU?]G3XJ_"OX5_LP>+OBU\/_VO_P!MGXQ?&""/QOK7
MPG3QQX'_ &JO&'QUG\">*[[XFV/P+\7^(/%/C#X8^%_BKI]MK/AG7?##VUO;
MS>*-$\&^([RVTO2H=;:MUO\ I_3)DI.+7P]F[.SVN];.R;:3T;T/V(TB3X7>
M#[K7KO0+?P1X=U+QYYWQ.\23:$N@:?J7C4:7X?\ #GAFX\?:E'IOEW_BAK#P
MKH7A'0'\1RQWS1:%I7AW2$NQ:6>FVJ>/?!7X;?L=?$'P7X"^-/P/^$_P+U/P
M;XPLO!GQ*^''CKPI\,O"FF1ZK:V-]X\\5^ _%VCW2^'[+4+2ZTK5?BU\3-?\
M.WS16VH:/J'Q'\;W]H+2[\5:Z][^)WPI_P""3O[2'PT\<?L5W/\ P@G[+FL7
MGPA_96_8S_9Z^-?Q:\1>)3\1K2[T+X%?LV^*/@'\:O#_ (1^&OCC]GJ?QSI6
MN>+-+\;>+/#7PN\;?#OXS?#'P=J_A#QAXAUCXU?#'5[O0AX7^(?ZB_\ !.[P
MG\7O@;\#OA!^R9\3?@+X>^%47[.W[+?[.^GS^./A[XHTSQ#\+_''Q'O=?^-G
M@;XA^%/!MMI?@KP5]GD\-Z3\+/A_\5]4U*XTVVNKZ#]H#2-*U#1]/U3P[J6H
MZTBEJDFM4M[*STW6]K]/+3R/2?@QX=_8L^,O@K1?%7PO^#OP?F\+^ O'?Q ^
M'GAR"?X4>$_#\_A'Q5\#?VL=;C\00:%HUYHEM<Z+:Z9^UE\"9/B!X8U+3[>V
MLM7^)'@SP[\1=#GFUVSTK5HM;Q/^PW^Q+X[@\-67C+]D3]G#Q9:>#?&/C7X@
M^%+#Q'\%OAUK5KX;\;_$K78?%_Q#\4Z187_A^ZATW6?'/BNVL?%/BZ^MX8YO
M$?B2UT_Q!JWVO5+*UOH/PKU[_@EMK^F>'?C_ ''[1?@3]FW]GCX5VVD_\%./
MB%\3OVS/A?K'_"8?&GXG:1^U1^T#\0OCQ^SYKGB+PR/@SX3\5:1XY_9#UL^
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M4OB;H6E?&GXF_LVGXP6GAG7=/UN77/#'C/\ 97\)^!?$7Q9U=+WX2_%?P7X
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M %)CG/\ ^KOS]3GD]Z6B@ H_S^5%% !WS]?ISC_#^=%%%  >?T_0Y_\ U^U
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M:@TF^T^^N0#]/:,_T_7I7Y=:C_P5S_90L?@"OQYCTW]H*^:S^-WA+]F[Q/\
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M/:IJ?VNTN([Z!7LR9P!=(^LZ*\B^(/QZ^#_PHU'3]*^)/CW1/!5YJEEINH6
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M  3T_;)?X+ZQ^Q-\</A#X'_:6^$7@;_@K?\ "#]IC0/&MGX?^&GP]^ WQ/\
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MR^#O"'Q_\+:[X0\'Z+\?;V:R\<^&;CQ-I4]]X@LM$^(WC+0M0\!VW_"2VO\
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M1[W]GWQO^T'%J/P&^ ^J?'B*7PQX;BUIO'GB_48_"_B+6_ZI1",<,RA@,JO
M[?GP,9.?EXZ8 GQQC)Z8SW^OUH;=V^[>^MOO[?H.--1C&/,WRQ2NO=;LDKR2
MT=W=M*RNWY,_F+_:O_:F_:RUT_&3XJ?"3XD?'W0/@[=_M1^+H?V</#%M\/?B
MU\')?C'\.],_8+_9(U'PS8?#CXLZ9^S%^T!X@\-:E)^TY=?''5_A1X,^*GP
M\2?#?]I;Q-?Z[X1C\7Z9IEKH"R>O^ ?CG^V_XJ_X*(6.B^(_$GBWX:>'M0^-
M-NEO\!_&/A#XVZI!_P ,H7WPFM=7@NM0\*>!?@1XA^ VBZ^GB?4=VN_M 7O[
M5 T3PW\4/#EW\*TM=7DUJS\)ZC_0HREE(W$$_P 0X(YSQ_+Z=<TQ8]N<N[ @
MC!Q@$\YQCK^?)SBEK?1^[;5-)Z][O5?+SN-QONW=;6T23:NK*]UIU[]#^<3]
MI_X+_$/Q[_P4R\9Z-I_B'X\:%:>-/B'_ ,$MO&6G>*?#$-K-%X#\$>#O"?\
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M2\+>+[OXGW<TR>"["ZT_^A94P""Q?)_BYX]/3%-:(DM^\<!OX1C 'H!CC_\
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M(()A'+:W$+J)8HY-S,CQQR1NHW:3:.P .<Y &<Y^G?N>OXTM PHHHH *RM;
M;2M27@$Z;J(R>< VDH(QWZ@GZ5JU2U%=UA>@C<#9W0*D##!H'&">HSTX(S0)
M[/T?Y,Q/#:LFCZ2".#8V9PS(Y#D1F0 H-HVEL @\\GCI745S/A[_ ) VD?\
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M*&&2DR\-G,;Y&&*] I)/&05##'()!!/\[Q_90_:D^%_C_3]"^"?P:^*Q\4_
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M:]K_ ')L_?XM@@8.20.G'?/)P,X!XSGIQS2%PIP0W()R$8KQR<D @<=,X!Z
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MC SQU7]:NHGSN_>_KYF.'=Z%-II^ZEIMITV6VP4445!L%%%% !28'H/R^O\
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M%06C=U9&D1B2RR;'E7>#G;-*ARLDBM:_S_G_ #W^M% #0H  .#P.< $GN3@
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MCI^/2EHH XWP[*1HFD;"JF32K+!X.UC"A!Y/(&=QZ<E6Y&,]5%)E5+%>2=S
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M2_\ 7R,Z56IS1CS*TI:KECKH^J2\G\NQ-%>,I>-F+N2JQD8/)4= 3@D$@X)
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( !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ex0301.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex0301.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" %+ J(# 2(  A$! Q$!_\0
M'0 !  (" P$!              8'! 4! @@#"?_$ & 0  $# P,"! (#"0<.
M"@D$ P$" P0 !1$&$B$',1,B05$4814R<0@6%R.!D971\"0S0E56H=0E-#=2
M4U1B=926L<'3X28G-39#8W*CL_$81$5'<X*$DK1&5V1ED[7"_\0 % $!
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M=9R%;-R+G*QM.4A/WM <$#'./0GM^4Q#K^ UT@Z<.I204HB#:HXQB*@XS_\
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M<?'@RG6$K=:PI2QM41E/F4H\>]8MKT+I6U;/HW3UKB['T24^%&2G#J$J2A?
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M")*0$92&\%:1DH5@GO6!!U=JJZ-:283>KLMNX2KJTM$:1#CSFVF5,);0^IU
M;+J,K)"0"0H<\&KL=O.DG;Q "Y]B<N4_PI$1(?:+SP\R4.-X\RAM*P% G@J
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M7!"FXSJ%B0Q&^'(*T/)4&U)*U#:0H%7?@YGN@=*LZ3TK;K.RYXPB(+9<;"D
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M^I:I%VD%Q0*0-J6@6A]N2E9SZ[@:NZ@T>K;U!TKI:X7>X)VPX3?B%#8&YPY
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M7:#:-.3]2RK-#N&H'W(\5$E;K6J)JTC<M:-A D9!!0>X_P!!H+$I5=-VO2J
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MVFONUI'K.G!/42T C@XM+7F&>,_BQZ>W^^KHI04PG276D$9ZDVM7VVEKV/\
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MKC=CTJLON6_[!.F?_JO_ ,IVK,N"U-QG5)QPVL\G SCBJS^Y;_L%:9_^J_\
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M2M+7<VC8_+7=9]FS"VMMD+<+O(.4(*0?7 'RH-T+E;%3PPWI-!:,GX<OEM@
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MTI1@*2M0R*[:)Z?WB#J:W/2;):;#"90HW1%LN+BXUV7X>U)$78A#8"R%Y[C
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MPGD84H%"O#5C.",'.*U*=*WUR_ZNE)D-QBN U;K(_G<6\MJ6Z\I.< EUP9P
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MJNY26UL6AUQQQOSH4^%->&-JTK!1A123COQ^6(Q^C]VAKMT^%?XR;K @1X#
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MG7"&U$A*1DX &2<>@YKSI<+'?;JN:F[2]1J?AZ&;?"HJY45+TY)64%:."MW
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MY-1O1DR[:8Z=6O0\CIS<;M>H\LLN,OQ +<Z \7/',@@HQC&"1D* X[9"UF]
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MZX1&V8[G@O.+>2E+;G'D42<!7(X//(KS1:;!J"W:.LLE>E)GPUMU='NJ8\6
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MY]ABB4X&.-OMCYUVI0" <9';M2E*!2E*!2E*!0@'N*4H%=5H"B,@'!]17:E
MYSWXKC&#Q@#VKFE!UVG.=Q_FH4=MN!@8'':NU*#HEEM*MP0D*]\?//\ I-<!
ME&T!2$GR[>WI[5]*4'&"3R01[8KH&0$;<@I PD%(PG]NU?2E!P   .^*YI2@
M  =J4I0" H8(SZUU0G:5$X).,D#%=J4"NH2H#E>3@#MQGWKM2@4I2@5P0#_N
MKFE!P4)*MQ2,\<_97) (P?MI2@#/J<T.?0TI0=/!1A0V\*5O/)Y/'ZA7<9]3
MFE*!CG//YZ4I0*4I0:\V:WG4 OAC(^E1%,(2,G<&2O?LQG&-P![9K84I0*4I
>0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !7 ? # 2(  A$! Q$!_\0
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MQX\*^)0[,/'FH*QVG:MA;! .. "GL>_USWE?1O&4,;M;>+;6>0#*)=Z6NUB
M>&*.N 3CD#C'?I75T4 <,U]\3+)6EDTCPYJB+QY-I=2V\C''./,4KUR.O<>]
M30?$2VMIX[;Q)I.HZ!,\@B62[CW6[,<8 F7*]^^*[.N!^(-X/$,4G@72E^T:
ME?*INR,;;.WW F1R00">-H'/<8XH [U6#=#TZ^U+45M EM:Q01C"1($4>@ Q
M4M !1110 4444 %%%% !1D9QGGTH)P"?2L1[N;6B\%A.([6*=H+J>/=EB.'2
M-A@@@Y!;L1@'.=H NH^)]/T^]&G%Q/JDBEHK*%E,D@'4C) &!UR1BLSR/&&J
M1[KF\@T1"<+#:(MQ,.#R9'^4_0)VSGM7#0QZ59^.]9\>K'=7.D:1 FG6LD8,
MSO<'Y',:]3C?M)8X)=N?[O1'4O%/C?2[-]%2+0M)G"2?;'99;B2-B0#'&N53
M@ Y8Y!QCD4 6=%O=>L?B"^@7&KMJM@FGBXGDGBC$EO(6VHN8POW@I;D?EFN[
MK'\/>&=.\,V<MMIRR_OI3-/--(9))G/5F9N2<8%;% !1110!PGA=?[;\>>)]
M5O97FDTRZ_LZQ1N!;Q[$9]HP.6;&2<Y P#CKW>.<UEV7A_3=.US4M7M86CN]
M1$?VHB1MKE 0&VYP#@XR/3ZYTP<D]>/:@#E_%_AV[U!K;6M%D$6O:=EK;<V$
MG7^*%_9NF>Q].:N^%_$]KXGTUIXXI;6\@(CO+&<;9;:3'W6!P?H>X_(:-[JN
MG:8B/J%_;6BOG:;B58]V.3C<17F?BC7_  3?ZFNIZ-XNM+#Q$J>6MS;$S+.@
MY\N5%^5U)QZGTZ4 >K9Y(YX]J6O--'^*EP]F_P#:7AC6YWA7F[T^PD:&; &2
MHD"LO4?*0>O4XS4VG?%[3=<9TT71]3O9HV</#F".0;1G[K2@@>^.@/?B@#T6
MBN0;Q+XL9CY/@:?'3$VHPISVZ%N#^G\FKKOC=L_\4;9K][EM6'O@\1_A[YR.
M* .QHKECJ?C5XD,?AW1U8D99M6=EP<<X$'^/XU5^V_$1E4#2_#2N5+!3>S9/
M3MY8[G^5 '9T5QPE^(KR,HB\+(H; /F7#X&.A&!SG/IP13HW\?,J-)<>&$RH
MSB&X())[$L/4 #OU[X !U]%<L\'CQ@I74?#L9R21]BF;MP,^:.^>>,^U12V/
MCV9@JZ_H5O\ +_!ILC$G\9>G(_3K0!UU%<G!HWC,R[KCQA:&,CE(='"$'V+2
M'^5=#IUO=6]NRW=\]Y*7+;VB6/:/[H '3ZY//6@"W1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !00""",@]J*CN)HK>VEGGD6.&-"\CL<!
M5 R23VP* /FWQJNJ?!GQQ<W?AHQPZ1J\#;8"NY%;&"O/=6(88Z @'(SGT#X*
M^!#H.C/XAU,"76-4^?>P):*(\XR>['YB1P>.O6N NK&[^.WCC4KFTN19:+IL
M0BMFE'S,3D)GCJS9)SR!@=:Z7X(^-I\W'@O69Q'?V3/]G\T_,ZI@-'N[E<'W
MV].E 'N%%)DYQCCUIHE!0'C<1G:&&3QG% &9X@\.:=XEL5M;]'!C<2P3PN4E
M@D'1T8<J1_\ KS7,67BG5/"EY::3XU\LQW+^3::O#Q#*1CB7)_=L<\9X.#S7
M6WFNZ5IPS?:A;6P"[B9957'&>>?2N6UCX@^!KRUGL+S5+&\C=662W53.3QTP
MF?S_  ZT =R"" 0<@]Z*\'U#QG9^#[G?X6U/7GT]I5$.G7&G/+;R$8_=QR2[
M7C!SCY=W48&.NK>^)/''CJ&W31O#5]8Z.<B\\V=+:><@_<0L<HO(!9>>HR*
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MW_B[C@_TH [?<" 1R#T(I:X=?A7H29Q>:UN))9_[4GW-Q@ _-CCJ.*0?"K1
MN#J&N$?+P=4FQ@=1][O0!W(((!!R#WHKAO\ A56AD /?:X_7DZI-SSG^]^'X
M4\?"SP_E2USK+,"I)_M6?YB!_O\ ^>U ';45Q(^%?AP(%$NL<*5S_:L_(/\
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..* "BBB@ H&>]%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>raines_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 raines_logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  S .\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]Y$2YU+4[
M\"_N;=+>98D2)(L8\J-OXD)SECWJ7^R+G_H+:A_WQ!_\;HTC_D)ZM_U]K_Z(
MBKYI_;._X*Y_#3]AOXVV'P_\4:)\0M;\1ZCH<?B&.+PYH?\ :*I://-;AFQ(
MK ^9"P/&.5YYJ9SC"//-V2[EPIRG)0@KM]CZ6_LBY_Z"VH?]\0?_ !NC^R+G
M_H+:A_WQ!_\ &Z^&/^(B#X/_ /1/OC[_ .$2_P#\=K>^$G_!>3X0?%_XQ^$_
M!%MX7^+FBZMXSU./2=-FUGPQ]BM7G?[H:1I>.A/ )XZ5S0Q^&G+DA4BV^B:.
MB> Q4(\\Z<DEW3/LG^R+G_H+:A_WQ!_\;H_LBY_Z"VH?]\0?_&ZY;X__ +2G
M@']E;P,GB;XC^+=#\%^'Y;I+%-0U:Y6W@:=U9ECW'C<0CD#_ &37*_ #_@H/
M\#OVJ?$TNB?#GXL> _&6LPQ&=]/TO6(9[KRQU<1!MY4=R!@=ZZSD/4_[(N?^
M@MJ'_?$'_P ;H_LBY_Z"VH?]\0?_ !NK]% %#^R+G_H+:A_WQ!_\;H_LBY_Z
M"VH?]\0?_&ZYSX4?M#>!_CIJGBBR\'^*=&\1W?@K59-$UV&QN!*^EWL?WX)0
M/NN/Y@CJ#794 4/[(N?^@MJ'_?$'_P ;H_LBY_Z"VH?]\0?_ !NK]% %#^R+
MG_H+:A_WQ!_\;H_LBY_Z"VH?]\0?_&ZOT4 4/[(N?^@MJ'_?$'_QNC^R+G_H
M+:A_WQ!_\;KCOVB/VJ_AQ^R5X5LM;^)GC3P]X'TC4;L6-K>:O=K;13SE&<1J
MS=6VHQQZ*:Y_]GC_ (* _!/]K7Q7>:'\,_B?X.\<:QI]H;ZYL](U%+F6" .J
M&1E7HNYT&?5A0!ZC_9%S_P!!;4/^^(/_ (W1_9%S_P!!;4/^^(/_ (W5^N-^
M+/[0?@KX%:AX6M?%_B/3?#]QXVUF#P]H4=VY4ZIJ$QQ%;1\<NQZ"@#H_[(N?
M^@MJ'_?$'_QNC^R+G_H+:A_WQ!_\;J_7,W7QD\+V7Q>M/ ,NMV*>,K_2I=<M
M](+_ .DS644J0R3@?W%DD12?5A0!K_V1<_\ 06U#_OB#_P"-T?V1<_\ 06U#
M_OB#_P"-U?HH H?V1<_]!;4/^^(/_C=']D7/_06U#_OB#_XW5^B@"A_9%S_T
M%M0_[X@_^-T?V1<_]!;4/^^(/_C=7Z* *']D7/\ T%M0_P"^(/\ XW1_9%S_
M -!;4/\ OB#_ .-U?HH H?V1<_\ 06U#_OB#_P"-TZR@GM-317O;FY1XG.V5
M8P 05P1M4'N:NU ?^0M#_P!<9/YI0!7TC_D)ZM_U]K_Z(BK\HO\ @JE_RFET
M?_LBD'_I]NJ_5W2/^0GJW_7VO_HB*OR"_P""S/Q5\._"'_@L7H6H^)M7L]&L
M9_@W;VT<URVU7D.MWC!1[X5C^!KY'CRC4K</XJG2BY2<=$E=O5=#ZW@2M3I9
M_A:E62C%2U;=DM'U*]<G/_R>O^S%_P!E*L__ $7)7+?\-O\ PE_Z'W0/^_Q_
MPJM\/?VA/!7Q?_;K_9JLO#/B33=:NK;XBV<\L5LY9HTV2#<>.F2!^-?S=X?Y
M+F-'B'"U:U"<8J6K<9)+1]6C^C>/<YR^MP_B:=*O"4G'1*46WJNB9]__ /!?
MWQ9I/@/X,?L^ZYKU[::;H6C?'SP??:C=W3!8+6VBGF>620G@(J*Q)/8&O)/^
M"BG[1OPE_;R^(OP"T7]G#6-#^(7QGT#XDZ5J]KK'A.+[0?#&DQ2,;^:[NXUV
M16S1X5HW;]X< *V*^C?^"Q/PD\2_%[P?^S]!X:\/:MXB;0_CKX1UK4X["S>Y
M^Q6$%S(9[F4*#MAC4@LY^4 \FN>\6?!7Q?\ \$P_VC9_'GPD\+ZSXO\ @=\2
MM5$GCGP'H=F]U>^%M1F8+_;>EVZ L\3G'VFV09_Y:(#@A?[ /Y%.S^-_[>/C
MWQ!^UKJOP.^ W@30/&?B_P (:=:ZIXPUSQ)J\FFZ%X72Z!:UMW,,4LTUS*@+
MA$4!5P2QY R_A[_P42^)&B_MR_#_ . 'Q/\ A1I?AWQ+XPTG5=8;7]&U][_1
M;FWM(XFC>U+P1R,[,TJR12A&BV1D&19 1PG]OZS_ ,$W?^"CGQK^(/B/P5XZ
M\3_";]H&'1=6MO$'AC0+G6I_#>H6-G]DEM;VUMT>Y6.1=LB2",J"2IYSC/LO
MB+XW_;!_X*^? 3XA:/\ "WX@:%\'_"'AOQ1I]OXAU[0I],ENKNXAM2SR6\JB
M6W@;9$D)G5&E=)]J[5#,@.[\,?\ !0+1_ 7[/'[7_P 1=$^%VA:/<_ ;Q?KM
MA>VMC<I;GQA<6-E;W)O)Y4@!267SMI++*1L!W-G H>,/V]OVE(/V;3\<M$^!
MW@1OAM;:(/$TF@ZCXOGB\676F"'SWF5%M#:Q2>5EUA:1FP "0YV#RN7]G+Q^
M?V#O^"CFB?\ "&>)O[8^(/COQ9>^&;+^SI?/U^"?2K*.&6U3;F9)'1U4H"&*
MD#I7V)XA\%ZO/_P35OO#J:9?-KS_  SDTY=.6!C<FY.EF,0B/&[?O^7;C.>*
M8'"_&#_@IS!;^!O@S'\*_",_Q \?_'_3%UGPEH5U?+ID%M8"VCN9KV_N"K^1
M#"DJ [5=G=@J GD8V@?M\?%CX!_M!^ _ W[0WP^\%:#I7Q3U'^Q/#?BSP9K\
M^I::FJF,O'87<5Q!%+$\H5Q'(NY688P.2/D[XE_L%:AI/PH_8P^*/CGX,ZQ\
M5/"_PX^&=OX-\?\ @E=-:XUK1UEM+=H[V&R)5Y9()T998E_>!3PIP<=]\+/A
ME\!?B5^TY\-8?@-^R%+<#1]=@U?7/&GBGPAJ'A:P\*0VY\Q9+9KR));B^$HC
M,:1QE>#N91\R@'I>A?\ !2+X[_M Z]\4M:^"_P (? GBWP7\)/%=]X2O-,U3
MQ;)8^*-?N;)@MPUM"(&@@!)/EK/("X&?ESBON+0=0FU;0[*ZN;*?3;BY@266
MSG9&EM7903&Q1F0LI)!*L5R."1S7Y*_MKWW@[XLZE\1-:T;X"_M%?!?]KJQF
MN[3PWJO@?1=0QXFN(V865S-J%FO]GW-K+B,RFY.Y$+J&.T$_J5\"4\4Q?!#P
M:OCEK=_&RZ'9#Q T&WRFU#[.GVDIM^7;YN_&.,=* /B?_@O'\0M'^%&M_LG^
M)/$%M>W>B:-\9[&ZO8;/3I=0GEC73[[(2WB5GE/^RJDGTKVKX$?\%&?@I\2=
M!\:Z]H>G>)_"^G> ]%EUO6[_ %OP1?Z!'#9QAG=E>X@C$A 0DJI)X'%<W_P5
M'^%/B;XE?%[]D^[\/:!J^MVWA?XQ6&K:Q+8VCSIIEFME>(UQ,5!$<89U!9L#
M+#GFO;/VW/V?Y_VK/V/OB;\-;6]33KOQQX:O]%MKJ3.RWEF@=(V;'.T,5SCM
MFD!\X>&?VY/VI/C-\*X/BIX"^ ?@.7X>ZC:C5-'T+7?&<MGXMUW3V7?',L:6
MSVMO)+'M9(I)2?F + FO O\ @I%^U9X:_;;\!_\ !/3XG^$?M::+XI_: \.2
MK;W:!+FRF2X>*:WE4$@21RHZ'!(RN02"*YSX)_#O]F_X3_ ;1?#'Q:_8O\<Q
M?&KPYIT6F:CHVD?#K4-7A\17D*",W%G?P*UF\4S+O#/,FW<0>F3U'[1G[)?C
MJZ^!?["=IHGP)M_A[-X7^.>C>)_$/A3P@DFI67A&R-W)+)//(B[4 5E:5ON*
M[-AB.:8'U!\0OV\OB5\5?VJ/%WPE_9]\!>%_%%W\-5MT\8>*?%FM3:=HNEW<
M\?FQV$*P0RS7%QY>&? 58\@,<G%>+_![XN>-OB'_ ,%]/#&E?$;P3!X)\8>&
M_@IJ\5REAJ/]I:3JD,FL6+1W5G<%(W:-L.I22-'1XV!!&UFV_AOXQU7_ ()8
M_MD_'IO&_@GQ[KGPR^-/B=/'&@^+/"WAZ[\0)8W4MM'#=6%[!:I)/"RO$IB;
MRRC*Q^8$8$?P+\7>/OVG?^"UVB_%4_"WQWX/^$]E\)=2\/Z-J_B#2);"?4+A
MM4LYF>6)QNMO,PWE12[966%W* ,*0'2_ #_@H=\>_P!M[P=XJU?X3?"'P#IM
MIX,\3ZIX:NKKQAXKN88M7FLKAXMMFMO:.V"@C+22[55W* /L9J9^SU_P4<^.
MW[=_PNO/$?P?^#?@_0QX8O)]$U^+QYXGFMC+K%MQ=65D+6VE\R*-L+]IE,89
MB0(_E8CM?^"-/PM\1_"']E/Q%IGBC0=5\.ZE<_$3Q3J$=MJ%J]M+);SZM<20
MS!6 )1XV5E;H001Q1_P1O^%OB/X1_LR^+M.\4:#JOA[4+OXE>*M1AM]0M7MY
M9K:?59Y(9@K $HZ%65NA!!%,#$TS_@LEX>3_ ()Z6/QJU/P7KMMXHOM??P1#
MX$MYDGU"Z\3+=O:?V9%+@(V98V828XC!;;D;:S/C-^W1^TY^R)\ ?$7Q3^)_
MP0^'E_X4T329]2NM/\)>,;B[U;1"L;-']I6:T2*6(/L662!B8U+2!)%4BOGN
MR_8F^*U]^PM9ZWH_@K59_&_P?_:4U3XKZ?X7OX?L=QXGL(=4NSY<!E &Z6WN
M&DB;HQ5<'D5ZQ^W'_P %!+_]KK]B+XG_  [^$/P>^-FL?$+Q=X3U+2Y].USP
M+J&CP:''+:R).9Y[B)8I)1&76**W:5I93&H&"6 !Z1\;O^"I.M?#+2/V91H7
MPPG\7Z[^TE8R2V.F6^L+;G2[G^S8KQ$:1XB&A!EQ)*0I2.-W".0$*2_MS?&?
M]G?]I#X:>$?CG\//A_I_ACXO:LWA[1/$/@WQ%<WZZ7J9B>6&UNXKFVA8B58V
M59(^-R\J,UPO_"BO&9^,?_!-Z[/A77_LOP]T35(?$\OV"39X?D?PG]G1;HXQ
M"3/^[ ?&7^7K7HO_  50^%?B7XF^._V69_#N@:OKD/AGXU:/K&K/8VCSKIME
M';W:O<S%0=D2EU!=L ;ASS2 ^NJ*^=[[XE/\(OV]/&4NKZ'X^NM(\4^%/#5E
MI5YI7A74]5T_[3#>:U]H5YK:"2* J+BV+&1E^5E)X&1Y5?>,]:F_8@_:"^&L
M/AKXFIX^G?XDW&F9\)ZK';W:W.JZO<6/V:^, MY#)#/;F(1RDG<H49&  ?;M
M0'_D+0_]<9/YI7A7[!_[-OB/]GS1?%<^NS:1I]OXJO[>_L/#6CW%S<:;X=5+
M2*&18GN,-NE=#(ZJB(&/"DEF/NI_Y"T/_7&3^:4 5](_Y">K?]?:_P#HB*J/
MB;X8>&O&M^EUK/A[0]6N8XQ$LU[813R*@)(4,ZDXR2<>Y]:O:1_R$]6_Z^U_
M]$15?H Y'_A0/@3_ *$KPE_X)[?_ .(JQI?P6\':'J,-Y9>$_#-G=V[!XIX-
M+@CDB8="K!00?<5TU% !1110 4444 %%%% !1110 4444 %%%% !1110 5P/
MQWUJ\T:7P3]DNKBU^U^*;.WG\J0IYT3++N1L=5.!D'C@5WU8WC;P!I'Q&TJ*
MRUFS%[;03K<QJ9'0I(H(5@5(((R>_>N+,:%6MAY4Z+M)VMTZWW5_R.W+J]*C
MB8U*RO%7OI?I;9V_,Q_BIXTU#P_>:5IVD2P_VGJ9E=(38O>2R1QJ-Q5!)&B@
M%D!9Y% W <DBN)C_ &D=5L_ N@ZO>6-D'U_1KAK:) PWZI'(B1P#YC\LFXX'
M)&P_,:[A/@/X6CL;>W73ID2UE>:)EOK@2(755<;P^[8P1<IG:=HR*M67P?\
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@*** "BBB@ HHHH **** "H#_ ,A:'_KC)_-*** /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
